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ABSTRACT 
 
This study sought to investigate factors that influence adherence to treatment 
amongst rural people living with HIV and accessing antiretroviral therapy 
(ART) at Shongwe hospital in Mpumalanga. Both quantitative and qualitative 
methods were used. From patients’ case files, a sample of twenty-eight 
respondents was recruited for the completion of questionnaires.  A focus group 
discussion with nine participants was held, followed by qualitative interviews 
with three key informants.  Findings indicated that a complex web of factors 
unique to each patient’s social context plays a role in determining whether or 
not patients adhere to their regimens. Obstacles to adherence are poor social 
support, problems relating to disclosure, unemployment and economic 
hardship, traditional and religious beliefs, the quality and nature of adherence 
counselling and treatment side effects.  
 
 
 
 
Key concepts: antiretroviral therapy, adherence, compliance, adherence 
counselling, loss to follow up 
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CHAPTER 1: OVERVIEW OF THE STUDY 
 
1. 1 INTRODUCTION  
 
This study is an investigation and an exploration of factors that contribute to 
people living with HIV being non-adherent to their antiretroviral (ARV) 
treatment. This chapter presents a background to the study undertaken. It 
provides information on the focus area of the study; outlines the research 
problem and the history of the ARV rollout programme initiated by the South 
African National government. In addition, it outlines the aims and objectives of 
the study and the definitions of key terms are provided and a brief outline is 
given of the different chapters of this dissertation. 
 
1.2 BACKGROUND TO THE STUDY 
 
Sub-Saharan Africa is the region that is hardest hit by the HIV epidemic with 
approximately 60% of all people living with HIV and yet this region has only 
10% of the world’s total population (Hardon et al 2006:24). Globally, there is an 
estimated 34.2 million people living with HIV as at the end of 2011 and out of 
this an estimated 23.5 million (69%) of those people are in Sub-Saharan Africa 
(EGPAF 2012). This region alone had 1.9 million new HIV infections in 2011 
compared to the 2.7 million new infections globally (UNAIDS 2011). According 
to the UNAIDS report the total number of people living with HIV and accessing 
ART in the region is estimated at 13.2 million (UNAIDS 2012). South Africa on 
the other hand, has only 0.7% of the world population but it is carrying 17% of 
the HIV and AIDS burden of the world (Motsoaledi 2011).  
 
The advent and roll-out of the antiretroviral therapy (ART) programme which 
was initiated in South Africa in April 2004, was welcomed with trepidation and 
uncertainty by many quarters.  According to Jones (2009:2), there were many 
clinicians, donors, governmental representatives and others who maintained 
that the expansion or general ‘roll-out’ of ART was politically and economically 
unworkable. This scepticism was the result of many factors such as lack of 
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adequate knowledge, a lack of economic resources, a lack of political will and 
leadership, and the fear that adherence would be a problem in resource-poor 
settings which would promote drug resistance and massive treatment failures 
(Jones  2009:2). At the level of the patient, the fear was that poverty, inequality 
and cultural or traditional habits would undermine the patient’s ability to adhere 
to treatment. The South African National ART programme has, however, 
brought a great deal of hope to many people who otherwise would have faced 
serious morbidity and mortality. It has managed to initiate an estimated 
1 163 522 people on ART as at the end of 2010 (Stats SA 2011) but the figure 
has recently been estimated to be at 1.7million as of July 2012 (Motlanthe 
2012).    
 
ARV drugs are currently the only available option for the suppression of the HI-
virus to undetectable levels to an extent that the production of new viruses is 
stopped and the CD4 count is improved. When the replication of the virus is 
stopped, it allows the immune system to recover and be strong enough to fight 
opportunistic infections such as tuberculosis (TB) and pneumonia. ART is not 
a cure for HIV, but if administered well it helps prolong people’s lives, decrease 
HIV and AIDS-related morbidity and mortality and generally improves the 
quality of life of those infected with HIV (Sunil & McGehee 2007:84). Haynes 
(2001:4) states that because this treatment does not cure the illness, patients 
must follow the treatment for as long as the illness persists which is for the rest 
of their lives. The prescription and adherence normally includes lifestyle 
changes such as adopting safer sexual practices, eating healthily and reducing 
or stopping the use of substances like alcohol, drugs and cigarettes. 
 
The national ART roll-out programme has had its fair share of challenges 
which include non-adherence and poor retention of patients on treatment;  the 
resultant high incidence of patients being lost to follow up or dropping out of 
the treatment programmes; epidemiological shift in the HIV disease burden 
and the scaling up of the number of people on ART. These will be discussed 
and elaborated on in chapter 2 of this dissertation. According to Leach-Lemens 
(2010) who carried out a  cohort study  in eight South African public treatment 
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programmes, almost 30% of patients initiated on ART were lost to follow up 
(LTFU) within three years. The study found that LTFU levels can reach 9% for 
the first six months after initiation and increase to 29% three years after 
initiation on ART. 
 
For the ART programme to be successful and beneficial to the person on 
treatment, rigid and consistent adherence to the prescribed ART regimen is 
required. Adherence to treatment implies that the patient take at least 95% of 
the prescribed treatment to ensure complete suppression of viral replication, 
increase in the CD4 count, strengthening of the immune system and a general 
improvement in the quality of life (NDOH 2004:52).  Good adherence to ART 
has the potential for turning HIV infection from an acute illness to a 
manageable chronic disease like other chronic diseases such as asthma and 
diabetes. The conversion of HIV infection to a chronic disease is due to the 
significant viral suppression achieved through ART and can only be realised 
with maximum levels of adherence by the patient (Frank & Duncan 2009:20). 
 
Poor adherence refers to missing doses and taking medication inappropriately 
(Jean-Baptiste 2008:5). Inconsistent and less-than-expected adherence can 
result in treatment failure, rapid disease progression and in some cases in the 
development of drug resistant strains of HIV. Chesney (2000:171) attests that 
poor adherence to antiretroviral medication accelerates the development of 
drug-resistant HIV and states that ‘without adequate adherence, antiretroviral 
agents are not maintained at sufficient concentrations to suppress HIV 
replication in infected cells and lower the plasma viral load’.  It is clear then 
that adherence is the cornerstone of a successful ART programme; it can 
promote retention of patients on ART for long periods and the attainment of 
optimal health. The National Strategic Plan (NDOH 2011:49) in emphasising 
the importance of adherence suggests having a communication strategy that 
includes daily adherence reminders and re-adherence counselling at every 
clinic visit.  
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Adherence to long-term medication for chronic conditions is reportedly at about 
50% in developed countries and is even lower in developing countries (WHO 
2003:xiii). According to Malangu (2008:49a), it is estimated in the case of ART 
that the average rate of adherence globally is approximately 70% although a 
100% adherence is the ideal. This is also attested to by Bangsberg and Deeks 
(2002) as cited by Amico, Barta, Konkle-Parker, Fisher, Cornman, Shuper, & 
Fisher (2009:67) who, based on a number of studies using diverse measures 
of adherence, also set the average level of ART adherence at approximately 
70%. In South Africa, adherence rates are estimated at between 40% and 50% 
as seen in a study conducted by Van Dyk (2011) using 450 ARV users. Only 
40.1% reported a 90% level of adherence and almost 60% reported a between 
70% and 90% level of adherence. From a cohort analysis done by Cornell, 
Grimsrud, Fairall, Fox, Van Custem, Giddy, Wood, Prozesky, Mohapi, Graber, 
Egger, Boulle and Myer (2010:2263) with adults initiating ART in 8 public 
sector programmes across South Africa, it was, however, found that 80% of 
patients initiated on ART were retained on treatment at 12 months and 64% at 
36 months. 
 
Because adherence is such an important part of the treatment of HIV and 
AIDS, it is important to identify, address and modify barriers to complete 
adherence as soon as possible when commencing ART (Bangsberg 2008: 
272-278). A number of studies have been undertaken to determine the factors 
affecting and influencing adherence to treatment regimens. The individual-level 
factors that tend to be identified as barriers to adherence both in Sub-Saharan 
Africa and South Africa are: 
 
 The high personal and household-related costs demanded by  
treatment costs, to afford a more nutritious diet or to pay for 
transportation to the clinic (Bangsberg, Ware & Simoni 2006: 140; 
Crane, Kawuma, Oyugi, Byakika, Moss, Bourgois & Bangsberg 
2006:437-442; Hardon, Akurut, Comoro, Ekezie, Irunde, Gerrits, 
Kglatwane, Kinsman, Kwasa, Maridadi Moroka, Moyo, Nakiyemba, 
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Nsimba, Ogenyi, Oyabba, Temu & Laing 2007:658-665; Tuller, 
Bangsberg, Senkungu, Ware, Emenyonu & Weiser 2009) 
 Fear of disclosing an HIV-positive status and stigma (Dahab, 
Charalambous, Hamilton, Fielding, Kielmann, Churchyard & Grant 
2008:63-67; Hardon et al 2007; Nachega, Stein, Lehman, Hlatshwayo, 
Mothopeng,  Chaisson & Karstaedt 2004: 1053-1056)  
  Alcohol abuse (Dahab et al 2008:63-67; Reda & Biadgilign 2012: 1-8)  
  Finding it difficult to follow complex drug regimens, poor self-efficacy in 
treatment adherence or an inability to tolerate the side effects of the 
treatment (Dahab et al 2008; Hardon et al 2007)  
  Long waiting times at clinics (Hardon et al 2007) 
  Sexual problems; decreased libido and satisfaction (Malangu 2008) 
 
Some of the above-referenced studies focus primarily on biomedical and 
psychological factors contributing to non-adherence. The researcher wanted to 
focus on socio-economic factors that operate at the level of the individual and 
his or her social environment. In this regard Reda and Biadgilign (2012:3) 
state:  
The patterns of infection have been shown to vary globally depending on 
the social and economic conditions of the country affected, with poverty 
having a significant role as a social determinant of HIV/AIDS and the 
spread of the virus as well as access and adherence to ART treatment. 
 
These issues of socio-economic barriers to adherence are explored in greater 
detail in chapter 2 of this dissertation. 
 
1.2.1 HIV and AIDS in South Africa 
 
The HIV and AIDS pandemic has been one of the most challenging health 
issues that the South African government has had to deal with. In addition, HIV 
and AIDS pose a serious threat to the social and economic development of the 
country. HIV and AIDS are considered to be a threat to the economic well-
being and social and political stability of many nations (UNAIDS 2004b:13).  
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UNAIDS (2004b:16) suggests that Southern Africa is the hardest hit region as 
it has the highest number of people living with HIV in the world. South Africa 
has only 0.7% of the world population but it is carrying 17% of the HIV and 
AIDS burden of the world (Motsoaledi 2011).  
 
Amongst all the nine provinces in the country Mpumalanga, which is 
predominantly rural, is the second highest after KwaZulu-Natal in terms of the 
adult HIV prevalence rates (NDOH 2010:30). Shongwe Hospital, which is the 
chosen research site for this study, was the first facility to be accredited as a 
Comprehensive HIV and AIDS Care Management and Treatment (CCMT) site 
for the ARV roll-out programme in the Mpumalanga Province. It has, therefore, 
been regarded as a pioneer in terms of the ARV programme in the province 
and as a result has experienced a great number of challenges with the 
implementation of this programme, particularly in terms of ensuring adherence 
to ART regimens and retention of patients. 
 
1.2.2 The chosen research site 
 
The study was undertaken at Shongwe Hospital which falls within the 
catchment area of the Nkomazi Local Municipality which forms part of the 
Ehlanzeni District Municipality. According to the Integrated Development Plan 
(IDP) of the Nkomazi municipality, it has an estimated population of 338 095 
people (IDP 2010/2011:19). The Nkomazi area is predominantly rural and 
approximately 24% of the population has no formal income. The rate of 
unemployment in 2008 was estimated to be at 24% (IDP 2010/2011: 24). The 
Nkomazi area is also close to the borders of Mozambique and Swaziland 
which contributes to the high rate of fluidity and mobility of most people 
accessing health care services in this district. The HIV prevalence rate of 
people infected with HIV in the Nkomazi local area was estimated to be 35.5% 
at the end of 2008 which was much higher than the national average of 11.4% 
(NDOH 2009). 
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1.3 THE RESEARCH PROBLEM 
 
Shongwe Hospital was the first CCMT site in the Mpumalanga Province to be 
accredited for the roll-out of the ART programme. It was regarded as a pilot 
project for all the other sites within the province. The site has a cumulative 
number of 9 532 patients initiated on therapy and of these 3 791 have either 
been transferred or referred. The site has managed to retain 43% of patients 
on therapy excluding transfer-outs as at the end of September 2011 (Right to 
Care 2011).The problem the study focused on, therefore, was the factors 
influencing adherence and non-adherence to antiretroviral treatment by the 
persons living with HIV within the rural areas of Mpumalanga Province. 
 
1.4 AIM OF THE STUDY 
 
The aim of this study was to investigate individual-level and social factors that 
influence adherence to ART for patients attached to the Shongwe Hospital in 
Mpumalanga.  
 
1.5 OBJECTIVES OF THE STUDY 
 
From the aim described above, the following specific objectives were derived: 
 To investigate the social context of patients on ART in order to identify 
possible factors related to adherence, non-adherence and fall out (that 
is, patients lost to follow-up)  
 To identify the socio-economic factors that support adherence  
 To identify the socio-economic factors that drive non-adherence and 
ultimately lead to fall out. 
 
1.6 RATIONALE FOR THE STUDY 
 
ART has the ability to turn HIV-infection from a terminal illness to a chronic 
disease. However, nearly perfect adherence is required to build up the 
patient’s immune system, achieve viral suppression, and protect against the 
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development of drug-resistant strains of the virus (Yoder, Mkhize & Nzimande 
2009:14). In terms of the mid-year population estimates from Stats SA (2011), 
South Africa has approximately 1 163 522 people who are currently on ART 
since the start of the roll out programme in April 2004. The South African 
Health Minister, following the launch of the HIV Counselling & Testing (HCT) 
campaign in early 2010, announced that the number of people on ART had 
increased significantly from 923 000 in February 2010 to 1.4 million in May 
2011 (Motsoaledi 2011). The recent figures are currently estimated at 1.7 
million people initiated on ART so far (Motlanthe 2012). 
 
According to Rosen, Fox and Gill (2007:1-20), ART programmes in Africa have 
managed to retain approximately 60% of patients on therapy two years after 
initiation of therapy. The remaining 40% accounts for those who have either 
died owing to HIV- or AIDS-related illnesses, or those who are regarded as lost 
to follow-up. Retention of patients on therapy helps to reduce attrition and in 
many cases prevents death amongst patients.  It is, therefore, crucial to gain 
an understanding of circumstances that either hinder or promote adherence to 
ART so as to develop programmes aimed at addressing this challenge. This 
study is intended to contribute to that body of knowledge. The findings of the 
study will contribute towards enhancing understanding of the phenomenon of 
adherence and also inform policy and programme development and 
implementation thereof. 
 
1.7 ASSUMPTIONS 
 
In this study interviews and a focus group were held with selected patients 
living with HIV who were initiated on ART and were either adherent or non-
adherent to their treatment regimen so as to learn as much as possible about 
their experiences.  
 
The assumptions in this regard were that: 
 Not all patients initiated on ART are retained in the programme after 12 
months of initiation on treatment 
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 Specific factors, such as the social and economic context of the patient, 
the quality of counselling concerning treatment and disclosure, play a 
significant role in determining whether individual patients adhere to 
treatment and, therefore, remain in the ART programme  
 
1.8 RESEARCH METHODOLOGY 
 
According to Mouton (2001:56), research methodology outlines the research 
process and the tools that are required to achieve the research objectives. The 
researcher used qualitative and quantitative research methodologies. This will 
be discussed in more detail in chapter 3 of this dissertation.  
 
The study population comprised all patients who have been initiated on 
treatment at the Shongwe Hospital for a period of at least 12 months as on the 
last day of June 2011. 
 
1.9  DEFINITION OF KEY TERMS AND CONCEPTS 
 
1.9.1 ADHERENCE  
 
Adherence can be referred to as ‘the degree to which a client accepts an 
active role in following a treatment regimen which has been designed in a 
consultative partnership between the client and health care worker/ counsellor’ 
(NDOH 2010:6). It is the outcome of the patient’s acceptance of his or her 
active role in his or her health care. 
 
1.9.2 AIDS 
 
Acquired immune deficiency syndrome is an infectious disease caused by the 
human immunodeficiency virus. It is characterised by the weakening of the 
immune system, which leaves the body ill-equipped to fight diseases 
(http://www.globalhealth.org/hiv_aids/glossary). 
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1.9.3 ART /ARV 
 
This can be referred to as medication designed to suppress the replication of 
the HI-virus and thereby prevent or delay progression to the AIDS stage. It is 
the medication for people living with HIV that can work to inhibit the weakening 
of the immune system and to protect patients from developing opportunistic 
infections.  (http://www.globalhealth.org/hiv_aids/glossary). 
 
 
1.9.4 CD4 T-CELL   
 
This refers to the white blood cells killed or disabled during an HIV infection 
(AIDSinfo 2011). 
 
1.9.5 CD4 CELL COUNT 
 
A CD4 cell count is a measurement of the number of CD4 cells in a sample of 
blood (AIDSinfo 2011). 
 
1.9.6 COMPLIANCE  
Compliance is the act of yielding, conforming, or acquiescing and, if compared 
with adherence, indicates a lack of sharing in the decision-making between the 
health care provider and the patient. (http://www.hivguidelines.org/quality-of-
care/best-practices-from-new-york-state/promoting-adherence-to-antiretroviral-
therapy/) 
1.9.7 HAART 
 
This is highly active antiretroviral therapy which refers to the use of 
combinations of various antiretroviral drugs with different mechanisms of 
action to treat HIV (http://std.about.com/od/glossary/g/HAART.htm) 
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1.9.8 HCT  
 
This refers to the HIV counselling and testing process which consists of a pre-
test, test and post-test counselling (NDOH 2010: 16-20). 
 
1.9.9 HIV  
 
Human immunodeficiency virus is a retrovirus that causes AIDS by infecting 
helper T cells of the immune system. It enters and destroys important cells 
which support the functioning of the immune system (Evian 2003:6). 
 
1.9.10 LOSS TO FOLLOW-UP 
 
This refers to the disappearance of the patient from the ART programme, for 
no reported reason (Rosen & Ketlhapile 2010:98). Depending on the different 
definitions some regard the patient as lost to follow-up when they have missed 
more than 90 days of clinic or pharmacy visit (Jordan, Bennett, Bertagnolio, 
Gilks & Sutherland 2008:17). 
 
1.9.11 VIRAL LOAD 
 
This refers to the amount of HIV virus in the circulating blood. It provides 
information about the number of cells infected with HIV and is an important 
indicator of HIV progression and of how well ARV treatment is working 
(AIDSinfo 2011).  
 
1.10 OVERVIEW OF CHAPTERS OF THE DISSERTATION 
 
The next section comprises of the review of all the chapters in order to 
familiarise the reader with the structure of the dissertation. 
 
CHAPTER 1: INTRODUCTION AND BACKGROUND 
The first chapter focuses on the overview and background to the study. 
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CHAPTER 2: LITERATURE REVIEW: HIV and AIDS; ARV TREATMENT; 
ADHERENCE AND THEORETICAL FRAMEWORK 
 
The focus of this chapter is on HIV and AIDS in Sub-Saharan Africa, South 
Africa and the Mpumalanga province; the ART programme in South Africa and 
its challenges; the definition of the concept of adherence in relation to 
compliance; the identification and discussion of common patterns of non-
adherence and how these can be measured; and an exploration of health-
seeking behaviour models and their relevance to treatment adherence. 
 
CHAPTER 3: RESEARCH METHODOLOGY 
 
This chapter is dedicated to the review of the research methodology used in 
the research starting from the research design and the approach used; 
sampling, data collection, analysis and interpretation thereof. Ethical 
considerations and issues of rigour, trustworthiness in qualitative research and 
reliability and validity in quantitative research are outlined in detail. The 
process of gaining permission to access is also discussed.   
 
CHAPTER 4: PRESENTATION AND DISCUSSION OF FINDINGS  
 
This chapter focuses on the data analysis process and presentation of the 
findings from the research study. The demographic characteristics of the 
respondents are presented, their socio-economic circumstances and the 
patterns of adherence to their ARV treatment regimens.  
 
CHAPTER 5: SUMMARY, RECOMMENDATIONS AND CONCLUSIONS 
 
This chapter is a summary of the findings, conclusions and recommendations 
for both health authorities and for further research opportunities. The findings 
of the study and the conclusions thereof are discussed in relation to the 
objectives of the study as set out at the beginning. The researcher also 
outlines the identified strengths and weaknesses of the study. 
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1.11 CONCLUSION 
 
In this chapter issues pertaining to adherence are introduced and background 
information is provided on the problem of adherence and the challenges of the 
ARV programme in South Africa. The research problem, aims and objectives 
of the study are also articulated. In the next chapter a detailed review of 
relevant literature and theoretical framework will be presented so that the basis 
of explanation of adherence can be understood by the reader.  
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
The purpose of a literature review is to enable the researcher to gain a better 
understanding of the complexity and extent of the research problem. The focus 
of this chapter is on HIV and AIDS in Sub-Saharan Africa, South Africa and the 
Mpumalanga province; the ART programme in South Africa and its challenges; 
the definition of the concept of adherence in relation to compliance; the 
identification and discussion of common patterns of non-adherence and how 
these can be measured and an exploration of health-seeking behaviour 
models and their relevance to treatment adherence. 
 
2.2 HIV AND AIDS IN SUB-SAHARAN AFRICA (SSA) 
 
The advent of ART has brought a great deal of hope to people living with HIV 
through improving the quality of and prolonging their lives. According to 
Levensky (2006:283) Highly Active Antiretroviral therapy (HAART) has been 
shown to reduce the rate of viral replication which often brings HIV to 
undetectable levels, decrease the incidence of opportunistic infections, delay 
progression to the AIDS stage and generally improve the quality of life of the 
client. The ARVs prevent HIV from multiplying rapidly and boost the immune 
system and in that way increase the length and quality of life and enable 
PLHIV to lead full and productive lives (Hardon et al 2006:24) 
 
Sub-Saharan Africa is the worst hit region in the world with approximately 60% 
of all people living with HIV and yet this region has 10% of the world’s total 
population (Hardon et al 2006:24). According to the Elizabeth Glaser 
Paediatric AIDS Foundation (EGPAF 2012) fact sheet, of the estimated 34.2 
million people living with HIV worldwide in 2011 an estimated 23.5 million 
(69%) of those people are in Sub-Saharan Africa. This region alone had 1.9 
million new HIV infections in 2011 compared to the 2.7 million new infections 
globally (UNAIDS 2011). It is, however, important to note at this stage that 
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there has been a 26% drop in the rate of new HIV infections in the Sub-
Saharan region from 1997 to 2010. According to the UNAIDS report 2012, 
there has been a notable increase in the number of people accessing ART in 
Sub-Saharan Africa where it rose by at least 19% between 2010 and 2011 to a 
total of 13.2 million (56%) of people on ART currently.  The prevalence rate of 
HIV amongst 15 to 49 year olds in SSA is estimated at 4.8% with some 
variations regionally (WHO/UNICEF 2010).  
 
2.3 HIV AND AIDS IN SOUTH AFRICA 
 
South Africa had approximately 5.38 million people living with HIV in a 
population of approximately 50.59 million people at the end of 2011, which 
translates to 10.64% of the total population (Stats SA 2011). An estimated 
16.6% of the adult population between the ages of 15 and 49 consists of 
people living with HIV. South Africa has nine provinces and according to the 
2010 National Antenatal Sentinel HIV and Syphilis Prevalence Survey each 
province is affected to a different degree by the HIV epidemic with the 
Mpumalanga Province, which is the focus of this study, being ranked second 
after the KwaZulu-Natal Province (NDOH 2011:39). 
 
Of those living with the HI-virus, an estimated 1.6 million people needed ART 
in South Africa by the end of 2009 (AVERT 2011) but this picture has changed 
dramatically. The South African ART programme managed to initiate an 
estimated 1.2 million people on ART by the end of 2010 (Stats SA 2011) but 
the figure has recently been estimated to be at 1.7 million (or close to 2 million) 
as of July 2012 (Motlanthe 2012). South Africa has thus made great strides in 
achieving universal access to ART with the total number of people receiving 
treatment reaching 80% of all in need of treatment by October 2012 (AVERT 
2012). 
 
According to Rosen et al (2007:1-20), ART programmes in Africa have 
managed to retain approximately 60% of patients on therapy two years after 
initiation of therapy. Despite reaching the 80% mark (which is higher than the 
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60% average for Africa estimated by Rosen et al (2007: 1-20) in terms of 
initiation on treatment, retention on treatment is still a major challenge for the 
ART programme. The South African National Department of Health (NDOH) 
has put in place programmes such as adherence counselling, buddy systems 
and peer support programmes to ensure treatment adherence and retention of 
patients on treatment. Despite all these programmes and the many 
advantages of being on ART, some patients still experience challenges with 
respect to adherence to treatment and remaining on treatment. As a result of 
non-adherence, patients drop out of the treatment programme and some even 
end up being lost to follow up completely. This is a serious challenge as the 
objective of the ART Programme is to have at least 95% adherence to therapy 
for treatment success to be realised (WHO 2005:12). The main aim of the 
South African ART roll out programme is also to initiate and retain HIV infected 
people on treatment to reduce morbidity and mortality. 
 
2.4. HIV AND AIDS IN MPUMALANGA 
 
According to the 2010 National Antenatal Sentinel HIV and Syphilis 
Prevalence Survey, Mpumalanga Province is second-highest in terms of HIV 
prevalence in the country, after KwaZulu-Natal (NDOH 2011:39). The report 
further states that Mpumalanga is amongst the few provinces that have shown 
an increase in the overall prevalence rate, that is, from 34.7% in 2009 to 
35.1% in 2010. This current prevalence rate is even higher than the national 
prevalence rate of 30.2%. A noted increase was evident in the National HIV 
prevalence rate in the general population from 29.4% in 2009 to 30.2% in 2010 
(NDOH 2011:40).  
 
In the Ehlanzeni District (under which the chosen research site falls), a 
significant increase in the HIV prevalence rate was noted from 33.8% in 2009 
to 37.7% in 2010 (NDOH 2011:43). According to a report by the Triad Trust 
(2010:6), a non-profit organisation operating in the Nkomazi Municipality, this 
area has an HIV rate of approximately 50%. These estimates may, however, 
only be based on the number of people that the organisation deals with and 
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may not necessarily be a true measure of the HIV prevalence rate in the area 
in question. 
 
2.5 THE ART PROGRAMME IN SOUTH AFRICA AND ADHERENCE 
 
The South African government, with the assistance of international funders 
and non-governmental organisations (NGOs), has managed to roll out a very 
effective ART programme since 2004 free of charge to the people living with 
HIV (PLHIV). South Africa has the largest ART programme in the world and it 
has made significant strides in improving ART coverage (UNAIDS 2012). At 
the end of 2009, an estimated 37% of infected people were receiving treatment 
for HIV (WHO 2010). In mid-2011, following the launch of the HIV Counselling 
and Testing (HCT) campaign by the SA National Department of Health in early 
2010, it was announced that the number of people on ART had increased 
significantly from 923 000 in February 2010 to 1.4 million in May 2011 (AVERT 
2011). Recently it has, however, been reported that South Africa has reached 
a target of universal access to treatment with 2 million people initiated on ART 
by October 2012.  
 
The introduction of the new treatment guidelines which prescribed that HIV- 
infected individuals be initiated on ART at a CD4 count of 350 and less has an 
impact on the attainment of this (NDOH 2010). This directly promotes the 
strategy of using ‘treatment as prevention’ which espouses the notion that 
putting people on ART earlier will positively impact on the lowering of the 
overall number of new HIV infections and therefore result in fewer people 
needing treatment (Van Dyk 2011; WHO 2011:6-7).  With the inability of 
various countries to control the HIV epidemic and the increasing number of 
new HIV infections, the treatment as a prevention strategy was introduced. 
ART has been shown to be effective in preventing the acquisition of HIV 
infection when given as a prophylaxis before or after exposure to HIV to 
prevent transmission from HIV infected persons (WHO 2011:7). This has 
shown well with the Prevention of Mother to Child Transmission (PMTCT) and 
the Post Exposure Prophylaxis (PEP) programmes which prevent transmission 
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to an uninfected person who has been exposed. A recent shift proposed in the 
approach to curbing the scourge of HIV is the ‘test and treat’ strategy. This is 
the model of universal voluntary HIV testing with immediate commencement of 
ART for those diagnosed HIV positive (WHO 2011:31). It is proposed as 
another form of using treatment as a preventative measure for HIV infection. 
The model is likely, however, to have its own challenges relating to adherence 
and needs to be explored further as a prophylactic model for HIV. 
 
The provision of ART to persons living with HIV and requiring treatment in 
South Africa has brought hope to people who otherwise would not have 
survived.  It has led to improved quality of life, reduced morbidity, mortality and 
the number of deaths resulting from AIDS-related illnesses and has generally 
prolonged the lives of many people living with the virus. According to the 
UNAIDS fact sheet (2012), there is a noted decline in the number of AIDS- 
related deaths by at least 24% since 2005 and in 2011 there were 1.7 million 
deaths reported. Despite these advantages, though, the ARV roll out 
programme has had its fair share of challenges such as non-adherence or 
poor adherence to ART and the resultant high incidence of patients being lost 
to follow up or dropping out of the programme. Rosen and Ketlhapile (2010: 
98) state that although public sector programmes for providing ART in the Sub-
Saharan region have matured tremendously, a high rate of patient attrition is 
still evident. They further note that while much of the attrition is due to 
mortality, loss to follow up or disappearance of patients from treatment, with no 
apparent reason, is very common. In a review of cohort studies conducted by 
Fox and Rosen in facilities around Johannesburg and published between 2007 
and 2009 it was found that approximately 59% had disappeared from the 
system and could not be accounted for in the first year of being initiated on 
treatment (Rosen & Ketlhapile 2010:98). 
 
Non-adherence can also have dire social consequences for people living with 
HIV and on ART at an individual, family and a societal level. This is attested to 
by Silva, Ximenes, Filho, Arraes, Mendes, Melo and Fernandes (2009:136) 
when they state that ‘non-adherence to the proposed ART regimen is 
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considered as one of the greatest dangers to the response to treatment on an 
individual level and the dissemination of resistant viruses on the community 
level’. Research has shown that the likelihood of transmitting HIV is greatly 
reduced if the individual takes his/her medication well and adheres fully. HIV- 
infected individuals with a high viral load are more likely to transmit the virus 
than those with an undetectable viral load (HIV Prevention Trial Network 
2009).  On an individual level, non-adherence can result in the person being 
very ill and, therefore, dependent on other people for daily upkeep; may 
experience loss of dignity, social rejection and isolation; displacement and loss 
of social support; and this may affect their ability to support themselves and 
their families financially if they can no longer work (Heyer & Ogunbanjo 2006: 
6-8; Mukherjee, Ivers, Leandre, Farmer & Benforouz 2006:124). 
 
In Shongwe hospital where the study was undertaken, the researcher became 
aware of the challenge posed by high numbers of patients who fall out of the 
ART programme. The ARV clinic has a cumulative number of patients 
commencing therapy of 9 532 patients and has transferred or down referred  
3 791 patients. The site has managed to retain 43% of patients on therapy 
excluding transfer outs as at the end of September 2011 (Right to Care 2011). 
These statistics reveal that there are some challenges in terms of adherence 
and, therefore, retention of patients on treatment. This study was undertaken 
in order to gain an understanding of factors that may be either hindering or 
promoting treatment adherence within this facility.  
 
2.6 LEGAL FRAMEWORK INFORMING THE SOUTH AFICAN ART 
PROGRAMME  
 
There are two important strategic documents informing the NDOH ART 
programme in SA: namely, the National Strategic Plan (NSP) and the National 
Antiretroviral Treatment guidelines to assist with the implementation of the 
programme. These two documents are discussed briefly below. 
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2.6.1 National Strategic Plan on HIV, STIs and TB 2012-2016 
 
One of the key objectives of the NSP is the significant reduction in deaths and 
disability as a result of HIV and tuberculosis (TB) infection through universal 
access to accessible, affordable and good quality diagnosis, treatment and 
care (NDOH 2012:48).  The NSP focuses specifically on expanding the quality 
and reach of health and wellness and is geared to addressing the gaps 
identified in the previous NSP of 2007-2011. The gaps identified include the 
ART programme reach, early diagnosis, follow up, support to adherence and 
retention in care.  The NSP suggests that these gaps be addressed through 
annual HIV testing for everyone in South Africa, initiation of every HIV-infected 
individual on ART when their CD4 count is 350 and less and the strengthening 
of adherence counselling programmes to ensure retention on treatment. 
 
2.6.2 National Antiretroviral Treatment Guidelines 2004 and 2010 
 
The first National Treatment Guidelines (2004: 52-57) focused on defining 
adherence and formulating strategies to support and improve adherence to 
ART, clearly defining roles and responsibilities of the Health Care Team. In 
these guidelines, the approach focused on providing the patient with a 
comprehensive treatment plan and on-going monitoring to ensure adherence. 
In 2010 the treatment guidelines were reviewed and a new set introduced 
which re-emphasised the importance of adherence and support so as to 
ensure positive treatment outcomes for patients and the identification of issues 
that impact on adherence. There was also a shift in the approach used as the 
NSP emphasises negotiating the treatment plan and allowing the person to 
commit to the plan. It further identifies main factors that have an impact on 
adherence and these are personal and environmental factors (NDOH 2010: 
17-18). These are listed below. 
 
In terms of personal factors, the following  issues are listed: ‘internalised 
stigma and external discrimination; denial of diagnosis; unresolved grief 
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reaction; lack of disclosure; guilt; alcohol and other substance abuse and/or 
addiction; mental illness and dementia’. 
 
Environmental factors include things like pill burden and side effects; income 
and food insecurity; negative staff attitudes; lack of training of staff; perceived 
lack of caring by health facility and staff; shift work and time off work to attend 
appointments. 
 
The focus of the guidelines, therefore, is on the treatment of the patient in a 
holistic manner which takes into account all factors that may either promote or 
inhibit adherence to antiretroviral treatment. 
 
2.7 CHALLENGES OF THE ART PROGRAMME 
 
The South African ART programme is one of the biggest programmes in the 
world and has brought a great deal of hope and improvement to the quality of 
lives of many people living with HIV and AIDS (UNGASS 2010). Despite the 
success of the programme, it is not devoid of challenges. A brief discussion of 
some of the identified challenges that may have an impact on adherence to 
ART in the long term follows. 
 
2.7.1 Retention of patients on treatment 
 
The biggest challenge facing the ART programme in Sub-Saharan Africa and 
South Africa specifically is the ability to initiate and retain people living with HIV 
on their treatment regimens (NDOH 2012; Rosen, Fox and Gill 2007: 1-20). 
There is strong evidence that many patients with chronic illnesses such as 
asthma, hypertension, diabetes and those living with HIV have difficulty 
adhering to their recommended regimens (WHO 2003:xiii). According to Paul 
Cook (as cited in Donohue & Levensky 2006:183) the summary of results from 
many years of research demonstrates that across many medical conditions 
50% or more of all patients stop taking their prescribed long-term medication 
within the first year of initiation. This could be due to a number of reasons 
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including the fact that patients have to submit to treatment for the rest of their 
lives, the number of tablets taken daily and co-infection with other chronic 
illnesses (WHO 2003:11). Geng, Nash, Kambugu, Zhang, Braitstein, 
Christopoulos, Muyindike, Bwana, Yiannoutsos, Petersen and Martin (2010) 
cite reasons such as stigma, ancillary costs associated with being on treatment 
and the fact that health care behaviours may be competing with other priorities 
that take precedence in the patient’s life. All these are likely to lead to non-
adherence and ultimately poor retention. From studies conducted by DiMatteo 
(as quoted in WHO 2006:28) over a period of 50 years on adherence to 
treatment for chronic conditions, adherence levels ranged from as low as 4.6% 
to 100%. Of all these studies, only 8 studies focused on adherence to ART and 
the mean adherence level in those was 88% in Sub-Saharan Africa which is 
below the 95% adherence rate as recommended by the World Health 
Organization (WHO 2005:12).  
 
The National Strategic Plan 2012-2016 (NDOH 2012) has as one of its main 
objectives ensuring that 80% of all eligible patients commence ART and that 
70% of those initiated be alive and still on treatment at the end of five years. 
According to Rosen, Fox and Gill (2007:1-20), ART programmes in Africa have 
only managed to retain approximately 60% of patients on therapy two years 
after initiation on therapy. In South Africa, the issue of retention on ART also 
remains a major challenge as evidenced in the following studies: 
 
 Thirty-two studies by Rosen, Fox and Gill (2007) in which the retention 
rate at two years of treatment is at 62% 
 Analysis of 33 studies by Fox and Rosen (2010) also reveals a retention 
rate of 72% at 3 years of treatment  
 A study conducted by Cornell (2010) in Khayelitsha, South Africa,  in 
which 3,595 adults enrolled in HAART over 5 years were analysed, 
revealed that the cumulative proportion of patients remaining in care at 
54 months after initiation on treatment was 78% (Geffen 2009) 
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2.7.2 High levels of loss to follow up and attrition 
 
Directly linked to the poor retention of patients on ART is the high rate of 
patients lost to follow up and attrition for various reasons. LTFU is particularly 
high within the public health system especially when referral to another facility 
is indicated (NDOH 2011:49). According to Bärnighausen (2008:141), attrition 
is measured as the proportion of patients who are lost to follow up, who die or 
stop ART whilst in care. From the two studies carried out in facilities around 
Johannesburg by Rosen, Fox and Gill (2007:1-20), it is evident that the largest 
contributor to attrition is loss to follow up with 56% of patients being lost as a 
result of attrition and 40% to death.  Rosen and Ketlhapile (2010:98) also 
established in a cohort study carried out from 2007 to 2009 that loss to follow 
up accounts for 59% of all reported attrition in the first year of treatment. Such 
a high rate of patients lost in care is an indication of challenges regarding non-
adherence to treatment which result in patients dropping out of the treatment 
programme. 
 
2.7.3 Epidemiological shift in the HIV disease burden 
 
Another major challenge facing the ART programme in South Africa and other 
developing countries is the changing nature of the disease prevalence. 
According to WHO (2003:23), the epidemiological shift in the HIV disease 
burden from an acute to a chronic illness has made the current health care 
models obsolete and ineffective in meeting the needs of those living with the 
HI-virus. 
 
With the launch of the ART rollout programme in 2004 according to the CCMT 
Operational Plan, the South African government aimed to provide 
comprehensive HIV care in an integrated manner so as to achieve universal 
access for all those eligible for ART (NDOH 2003). Despite the aim to deliver 
the programme in an integrated manner it was implemented as a vertical and a 
stand-alone programme (Uebel, Timmerman, Ingle, Van Rensburg & Molentze 
2010:589). It was not implemented as part of the Primary Health Care package 
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with all the other diseases attended at a clinic level. This may have given rise 
to what is referred to as HIV exceptionalism which promotes treating HIV 
infected people differently and the disease as being different from other 
chronic diseases (Cameron 2010:6). Uebel et al (2010:589) also contend, in 
their study conducted in the Free State, that this vertical approach may have 
contributed to the programme not achieving universal access to treatment for 
people living with HIV and eligible for ART as is evident. 
 
The vertical approach or model used to deliver health care services has the 
potential to affect the patients’ adherence to their treatment regimens with 
special reference to the following areas: 
 
(i) Availability of adequately trained staff 
Health care providers are an integral part of a successful ART 
programme and with relevant training they can promote an efficient and 
effective ART programme. Vawda and Variawa (2012) identify and 
attribute the challenge facing the ART programme to the shortage of 
adequately trained healthcare personnel. This can negatively impact on 
the patients’ ability to adhere to their treatment if they do not receive the 
desired support and guidance from health care providers. 
 
(ii) Level of on-going communication with  patients 
Lack of or poor communication between health care providers and 
patients can have an effect on the interaction and the treatment 
outcomes if patients feel that they are not supported. According to Van 
Dyk (2011) and Moola (2010: 16-17), one of the key challenges that 
people on ART are experiencing is the inability of or difficulty with 
communicating with health care professionals. This impacts on their 
adherence to their treatment. The NSP 2012-2016 (NDOH 2011:49) 
advocates on-going communication as it has been shown that for 
adherence to be achieved fully, there needs to be constant adherence 
messaging through various means such as daily adherence sessions at 
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a clinic level, community structures and the media playing a significant 
role in this. 
 
2.7.4 Scaling up of the number of people on ART 
ART is now recognised as a critical HIV and TB prevention intervention 
strategy. Evidence suggests that ART can help reduce the risk of HIV 
transmission sexually to an HIV negative partner (NDOH 2011). It also helps to 
minimise the likelihood of contracting TB whilst on treatment and this results in 
lowered TB incidence on the whole. To be able to achieve this, NSP 2012-
2016 (NDOH 2011:48) advocates the early initiation of HIV-infected people by 
‘scaling up the uptake and increase(ing) the number of people on ART by 
initiating at least 80% of eligible patients on ART and that at least 70% of those 
initiated on ART are alive and on treatment at the end of five years’. The 
strategic focus of the current NSP, compared with the previous one, is more on 
expanding the quality and reach of health and wellness, particularly on 
ensuring support to adherence and retention in care. Increasing quality, reach 
and the number of people on treatment also has its own challenges including 
the need for recognition of the value of testing and subsequent treatment and 
life-long commitment to ARVs. This is likely to have an impact on the process 
of initiating patients on treatment including adherence counselling and other 
important steps necessary to prepare, encourage and ensure adherence to 
ARV treatment. The proposed ‘test and treat’ strategy may also further 
influence adherence levels as more people will be initiated on ART without any 
counselling done if this is implemented. 
2.8 ADHERENCE VIS-A-VIS COMPLIANCE 
 
Adherence is the cornerstone of a successful ART roll-out programme. It can 
be defined as ‘the degree to which a client accepts an active role in following a 
treatment regimen which has been designed in a consultative partnership 
between the client and health care worker/ counsellor (NDOH 2010:6). 
According to Heyer and Ogunbanjo (2006:5), ‘close to perfect adherence is 
required to suppress a patient’s viral load to undetectable levels and prevent 
42 
 
the development of drug resistant viruses’. The South African ART Guidelines 
(NDOH 2004:53), on the other hand, state that ideal adherence means that 
patients must take more than 95% of their prescribed doses. This is equivalent 
to missing no more than three doses per month.   
 
WHO (2003:3) broadens the definition of adherence by referring to ‘the extent 
to which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes – corresponds to agreed recommendations from a 
health care provider’. This definition encompasses not only the act of taking 
the tablets but also the availability of an appropriate diet to complement the 
treatment regimen; the ability to adapt one’s eating patterns/habits and the 
practising of safer sex for the prevention of re-infection with the HI-virus. In 
terms of the South African ART Guidelines (NDOH 2004:53), if a person takes 
less than 95% of their doses, they are at a risk of developing virological 
resistance to the treatment and if they take less than 80% it is highly unlikely 
that the treatment will have successful outcomes. 
 
Sometimes the term adherence is used interchangeably with compliance and it 
is taken to mean the same thing. According to Donohue and Levensky 
(2006:4), the term adherence is now used more frequently than the term 
compliance. They assert that this shift came as a result of insights from health 
care professionals suggesting that compliance suggests passivity and 
obedience on the part of the patients whereas adherence implies patient-
provider collaboration and an active role of patients in developing their 
treatment programme. Compliance implies subservience by the patient and it 
constitutes some kind of blaming of the patient in case of non-compliance 
(Haynes 2001:4).  Munro, Lewin, Swart and Volmink (2007:104) assert that the 
term adherence is ‘a more neutral term than compliance which can be 
construed as being judgemental’. Compliance assumes that the patient is a 
passive participant who is not capable of making valuable inputs regarding his 
or her treatment. At the same time, compliance regards the health care 
professional as the expert in as far as treatment is concerned.  
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It is, therefore, important to differentiate between compliance and adherence 
for the purposes of this study. The main difference is that adherence requires 
the patient’s agreement with the recommendations from the health care 
provider (WHO 2003:4). Adherence implies that the patient is actively involved 
in the development of his or her treatment plan. It entails more than simply 
remembering to take one’s medication at the recommended time and 
considers the role played by social, cultural, economic and personal factors in 
adherence (Chabikuli, Datonye & Nachega 2010: 351). Adherence also implies 
that the patient is actively involved in the decisions regarding the issues such 
as whether to disclose his or her HIV status, the appropriate time to disclose 
and to whom, the appropriate and convenient time for taking medication, 
change of lifestyle and generally committing to lifelong treatment. In 
adherence, therefore, the patient has an opportunity to own the process, 
determine how it will progress and ensure positive treatment outcomes with 
the assistance of health care professionals. 
 
2.9 COMMON PATTERNS OF NON-ADHERENCE AND/OR POOR 
ADHERENCE 
 
Non-adherence to treatment involves ‘not taking medication at all, self-
adjusting doses so as to modulate side effects, prematurely terminating 
treatment, not honouring clinic appointments and not filling prescriptions’ 
(Kagee 2006:414). Poor adherence on the other hand refers to missing doses 
and taking medication inappropriately (Jean-Baptiste 2008:5). It implies not 
taking the treatment in the recommended dosage, at the recommended time 
and in the recommended way. Non-adherence may also involve not making 
other recommended behavioural changes and lifestyle adjustments like 
practising safer sex and stopping alcohol drinking and smoking. Non-
adherence to ART regimens may take many forms ranging from not initiating 
treatment when it is indicated; stopping treatment soon after initiation for no 
known reason; skipping some dose(s) and taking what is normally referred to 
as ‘medicine holidays’ when treatment is completely stopped, which may 
happen on a regular basis such as on weekends or holidays, to reducing or 
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increasing doses (Dunbar-Jacob 2004:8). In addition, Levensky and Donohue 
(2006:4) state that non-adherence includes instances in which the patient does 
not attend or comes late for clinic appointments and does not complete 
behavioural change recommendations. It is further stated that non-adherence 
also includes sharing of medication with other people which could be a spouse 
or other family members (Levensky & Donohue 2006:184). In this way the 
patient may end up running short of his/her medication and therefore become 
non-adherent. According to WHO (2003:118), some patients may self-adjust 
regimens because they experience side effects, toxicity or because of their 
personal beliefs. A number of factors may contribute to these different types of 
non-adherence which all have detrimental effects on treatment outcomes. 
 
2.10 FACTORS INFLUENCING ADHERENCE TO ART 
 
A wide variety of factors play a role in determining treatment adherence 
amongst patients who are on chronic medication, particularly ART. Enrolment 
in the ART programme is a lifelong commitment on the part of the patient 
which presents many challenges that may ultimately have an impact on 
treatment adherence. Sunil and McGehee (2007:84) assert that adherence to 
treatment is important as it decreases morbidity and mortality rates related to 
any chronic illness including HIV- and AIDS-related illnesses.  Non-adherence, 
therefore, can result in the development of treatment resistance and ultimately 
treatment failure (Erlen, Mellors & Lehman-Trzynka: 2004).  
 
South Africa is currently facing a major challenge in terms of maintaining and 
retaining patients on ART for a period after initiation (Rosen, Fox & Gill: 2007: 
1-20). In Africa the retention rates are estimated at 60% two years after 
initiation on treatment whilst studies conducted in South Africa in 2007 and 
2010 indicate a retention rate of 62% after two years of treatment and 72% 
after three years of treatment respectively. There is a close link between 
adherence and poor retention of patients on ART and this makes it necessary 
to develop an insight into the factors impacting on the phenomenon of 
treatment adherence.  
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A wide range of factors may contribute to patients being non-adherent 
regarding their medication and these could include psychological, social, 
cultural and economic factors. The National Strategic Plan (NDOH 2011:17-
18) group the factors that can impact on adherence into personal and 
environmental factors.  WHO (2003: 27) and Simoni, Amico, Pearson and 
Malow (2009:192), group the factors affecting adherence into the following 
categories:  
 health care-related factors, including the patient-provider relationship  
 socio-economic factors  
 condition-related factors, including factors related to the specific 
treatment regime   
 patient-related factors. These factors are discussed in greater detail 
below.  
 
2.10.1 Health system or care team-related factors 
 
These are factors that relate to the health care services provided, the health 
care system and the relationships between the patient and the health care 
professionals. In South Africa the identified factors impacting on adherence are 
the negative attitudes of staff, a perceived lack of caring by health facility and 
staff and lack of training of staff (NDOH 2011:17). The factors related to poor 
adherence include: 
 
 Poor communication between provider and patient. According to 
Oldridge (2001:337), improving provider communication skills is very 
important because patient adherence and outcomes depend to a 
considerable extent on good provider-patient communication. NSP 
2012-2016 (NDOH 2011:17) identifies negative staff attitudes and a 
perceived lack of caring by health facility and staff as factors that 
impact on adherence to treatment. The relationship between a patient 
and a health care provider is regarded as a crucial adherence mediator 
as it directly influences how the patient views the illness and how this 
will be treated (Frank & Duncan 2009:21) 
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 Exclusion of patients in decision making. In a study conducted with 18 
HIV-positive participants from two large clinics in Kansas City by 
Amico, Barta, Konkle-Parker, Fisher, Cornman, Shuper & Fisher 
(2009:66-75), it was found that adherence information exchange in a 
caring patient-provider relationship is a critical component for 
adherence mastery. Giving of adherence information alone is not 
enough to encourage behaviour change but showing positive regard 
and respect for the patients and their opinions can play a significant 
role in influencing adherence.  
 
 Inadequate follow-up and monitoring. For patients on ART, retention in 
care is crucial to ensure prevention of treatment interruptions, prevent 
development of drug resistance and to enable the monitoring of 
treatment efficacy (Geng et al 2010: 234-244). Evidence suggests that 
lack of adequate follow up and monitoring of patients on treatment can 
impact on retention in care and ultimately on treatment adherence 
levels. This is attributed to the high number of patients initiated on ART 
mainly and the shortage of staff within the public health sector (NDOH 
2007:21).  According to a study conducted by Cornell (2010) in 
Khayelitsha, South Africa, the number of patients on ART affected the 
ability of clinics to monitor and follow up on the non-collection of pills. 
This five-year study of the ARV treatment programme found that the 
rapidly growing number of patients on ARVs had put extra pressure on 
the health care system.  
 
 Inadequate training of health care providers (HCP). NSP 2012-2016 
(NDOH 2011:17) identifies lack of training of staff as one of the key 
challenges that impact on adherence to ART in South Africa. In a study 
conducted, 20% of ARV users even complained about not being 
adequately prepared for commencement of treatment by health care 
providers which could be due to lack of necessary skills and training on 
the part of HCP (Van Dyk: 2011).  Vawda and Variawa (2012) also report 
that HCP experience high stress levels owing to their demanding 
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working circumstances. A study cited in Vawda and Variawa (2012) 
found many reasons for the high levels of stress including the lack of 
support for and training of health care providers. This situation is even 
more serious in rural and informal settlements where there is a dire 
shortage of skilled personnel. Adequate training of staff is important to 
ensure that appropriate education and imparting of up-to-date 
information to patients is achieved. 
 
According to Chesney (2000:171), these system-of-care-related factors may 
be greatly influenced by dissatisfaction caused by past experiences of the 
health care system which may result in the avoidance of future encounters.  
 
2.10.2 Socio-economic factors  
 
According to Kagee (2006:415), social and economic factors may combine to 
yield poor adherence outcomes in South Africa especially for those living in 
poverty in circumstances in which there are limited or no financial resources to 
meet treatment requirements. On the contrary, however, Heyer and 
Ogunbanjo (2006:8) state that socio-economic factors are not consistently 
predictive of adherence. They assert that in studies carried out in India and 
South Africa no association was found between adherence and the patient’s 
economic status.  
 
A number of investigators relate the costs of accessing treatment at the level 
of the individual and his or her family to poor adherence outcomes. For 
example, Roura, Busza, Wringe, Mbata, Urassa and Zaba (2009:48) regard 
cost such as transport and waiting times as important barriers in addition to 
stigma, family pressures and religious beliefs. Hardon, Davey, Gerrits, 
Hodgkin, Irunde, Kgatlwane, Kinsman, Nakiyemba and Laing (2006), in a 
review of studies conducted in Tanzania, Uganda and Botswana conclude that 
although patients are highly motivated to adhere to their medication as 
prescribed, constraints such as transport costs, user fees, long waiting times, 
hunger, stigma and discrimination, lack of social support, side effects and lack 
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of appropriate counselling all undermine such intentions. Mukherjee et al 
(2006:124) also confirm that costs such as payment for transportation to and 
from clinics serve as a deterrent to ART adherence. They further state that the 
lack of adequate food has also been associated with poor adherence to ART. 
 
Socio-economic factors reported to have a significant impact on adherence are 
poor socio-economic status, poverty, illiteracy, low levels of education, 
unemployment, lack of effective social support networks, unstable living 
conditions, long distance from treatment centres, high costs of transport and 
medication, changing environmental situations, cultural and/or traditional 
beliefs about illness and treatment and family dysfunction (WHO 2003:28). 
Heyer and Ogunbanjo (2006:5-9), however, state that educational levels, 
literacy, income and housing status are not predictive of adherence. They 
report that from the 22 studies conducted; only 5 demonstrated an association 
between socio-economic factors and adherence. A study in Cape Town also 
found no association between socio-economic status and ART adherence 
(Orrell, Bangsberg, Badri & Wood 2003). WHO (2003:28), however, maintains 
that the socio-economic status of the patients is associated with adherence to 
treatment, because ‘in developing countries low socio-economic status may 
put patients in the position of having to choose between competing priorities’.  
 
Poverty can influence adherence because access to the financial means to 
travel to and from the ART clinic, to pay for child-minders during a parent’s 
absence to access treatment and to attend to several, competing needs and 
responsibilities all come into play (Simoni et al 2009:192; Kagee 2006:416). 
For the poor and the unemployed, lack of financial resources to pay for the 
kind of food stuffs required to be taken alongside medication may be of 
particular concern. Nevertheless, studies from several resource-poor countries 
demonstrate that high levels of adherence can be achieved, for example, in 
Rwanda (Demeester, Omes, Karasi, Schneider, Mugabo, Maliboli & Arendt 
2005:113-114), Haiti (Koenig, Leandre & Farmer 2004: 521-525), and Uganda 
(Weidle, Wamai, Solberg, Liechty, Sendagala, Were, Mermin, Buchacz, 
Behumbiize & Ransom 2006:1593).  
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According to the NSP (NDOH 2010:9) in SA, poverty is one of the major 
contributors to poor health and treatment outcomes through food insecurity in 
as far as HIV and TB acquisition and treatment adherence are concerned. The 
SA government, in order to support adherence through its social development 
department, introduced a chronic disease grant assistance for those HIV 
infected  who cannot support themselves and their families (NDOH 2007:114; 
ETU 2012). The qualification criterion for the grant is that an HIV-infected 
person must be too sick to work and when their health improves the grant is 
terminated (SASSA 2012). From a  study conducted in the Cape Peninsula, 
South Africa with 29 patients it was found that in order to keep their CD4 
counts low, some  manipulated the treatment so that their viral loads remained 
high (De Paoll, Mills &  Gronningsaeter 2012: 6). This is further attested to by 
Van Dyk (2011) as she  reports that a commonly cited reason for non-
adherence is the fear of losing one’s grant and that this  results in some 
patients  ‘managing‘ their CD4 counts by skipping some doses. This ensures 
that the viral load is not completely suppressed and this enables them to 
continue receiving the grant as long as there is no improvement in the CD4 
count. This can have devastating effects in terms of developing treatment 
resistance and treatment failure in the long run and the patient may end up 
with fewer treatment options. 
 
As far as social factors are concerned, WHO (2006:28) suggests that positive 
attitudes of the community towards people living with HIV play a significant role 
in influencing adherence. Adults on ART and receiving community-based 
support have been reported to be less likely to be lost to follow up. This was 
evident in a prospective cohort study which compared those receiving 
community-based adherence support and those not receiving the support. It 
was found that of the 19,668 patients only 6% of those receiving community-
based adherence support were lost to follow up compared with 9% of those 
not receiving any community-based adherence support (AIDSmap 2012).  
 
According to Campbell and Murray (2004:189), many key determinants of 
individual health are of a social nature, and as such the challenge facing the 
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health practitioners is that of changing not only individual patterns of behaviour 
but also that of the community and the social context that help sustain ill-
health. To create a health-enabling environment, therefore, requires 
participation in collective action that promotes community networks and 
collaborations capable of serving as a good source of social support, buffering 
individuals from the health-damaging effects of everyday stressors which may 
impact on the individual’s health. The emphasis is on creating a safe 
environment for marginalised social groupings such as those living with HIV 
and on ART and are, therefore, more susceptible to having adverse social 
conditions undermining their health. One such initiative was the introduction of 
lay counsellors and patient advocates which is an effective alternative to 
creating health-enabling communities for ART users (Campbell & Murray 
2004:189-190; Kagee 2006:416). The clinic based community outreach 
adherence support programme also introduced treatment advocates who 
helped with the scaling up of ART access, on-going adherence counselling 
and psychosocial support at a community level (AIDSmap 2012).   
 
A study conducted by Yoder, Mkhize and Nzimande (2009:70) in five different 
sites in KwaZulu-Natal on the experience of patients on antiretroviral therapy 
findings suggests that challenges such as the availability of a treatment 
supporter, adequate household income and side-effects are all determinants of 
adherence, non-adherence and/or ultimate drop-out from treatment. Another 
important social factor which is associated with adherence is the support of 
significant others in a patient’s life as they provide support and understanding 
for the patient. Heyer and Ogunbanjo (2006:6-7) confirm this by stating that the 
presence of social support systems such as supportive family members, 
friends and treatment supporters have been consistently associated with good 
adherence to treatment.  
 
2.10.3 Condition-related factors 
 
 Condition-related factors are the illness-related demands placed on the 
individual patient which require behaviour change (WHO 2003:30). These 
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include factors such as the severity of the illness, the rate of progression of the 
disease, level of disability if any, and the availability of treatment for such an 
illness. All these factors are likely to have an impact on the patient’s perception 
of the risk and therefore influence adherence or non-adherence to their 
treatment regimens.  
 
Co-infection with other illnesses also needs to be identified and treated as this 
may possibly affect adherence. It has been established that a high number of 
HIV-infected individuals will most likely be co-infected with TB because of 
compromised immune systems. South Africa is ranked as the third highest 
country in the world in terms of the TB burden which makes all HIV-infected 
individuals more susceptible to contracting this disease (NDOH 2012:13). STIs 
such as herpes simplex can also play a significant role in the acquisition of HIV 
which puts anyone with this infection at a high risk of contracting HIV. Co-
infection is, however, not only limited to STIs and TB but may include even 
depression, anxiety and other psychological illnesses. According to Brief et al 
(2004, as cited in Frank & Duncan 2009:21), post-traumatic stress disorder 
(PTSD) and depression have been generally associated with poor levels of 
adherence. Being afflicted with these illnesses at the same time may have an 
impact on adherence and may lead to pill burden or may even lead to fast 
progression in illness if adherence is not good.  
 
The fact that there is no cure for HIV and AIDS may also impact on the 
perceptions of the individual of the illness and the significance of taking 
antiretroviral therapy which may in turn impact on adherence levels. According 
to Mehta, Moore and Graham (1997:1669), patients’ knowledge of their 
diagnosis and acceptance thereof, and the expected course of the illness and 
treatment associated with increased adherence levels. 
 
2.10.4 Therapy-related factors 
 
These are factors that relate to the type of regimen that the patient is on and 
the factors associated with the regimen like side effects, schedule and other 
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requirements. According to Kagee (2006:415), regimen-specific factors include 
dosage, the requirement of eating specific foods, toxicity and the side effects. 
Mehta et al (1997:1667) suggest that therapy-related factors include the form 
of medication, the complexity of the prescribed regimen and the side effects. 
According to Van Dyk (2011), the most common regimen-related reason for 
non-adherence is the treatment’s side effects. This is evident in her study of 
patients on ART in which 60% of the patients studied experienced side effects 
at different points of their treatment span. Heyer and Ogunbanjo (2006:6) 
emphasise the importance of dealing with side effects effectively so as to 
prevent discontinuation of treatment.  They further state that the more complex 
the prescribed regimen, the more difficult it is for patients to adhere and 
incorporate it into their daily routine. The imminent introduction of the new 
triple fixed dose combination pill of ARV treatment from April 2013, however, 
will help to simplify the treatment regimen and greatly improve adherence 
levels for patients (Motsoaledi: 2012).  This will mean that patients do not have 
to take three tablets a day but can now take one tablet once a day.  
 
Understanding of one’s treatment regimen has also been associated with good 
adherence to treatment. Heyer and Ogunbanjo (2006:6) state that patients on 
ART who do not have a good understanding of the relationship between 
adherence, viral load and disease progression adhere significantly more poorly 
than those who understand these matters. It is crucial that patients understand 
how the treatment works and the impact that non-adherence or poor 
adherence will have on the viral load and treatment outcome. 
 
It is important to view the issues discussed here as therapy-specific factors in 
conjunction with the other factors that affect adherence and to understand that 
these factors are interrelated and may amplify the impact each has on 
adherence. In this respect Oldridge (2001:337) identifies factors such as 
waiting times at the health care facility, frequency of appointments and the 
continuity of care including issues of accessibility of the health care facility as 
having an impact on adherence to treatment. According to Simoni et al (2009: 
192), therapy-related factors extend to the dietary restrictions that may be 
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necessary for effective adherence to treatment, for example, having to take 
medication on an empty stomach or avoiding certain foods when taking 
medication. According to Kagee (2006:415), food required to be taken 
alongside medication may not even be easily affordable and money for 
purchasing adherence supporting tools such as alarms and diaries may not be 
available. In a comparative study conducted by Van Dyk (2011), it was found 
that 37% of non-adherent ARV users and 21% of adherent ARV users 
reported having insufficient food and this impacted on their ability to take their 
treatment fully. 
 
In South Africa poverty and food insecurity is still an issue of concern as it 
contributes largely to poor health which in turn promotes the  acquisition of HIV 
and TB and poor treatment adherence (NDOH 2012: 37). The situation that the 
majority of people live under is such that there is little or no household income 
and they are faced with many competing responsibilities and priorities such as 
providing food for the whole family instead of directing the limited money to 
travel fares to the clinic. This may hinder the acceptance and 
acknowledgement of the importance of adhering to treatment regimens for 
positive health outcomes.  
 
2.10.5  Patient-related factors 
 
In many studies undertaken on adherence, it seems that the most important 
factors affecting adherence are those that operate at the level of the individual 
patient (Chesney 2000:173). The most common patient-related factors include 
substance abuse/addiction (alcohol and drugs), mental illness and dementia, 
internalised stigma, feelings of guilt, denial of diagnosis and lack of disclosure 
(NDOH 2010:17). Chesney (2000:172) further identifies other factors relating 
to the individual patient like active substance abuse or addiction, active 
depression and anxiety, lack of self-efficacy and the age of the individual.  
 
According to Simoni et al (2009:192), patient-related factors include socio-
demographic factors and psychosocial factors such as active substance 
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abuse, active or acute psychological and/or psychiatric conditions and the level 
of social support they receive from their significant others. WHO (2003:30) 
states that patient-related factors represent the resources, knowledge, 
attitudes, beliefs, perceptions and expectations that the patient may have. The 
following five patient-related issues are discussed in greater detail below: 
substance abuse, active mental illness, self-efficacy, health literacy and 
general factors. 
 
(i) Substance abuse 
Alcohol and drug abuse has been directly linked to the inability to adhere to 
treatment regimens as it can affect the ability to remember taking one’s 
treatment when under the influence. According to Kalichman and Rompa 
(2003  as cited in Frank & Duncan 2009:21), substance abuse is perceived 
as a correlate of sexual risk practice in HIV-infected individuals and may 
serve as an indicator of health compromising behaviour including poor 
treatment adherence. 
 
(ii) Active mental illness 
Certain psychological states have been perceived as affecting the person’s 
level of adherence and these include high levels of emotional distress, 
depression, anxiety and psychotic episodes (Frank & Duncan 2009:21). A 
person suffering from depression normally has no interest in or desire to 
engage in any important life activities, let alone having to commit to taking 
medication on a regular basis for a life time.  
 
(iii)Self-efficacy 
Self-efficacy is the belief in one’s ability to successfully execute behaviour 
required for positive outcomes (Martin, Harskard-Zolnierek & DiMatteo 
2009:4). It has been found that higher measures of self-efficacy, that is, 
confidence in one’s ability to take all or most of one’s  medication, predict 
high levels of adherence (Chung et al cited in Frank & Duncan 2009:21). 
Linked to this is the feeling and belief that one has no control over the 
illness which may seriously hamper adherence. This is evident in a study 
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conducted by Van Dyk (2011) in which 44% of respondents believed that 
their health was in the hands of other people who were more powerful than 
they like their sexual partners and health care professionals. 
 
(iv) Health literacy 
The amount of knowledge and understanding that a patient has about his 
or her illness and the treatment has an impact on the level of adherence to 
the treatment regimens. According to Mehta et al (1997:1669), patients’ 
lack of knowledge of their diagnoses and the expected course of illness 
and treatment has been associated with decreased levels of adherence. 
 
(v)    General patient-related factors 
Other factors identified as impacting on adherence include: 
 
 Treatment fatigue and pill burden. According to Van Dyk (2011), 
having to take a number of pills as a result of co-infection with other 
illnesses such as TB and hypertension can result in fatigue and pill 
burden. This can result in patients adhering sub-optimally to their 
treatment. Some patients may also develop ‘treatment or pill fatigue’ 
after being on treatment for a long time and they may suddenly find 
it difficult to adhere to their recommended treatment regimens. 
Several research studies have reportedly shown adherence 
declining over time for people on long-term treatment and even with 
people who have been very successful in taking their medication 
(AIDSinfonet 2012). 
 
 Lack of disclosure, fear of stigma and discrimination (Van Dyk 2011; 
Kagee 2006:419). People living with HIV are often subjected to a 
great deal of stigma and discrimination which may result in their not 
being willing to disclose their HIV status for fear of being 
discriminated against.   
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 Cultural and religious beliefs (Kagee 2006:422) play a very 
significant role in shaping and  determining beliefs and values which 
may directly influence attitudes to treatment and adherence. 
 
 Forgetfulness and lack of planning (NDOH 2010:18; Van Dyk 2011). 
These factors may be manifest when the patient attends social 
functions on weekends or is away from home and no provision has 
been made in terms of having adequate treatment available. 
 
 Lack of adequate financial resources and food insecurity (NDOH 
2010:18) is cited as one of the major problems experienced in South 
Africa. This may result in the lack of money for transport to attend 
clinic, money for food to take with the medication and this can affect 
adherence. 
 
Over and above all of these factors, the individual’s motivation, 
determination and an ability to manage his or her illness, available 
resources and support systems, understanding of possible consequences 
of non-adherence and expectation of positive treatment outcomes all 
interact to impact on adherence.  
 
2.11 ASSESSMENT AND MEASUREMENT OF ADHERENCE 
 
Adherence to ART can be measured in two ways: namely, through subjective 
and objective assessments. Accurate measurement of adherence can be very 
difficult and can only be estimated by use of indirect measures (WHO 2006: 
27). Subjective measurements include self-reported adherence by patients 
(Levensky & Donohue 2006:5). Objective measurements are done through pill 
counting, tests such as CD4 count, viral load and clinical presentation of the 
patient.  
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2.11.1 Subjective assessment 
 
Subjective assessments mainly refer to patients’ self-report of adherence 
during their clinic appointments or visits. According to WHO (2003:96), the 
main shortfall of this method of adherence measurement is that patients tend 
to over-exaggerate their self-reported adherence. This could be due to both a 
recall bias and a desire to please the health care provider or to avoid criticism.  
Consequently, this may lead to a significant underestimation of the adherence 
levels within a particular population. Dunbar-Jacob (2004:9) states that a 
number of issues influence patients’ self-reporting of adherence. These include 
factors such as the structure of the self-report measure; the tendency to report 
only what is regarded as ‘good behaviour’ and a failure to remember certain 
events.  
 
2.11.2 Objective assessment 
 
Objective assessment or measurement includes methods such as pill 
counting, audits of pharmacy refill records, tests such as CD4 count and viral 
load and the clinical presentation of the patient. Methods like pill counting can 
sometimes be an inadequate measurement tool as some patients have been 
known to dispose of their medication prior to a scheduled appointment or clinic 
visit in order to appear adherent (WHO 2003). The CD4 count and viral load 
are also referred to as biological indicators of the level of adherence as they 
test the blood to determine levels of adherence.  According to Dunbar-Jacob 
(2000:9), the biological indicators may also prove to be inadequate as a 
measure for adherence. The ineffectiveness of biological indicators in 
measuring adherence could be due to the influence that the adequacy of the 
treatment regimens, treatment interactions with other drugs, metabolism of 
drugs and other individual characteristics may have on them. 
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2.12  MODELS OF HEALTH-SEEKING BEHAVIOUR 
 
A wide variety of theoretical approaches are used to explain and predict 
patients’ health-seeking behaviour patterns in as far as taking of medication for 
chronic illnesses such as HIV is concerned.  These theoretical approaches 
largely originate in the fields of social psychology and sociology and they 
explain factors that may promote adherence or non-adherence to ART.  
According to Haynes (2001:13), theories from psychology can provide a basis 
for understanding why certain behaviour change strategies work and others do 
not. He further states that adherence interventions can be broadly categorised 
into three categories, that is, cognitive, behavioural and social support.  
 
In this study, the researcher adopted three theoretical models based on this 
categorisation: namely, the Health Belief Model (HBM), Social Learning or 
Cognitive Theory and the Information Motivation and Behaviour (IMB) Model. 
These approaches all attempt to offer explanations for what motivates patients 
to seek health-promoting behaviours and to adhere to their treatment 
regimens. These models enabled the researcher to identify the factors that are 
potential barriers to treatment adherence. According to Simoni et al (2009: 
193), these theoretical models seek to identify a collection of constructs that 
influence adherence and assist in understanding the manner in which all these 
constructs co-exist and influence one another. These models are discussed in 
detail hereunder. 
 
2.12.1 The Health Belief Model (HBM) 
 
The HBM was first introduced in the 1950s by a group of American social 
psychologists in order to understand human behaviour in relation to health 
matters. It was updated in the 1980s. It attempts to explain and predict health 
behaviours through examining and understanding attitudes and beliefs of 
individuals regarding long-term treatment.  HBM has also been used to explain 
change and maintenance of desired health-related behaviour changes (Janz et 
al 2002 as cited in Moola 2010:30). According to Masokoane (2009:21), the 
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HBM posits that the perceived benefits of a healthy lifestyle will more likely 
encourage people to follow positive health regimens so as to achieve positive 
treatment outcomes.   
 
The HBM focuses primarily on beliefs as motivators of health behaviour 
(Martin et al 2009:3). The model is based on four key tenets that are discussed 
below.   
 
(i) Perceived benefits of the recommended health action 
 
This refers to those aspects of an action that the individual perceives as a 
possible benefit should he or she follow a recommended health action. The 
perceived benefits can be of a physical, social or a psychological nature. 
According to Hayden (2009:32), this is the person’s opinion of how valuable or 
useful a new behaviour can be in reducing the risk of likely infection, morbidity 
or mortality from a disease.  It is the belief in the effectiveness of strategies 
designed to reduce the threat of illness and the benefit that can be derived 
from engaging in recommended behaviours. The premise here is that people 
who are on ART and have a good understanding of what positive changes the 
treatment will bring about physically and otherwise are more likely to adhere to 
their regimens. This can be an incentive for them to be adherent so as to 
achieve the possible positive health outcomes like an improved CD4 count, 
decrease in viral load and a general improvement in their health. The basic 
principle is that for the behaviour to be undertaken the patient must evaluate 
the benefits of the recommended change as more valuable than the action 
required. 
 
(ii) Perceived barriers to the recommended health action 
 
This refers to the perceived negative and detrimental circumstances that will 
prevent the patient from taking the recommended health action. These 
negative consequences may include social, psychological, economic and even 
physical expectations or demands on the individual. This is an individual’s 
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evaluation of the perceived obstacles that can prevent them from adopting a 
new behaviour (Hayden 2009:33). The recommended action may not be taken 
even if a person believes that the benefits of taking action will yield positive 
outcomes if there are perceived barriers. Barriers are regarded as those 
situations that prevent or discourage the patient from taking recommended 
action. The recommended behaviour change may be perceived as 
inconvenient, painful or unpleasant and may be even costly for the patient to 
undertake. In ART adherence over and above taking all dosages in the 
recommended manner, patients are required to practise safer sex and to adopt 
a healthier lifestyle. Adopting a healthier  lifestyle may require that the patient 
at least have the financial resources to be able to meet this and it may be a 
barrier if he/she is unemployed and has no other source of income (NDOH 
2010:18). Practising safer sex requires that the patient understand the link 
between infection and hyper-infection and unsafe sex and be sufficiently 
motivated to change his or her behaviour accordingly.  In addition, it may also 
depend on the individual’s bargaining power in intimate relationships to 
negotiate for and adopt safer sex practices.  
 
(iii)  Perceived susceptibility to the disease or the consequences of 
not adhering to treatment 
 
This refers to the perceived vulnerability to or risk of being infected with a 
particular illness or disease and the consequences that may come about as a 
result of not taking the recommended health action. The individual’s subjective 
belief that they may be vulnerable to contracting a certain disease may deter 
them from engaging in certain behaviours or spur them on to actively seek 
healthier behaviours like adhering to their treatment if already infected (Kagee 
2006:420). In ART adherence the belief that the risk of non-adherence may 
result in treatment failure, development of drug resistance and a possible  
progression from being infected with the HI-virus to the AIDS stage may be a 
deterrent to the patient engaging in unhealthy behaviours (Evian 2011:465). In 
a study by Chung et al (2002: 301-310 as cited in Frank & Duncan 2009:21) it 
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was observed that a strong belief in the development of resistant HIV strains 
as a result of non-adherence served as a positive motivator for adherence. 
 
(iv) Perceived severity of the disease 
 
This refers to the feelings that individuals may have regarding the seriousness 
of having or contracting a particular disease and the seriousness of 
consequences that may result from not adhering to their treatment 
(Rosenstock, Strecher & Becker 1988:177). These negative consequences 
can be either physical, that is, deterioration in health condition (Kagee 
2006:420) or social consequences which may mean being unable to perform 
one’s social tasks like holding a job and providing for one’s family as a result of 
ill-health. 
 
Although positive perceptions of benefits and a minimisation of the barriers to 
healthy behaviours induce the preferred health action, an individual still 
requires some triggers or stimuli which will promote taking action. These are 
referred to as ‘cues to action’ and ‘self-efficacy’. Hayden (2009:33) states that 
cues to action can be people, events or things that move people to take action 
so as to change their behaviour. Wekesa (2007:8) explains the cues to action 
as ‘internal and external factors which influence action e.g. mass media, family 
and symptoms of illness’. Self-efficacy, on the other hand, is the belief in one’s 
ability to successfully execute behaviour required for positive outcomes (Martin 
et al 2009:4). 
 
In terms of ART adherence the basic assumption of HBM is that a person who 
believes that HIV and AIDS are severe diseases, sees more benefits in  being 
on treatment than barriers and has confidence in his or her ability to take 
medication even under difficult circumstances (Wekesa 2007:8). The 
researcher included questions about the perceived benefits and barriers of the 
recommended health action, cues to action and self-efficacy in the instruments 
used in the study.   
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The major shortfall of HBM is that it places greater emphasis on the 
individual’s perceptions and feelings about the illness and the recommended 
health action at the expense of other factors such as the environment, social 
and economic factors. Moreover HBM portrays individuals as social economic 
decision makers, making its application to health issues related to sexual 
behaviour limited (Sheeran & Abraham 1996). For example, condom 
promotion for safer sex that is only directed at women will have a minimal 
impact as women do not have autonomous control over their sexual 
encounters (MacPhail & Campbell 2001:1614). 
 
 
Figure 2.1: A depiction of the major tenets of the Health Belief Model 
(Adapted from Martin et al 2009) 
 
2.12.2   Social Learning or Social Cognitive Theory 
 
According to the social cognitive theory, human behaviour can be defined as a 
three dimensional interaction of three significant factors: namely, personal 
factors, behaviour, and the environment.  In other words, behaviour change 
can be influenced largely by any one of the three factors. People learn by 
observing others, with the environment, behaviour, and cognition all as the 
chief factors in influencing development. 
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Martin et al (2009:16) state that social learning theories posit that both 
personal expectancies and environmental factors (e.g. reinforcements) 
determine behaviour, and that modifying either of these two factors can result 
in behavioural change. According to Rosenstock, Strecher and Becker 
(1988:176), social cognitive theory, which has been relabelled as social 
learning theory, holds that behaviour is determined by expectancies and 
incentives. Expectancies include three main components: namely, 
expectancies about environmental influences, expectancies about the 
consequences of one’s actions and expectations about one’s competence to 
perform the behaviour needed to influence the outcome. Incentives on the 
other hand refer to the ‘value of a particular object or outcome’ (Rosenstock et 
al 1988:178). This can be referred to as the gain or benefit derived if a 
particular behaviour is performed. 
 
The key principle of the social cognitive theory is the concept of self-efficacy. 
This implies that a person has to believe that they have the ability to perform a 
particular behaviour and expect to have a positive and desired outcome as a 
result of the behaviour. In addition there must be a perceivable incentive and 
benefit for the person to perform the behaviour. Self-efficacy can be improved 
upon in several ways, amongst them by providing clear instructions, providing 
the opportunity for skill development or training, and modelling the desired 
behaviour. Rosenstock et al (1988:180) cite two major ways of improving or 
increasing self-efficacy: namely, through vicarious experience and verbal 
persuasion. In vicarious experience the person observes successful and 
unsuccessful behaviours of others and learns from those performances. This is 
equivalent to peer counselling amongst patients and the support groups that 
patients attend in order not only to support one another but also to learn from 
other patients’ experiences. Verbal persuasion is mostly used in health 
education programmes to teach a person the best action to take for behaviour 
change. In ART programmes this can refer to the adherence counselling 
process through which patients are taught about the treatment, possible side 
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effects, expected outcomes of the treatment and strategies and techniques 
that can be applied so as to ensure adherence to treatment regimens. 
 
The Social Learning Theory attempts to predict health behaviour by assuming 
that health is influenced by behaviour and that behaviour is modifiable (Conner 
& Norman 1996). Such assumptions imply that individuals are rational decision 
makers who are able to systematically review available information to derive 
intentions from this. This renders health decision making a cognitive process 
whilst ignoring the role played by the complex social contexts in moulding 
people’s decisions and behaviour.  
 
2.12.3 The Information Motivation and Behavioural Skills (IMB) Model 
 
According to Martin et al (2009:19), the basic principles underlying the 
Information Motivation Strategy Model (IMB) are that before a person can 
achieve health behaviour change, that person must know the change that is 
necessary (information); have the desire to change (motivation); and have the 
necessary tools to achieve and then maintain the change (strategy). The IMB 
model suggests that having the necessary health-related information and 
knowledge, the motivation and appropriate skills to apply the information 
gained will largely determine whether the health behaviour will be performed or 
not. This model of adherence addresses information about adherence and the 
motivation to maintain adherence that includes personal and social motivations 
and the necessary behavioural skills for adhering to ART. According to Simoni 
et al (2009:194), the IMB model  
 
proposes that ARV adherence is a function of one’s fund of accurate 
regimen-specific information, social and personal motivation, and 
adherence related behavioural skills, which is further considered in 
relation to the relative presence of moderating factors such as 
homelessness, or depression.  
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The information component of the model may include health knowledge, 
beliefs and the ability to remember what to do to ensure adherence. Motivation 
on the other hand refers to attitudes, feelings, confidence and expectations, 
amongst others. Finally, the strategies refer to both physical and social tools 
such as time, financial resources and the social support of family and friends 
(Martin et al 2009:20). 
 
This model also considers situational and individual characteristics such as the 
ease or difficulty of access to medical care that can affect the relationship 
between IMB model constructs and adherence behaviour (Amico, Barta, 
Konkle-Parker, Fisher, Cornman, Shuper & Fisher 2009:67). In terms of ART, 
this model holds that people living with HIV who are well informed, motivated 
to act and possess the necessary behavioural skills that enable them to act 
effectively, will adhere to the ART programme (Fisher, Fisher, Amico & 
Hamann 2006). There are, however, other factors such as personal and 
situational factors which may have a bearing on whether the patient adheres to 
treatment or not. An individual’s unique experiences, beliefs and personal 
attributes influence his or her responses to new information, to environmental 
reinforcements, to motivational messages, and to all of the other things that 
are potential triggers for behavioural change. There is always an interaction 
between personal factors and environmental factors which determine whether 
behaviour change happens or not. Despite having the knowledge or 
information, the motivation and skills necessary to perform the behaviour, the 
individual and situational factors such as disclosure of one’s status, one’s 
beliefs and past experiences and the support of family members, accessibility 
of the health facility, reliable transport system and/or affordability thereof can 
all have a bearing on whether the patient adheres to his or her treatment. The 
implication for health care professionals is that developed health care 
intervention programmes should be such that they take into account even 
personal and situational factors for them to be effective. Figure 2.2 illustrates 
how the four factors can lead to treatment adherence.  
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Figure 2.2.  A depiction of the major tenets of the Information Motivation 
Strategy Model 
(Adapted from Pomeroy et al 2007) 
 
 
2.13  CONCLUSION  
 
In this chapter, HIV and AIDS both in Sub-Saharan Africa and South Africa as 
well as the ARV programme in SA and its challenges were discussed. The 
concept of adherence was also defined in relation to compliance. The common 
patterns of non-adherence were also identified and discussed and how these 
can be measured. An overview of the different theoretical approaches to health 
behaviour change was presented. In the next chapter the research 
methodology and design utilised in this research will be discussed in detail. 
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 Behavioural Intent  
Adherence Behavioural Skills 
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CHAPTER 3: RESEARCH METHODOLOGY 
 
3.1 INTRODUCTION 
 
This chapter is dedicated to the description of the research methodology used 
in the research starting from the research design and the approach used; 
sampling, data collection, analysis and interpretation thereof. Ethical 
considerations and issues of rigour, trustworthiness in qualitative research and 
reliability and validity in quantitative research are all outlined in detail. The 
process of gaining permission to access is also discussed.   
 
3.2 RESEARCH DESIGN 
 
The researcher used a two-phased research design in which the first phase 
was a quantitative survey design and the second phase a qualitative focus 
group discussion design. According to Mouton (2001:55), research design can 
be defined as ‘a plan or blueprint of how one intends to conduct research’.  
 
Babbie and Mouton (2001:80-81) identify three most important purposes that 
different researchers may have when undertaking research and these are 
exploration, description and explanation. The approach adopted in this study 
was the use of both a qualitative and a quantitative research design and it had 
two distinct phases. In the first phase of the study the researcher collected 
data through the survey interviews with patients identified through their case 
files.  The second phase entailed the use of qualitative methods such as focus 
group interviews and face-to-face interviews with key informants that included 
lay counsellors, a pharmacist assistant and a social worker. In both phases the 
orientation was to obtain data that would meet the goals of description and 
exploration of the topic. Each of the two phases is discussed in greater detail 
below. 
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3.2.1 The quantitative phase 
 
Quantitative research is aimed at determining the extent of something or 
detecting the relationship between variables within a particular population by 
managing and presenting data numerically. Taylor (2005:235) states that it is 
designed to provide objective descriptions of phenomena and how these can 
be controlled. According to Grinnell (2001:91), quantitative studies seek to 
answer research questions about quantity. In this study the researcher utilised 
two sources of data: namely, the patients’ case files and survey questions 
posed to a sample of patients in a face-to-face interview. The case files were 
studied in order to obtain demographic details such as age, gender, level of 
education and employment status with the aim of gaining a clear profile of the 
units of observation  and this was, therefore, descriptive in nature. 
 
3.2.2 The qualitative phase 
 
Monsen and Van Horn (2008:65) define qualitative research as any data-
gathering technique that generates open-ended, narrative data or words rather 
than numerical data or numbers. It tends to be exploratory and descriptive in 
nature and is designed to develop an understanding of individuals in their 
natural environment. According to Dawson (2002:14), this method explores 
attitudes, behaviour and experiences through such methods as open-ended, 
face-to-face interviews and focus groups. In this study of socio-economic 
factors influencing adherence to treatment, data were collected using a focus 
group which built on the information collected from the survey interviews. 
Qualitative research typically focuses on having smaller samples owing to the 
nature of data that are rich in description collected (Crabtree & Miller 1999:34). 
 
3.2.3 A descriptive study 
 
Descriptive studies seek to ‘define and describe social phenomena of interest’ 
(Grinnell 2001:28; Rosnow & Rosenthal 2005:1). The aim of this type of study 
is to describe a social phenomenon, the factors associated with that 
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phenomenon and to state the nature of those factors or actions. In this study 
the aim was to describe who the patients were; what their social circumstances 
were; capture their understanding of adherence; and the factors that lead to 
non-adherence.  
 
3.2.4 An exploratory study 
 
According to Babbie & Mouton (2001:790), the main goal of exploratory 
studies is to explore a new area of interest or topic so as to gain an insight and 
familiarity with it. Exploratory studies usually lead to greater insights and 
comprehension of the phenomenon but may not necessarily provide ‘detailed, 
accurate and replicable data’ (Babbie & Mouton 2001:80).  
 
3.3 THE STUDY POPULATION 
 
The target population for this study comprised of people living with HIV and 
meeting the following eligibility criteria for the survey part of the study: 
 Participants had to receive treatment from Shongwe Hospital, 
Mpumalanga 
 Participants should  have been on ART for a period of at least 12 
months prior to commencement of the study 
 Participants had to reside within the catchment area of Shongwe 
hospital  
 
3.4  SAMPLING STRATEGIES FOR THE STUDY 
 
According to Grinnell (2001:207), ‘sampling is defined as the selection of some 
units to represent the entire population (set) from which the units were drawn’.  
With non-probability sampling, the probability for the participant to be selected 
cannot be estimated and is therefore not known (Grinnell 2001:215). There is 
very little or no assumption that the sample will be representative of the larger 
population and as a result the findings cannot be generalised. In purposive 
70 
 
sampling the researcher uses his/her own judgements when selecting possible 
participants for the study (Grinnell 2001:216).  
 
3.4.1 Sampling strategies for the quantitative phase 
 
A non-probability, purposive sampling technique was chosen. The researcher 
undertook a retrospective review of 50 patients’ case files to find those cases 
already identified as defaulting on treatment, or having missed one or more 
clinic appointments, or as having a high viral load despite having been on 
treatment for the past 12 months. This formed a sampling frame of potential 
defaulters. From these case files it was possible to identify characteristics such 
as the ages, genders, marital status, employment status, and disclosure status 
of these patients. Using this method the researcher could, out of the 50 case 
files, identify 35 patients that fitted the eligibility criteria as listed under sub-
heading 3.3 above and who were traceable for inclusion in the survey part of 
the study. Of the 35, only 28 patients were willing to participate in the study. 
Igumbor, Scheepers, Ebrahim, Jason and Grimwood (2011) also used 
retrospective patient files to conduct their study on ART adherence, but they 
used only the patients’ records as their primary data and did no additional 
data-generation.  
 
3.4.2 Sampling strategies for the qualitative phase 
 
The participants for the focus group interviews were purposefully chosen as 
two groups of patients fitting the eligibility criteria listed earlier in the chapter 
and visiting the hospital on two separate days.  The researcher identified and 
approached those attending the clinic and only nine participants volunteered to 
participate in the two focus group discussions. The participants for the key 
informant interviews were purposefully chosen as the key staff rendering 
services to the patients.  
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3.5 INSTRUMENTATION 
 
The development of the research instruments was largely informed by the 
reading and preparation done during the research proposal writing phase. The 
first draft of the questionnaire was submitted to the supervisors for their 
comments after which amendments and revision of the same were done 
accordingly. The instrument was also pre-tested with five patients from the 
Thembalethu Clinic (which is outside of the study area). Because these five 
respondents did not fit the eligibility criteria, their responses were only used to 
test the questionnaire and were not included in the analysis. The final 
questionnaire (see Annexure 3) has three distinct sections which focus on:  
Section A: Biographical information (the veracity of this was checked against 
the patients’ files) 
Section B: Socio-economic factors 
Section C: Treatment and adherence factors 
 
The questionnaire comprised closed and structured questions in sections A 
and B of the questionnaire and open-ended questions in section C.  
 
The qualitative phase of this research involved the conducting of focus group 
discussions in order to collect contextual data about the meanings that patients 
attach to adherence (Walliman 2011). Babbie and Mouton (2001:292) state 
that focus group discussions can be used to obtain information that one would 
not otherwise be able to access. According to Liamputtong (2011:5) focus 
group discussions are an ideal way of exploring people’s stories, experiences, 
points of view, beliefs, needs and their concerns. This method allows the 
participants to interact with others who are in a similar situation and can share 
their own views in their own way without necessarily agreeing with them.  The 
researcher developed a guide for the discussions that was informed by the 
questionnaire used in the quantitative phase of the study.  In particular, the 
researcher guided the respondents to explain the conditions and/or 
circumstances they thought could either promote and encourage or discourage 
adherence to treatment.  
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3.6 DATA GENERATION STRATEGIES 
 
For the quantitative phase of the study, the researcher opted for a survey 
approach using a structured questionnaire applied to 28 face-to-face 
interviews. This phase took place from 5 to 9 September 2011 and each 
interview lasted 20 to 30 minutes. The researcher explained in detail the 
objectives of the study, issues of confidentiality, privacy and anonymity; 
voluntary participation and the need to record all the proceedings. Formal and 
written consent was obtained from eligible patients before they were 
interviewed. Interviews were held with individual participants in an office that 
the researcher was allocated by the facility. The interviews were conducted in 
English and siSwati and IsiZulu for those respondents who were not 
conversant in English. 
 
The second phase of the study was the focus group discussion in which nine 
participants were involved. Babbie and Mouton (2001:292) suggest that it is 
always a good idea to over-recruit at least by 20% to compensate for those 
participants who do not show up. The researcher learned a valuable lesson as 
for the first focus group discussion only two persons arrived and the planned 
group meeting had to be cancelled and rescheduled. Eventually two focus 
group discussions could be conducted, consisting of four and five members 
respectively.  
 
The researcher also conducted interviews with the three different informants 
who work closely with the patients on a daily basis and could provide valuable 
insight into the issue of non-adherence. These discussions were held on 6 
September 2011.  
 
(i) Social worker 
 
The social worker is tasked with the responsibility of tracing all patients who 
are either defaulting and/or are non-adherent regarding their treatment. It was, 
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therefore, logical for the researcher to interview her so as to gain more insight 
into the phenomenon from a service provider perspective. 
 
(ii)  Lay counsellors 
 
The researcher also interviewed two lay counsellors who were allocated to do 
adherence counselling at the ARV clinic. They were in a position to provide 
insights into what they considered to be factors influencing non-adherence. 
 
(iii) Pharmacist assistant 
 
Every patient on ART has to go to the pharmacy at each regular clinic visit to 
receive their medication. The treatment refill records are normally a good 
indicator of adherence or non-adherence to treatment. The pharmacist or 
pharmacist assistant usually interviews patients to find what the reasons for 
their non-adherence are. The researcher conducted an interview with the 
pharmacist assistant as there was no pharmacist at the hospital during the 
time of data-gathering.  
 
3.7 ETHICAL CONSIDERATIONS 
 
The basic considerations when conducting social research involve recognising 
and making ethical choices, making principled decisions,  ensuring 
confidentiality and obtaining informed consent from participants whilst 
maintaining research integrity (Babbie & Mouton 2001:520-528). This is done 
in order to minimise any possible harm and distress that may be caused 
through participating in the survey (Curtis & Curtis 2011:160).  Ethical 
considerations in this study included gaining permission to access research 
participants' and patients’ case files from the Mpumalanga Provincial 
Department of Health Research and Ethics Committee, The Higher Degrees 
Committee of the Department of Sociology, University of South Africa (UNISA) 
and obtaining consent from the participants. 
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3.7.1 Permission to access the study population 
 
It is very important for a researcher to obtain permission to access any study 
population. In many cases the researcher will have to negotiate access to the 
facility or the participants with a number of gatekeepers (Henn, Weinstein & 
Foard 2006: 178).  It is even more crucial when the subjects of the study are 
patients and ethical issues may potentially arise during research study. Prior to 
conducting this research, the researcher sought ethical clearance from the 
Department of Sociology; University of South Africa and it was obtained on 11 
March 2011 (see Annexure 6). 
 
The researcher then proceeded to request permission from the Mpumalanga 
Provincial Department of Health Research and Ethics committee and Shongwe 
Hospital where the study was to be undertaken. The hospital was not in a 
position to grant permission and the researcher was referred back to the 
Mpumalanga Provincial Department of Health. The application was made in 
April 2011 and was only granted on 24June 2011 (see Annexure 7).  
 
3.7.2 Informed consent 
 
Informed consent implies that the researcher makes participants aware of what 
the research study is all about and the processes that will be followed so that 
they are in the best position possible to make informed decisions regarding 
participation (Curtis & Curtis 2011:16). In this study informed consent was 
obtained from each respondent prior to conducting the survey interviews, the 
focus group discussions and the individual interviews with the key informants. 
The process involved the researcher explaining verbally to each respondent 
and participant the objectives of the study and assuring them of anonymity and 
confidentiality, emphasising that participation was voluntary.  Consent forms 
were signed for this study by both the respondents and the researcher (see 
Annexure 2).  
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3.7.3 Voluntary participation 
 
The researcher explained and emphasised that participation was voluntary and 
participants could choose to withdraw at any point with no penalty or even 
decide not to participate at all without any repercussions for them. During this 
study seven of the patients selected for the survey opted not to participate in 
the study.  
 
3.7.4 Confidentiality 
 
Confidentiality refers to protecting and not sharing any personal information of 
the respondents without their consent (Henn, Weinstein & Foard 2006:85). In 
this study the names and identity of all participants were kept confidential. 
Instead of names, the researcher used codes in order to link each completed 
questionnaire with the correct patient file. The list of codes was kept under lock 
and key and only the researcher had access to it. The patients’ files were 
returned to the hospital. The completed questionnaires and the notes taken 
during the focus group interviews and the key informant interviews and all 
signed consent forms were kept in a locked cupboard by the researcher. This 
material will be shredded five years after the degree has been conferred. 
 
3.8 RELIABILTY AND VALIDITY IN QUANTITATIVE RESEARCH 
 
According to David & Sutton (2011:266), reliability is ‘the degree to which the 
indicator or test is a consistent measure over time’. On the other hand, validity 
refers to ‘the degree to which a measuring instrument actually measures and 
describes the concept it was designed to measure’ (David & Sutton 2011: 
268). 
 
3.8.1 Reliability  
 
Reliability is the extent to which observations when repeated under the same 
circumstances still produce similar findings. This means being able to obtain 
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consistent results from the same measure over time (Babbie 2010:155). To 
ensure reliability in this study the researcher pre-tested the data collection 
instrument so that when it was used in the main study it was more appropriate 
and reliable. The coding of the responses was checked by the supervisors who 
also verified the accuracy of the data entry on the computer. The biographical 
details of each of the 28 respondents were verified against the patients’ case 
files.  
 
3.8.2 Validity 
 
According to Galofshani (2003:599), validity refers to whether the means of 
measurement are accurate and whether they are actually measuring what they 
are intended to measure. It means getting the results that accurately reflect the 
concept it was intended to measure in the first place ( Babbie 2010:155).  The 
goal of this particular study was to investigate the social context of people 
living with HIV who are on ART so as to identify contributing factors to 
adherence or non-adherence. The question items included in the survey 
questionnaire were developed from a review of the literature. This instrument 
was pre-tested at the Thembalethu clinic, Johannesburg.  
 
3.9 TRUSTWORTHINESS OF THE DATA GATHERING FOR THE 
QUALITATIVE PHASE OF THE STUDY  
 
 According to Babbie and Mouton (2001:276), the key principle of good 
qualitative research is found in the trustworthiness of its findings.  According to 
Dzindza (2007:76), four aspects need to be considered to ensure 
trustworthiness of research findings and these are credibility, transferability, 
dependability and confirmability.  
 
3.9.1 Credibility 
 
This refers to the extent to which the researcher has established confidence in 
the findings of his/her study. According to Babbie and Mouton (2001:277), 
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credibility asks whether there is any correlation between the constructed 
realities in the respondents’ minds and what is being attributed to them by the 
researcher. A researcher can ensure credibility in different ways and in this 
study the researcher used prolonged engagement through spending as much 
time with respondents as possible and establishing a trusting relationship with 
them as proposed by Padgett (1998:94); audio recording the focus group and 
key informant interviews and triangulating different data sources to ensure 
credibility of findings (Dzindza 2007:76).  
 
3.9.2 Transferability 
 
According to Babbie and Mouton (2001:277), transferability refers to ‘the 
extent to which the findings can be applied in other contexts or with other 
respondents’. In this study the sample size was small and, therefore, it cannot 
be claimed that it was representative of the total population. The researcher 
ensured transferability through the use of thick description of data collected 
and reported it accordingly. The researcher also used purposive sampling so 
as to maximise the nature and range of information that can be obtained 
(Babbie & Mouton 2001: 277)  
 
3.9.3 Dependability  
 
According to Dzindza (2007:77), dependability considers whether the findings 
would be consistent if the inquiry were to be replicated with the same subjects 
or in a similar setting. Grinnell (2001:533) states that dependability refers to 
the ‘soundness of both the steps taken as qualitative data analysis and the 
conclusions reached’. To ensure dependability in this study both key informant 
interviews and focus group discussions were employed for triangulation 
purposes.  Data was recorded using both the digital recorder and detailed 
notes were also taken. Babbie and Mouton (2001:278) further state that there 
can be no dependability without credibility in as much as there is no reliability 
without validity in quantitative research.  
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3.9.4 Confirmability 
 
This refers to the extent to which the research results can be corroborated or 
confirmed by others and the extent to which the results of the study are an 
objective reflection of the study and not the subjective biases of the 
researcher. Babbie and Mouton (2001:278) state that ‘confirmability is the 
degree to which the research findings are a direct result of the inquiry and not 
the perceptions and prejudices of the researcher’. Lincoln and Guba (as cited 
in Babbie & Mouton 2001:278) suggest the use of a confirmability audit trail 
which will enable the auditor to see if the interpretations and conclusions 
arrived at are in line with the available inquiry data. This chapter is a full 
disclosure of the steps taken to generate record, analyse and interpret the 
data. 
 
 3.10 DATA ANALYSIS 
 
Data analysis is the process by which all data is arranged and reduced from its 
raw form to a point at which it is more manageable and can yield meaningful 
findings.  The two research approaches adopted in this study have different 
ways of analysing data and these will be discussed hereunder. 
 
3.10.1 Data analysis strategies for the quantitative phase 
 
 Walliman (2011:112) states that quantitative data analysis manages data 
numerically and uses mathematical operations to investigate its properties. 
The data collection method used in this instance was the review of case files 
and face-to-face interviews in a survey using a questionnaire.  
 
In this study the researcher used descriptive statistics to analyse the data 
collected in the quantitative phase. According to Babbie and Mouton 
(2001:459), descriptive statistics implies presenting numerical data in a 
manageable form.  For the survey, the researcher gave numerical codes to all 
of the answer options. A respondent code linked the interviewee with his or her 
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respective case file to enable the cross-checking of the biographical data. The 
list of codes was checked by the supervisors who also adjudicated the 
accuracy of the coding and the entering of the data into the computer. SPSS 
18 was used to generate descriptive tables.  
 
3.10.2 Data analysis strategies for the qualitative phase 
 
According to Walliman (2011:132), qualitative data analysis involves data 
reduction through a coding process, categorisation and summarising of the 
data collected. Liamputtong (2011:165) states that the first most important step 
in analysing focus group data is the transcription of data. In this study the 
researcher used a recording device to tape record the focus group discussions 
and the interviews with the key informants. In addition, she took detailed notes 
of group interactions and discussions. The audio-recordings were personally 
transcribed by the researcher.  
 
In thematic analysis the researchers are predominantly interested in the 
emergence of themes from the collected data. Liamputtong (2011:173) defines 
this as a ‘method or identifying, analysing and reporting patterns (themes) 
within the data’. The transcribed interviews and notes taken during the 
interviews and focus group discussions were first read several times and 
checked for accuracy against the recordings. The researcher then searched 
for repeated themes that emerged from the data to draw up a list of themes.  
These themes were given codes and the codes applied to the printed text.  
 
3.11 INFERENCES: SYNTHESIS OF THE DATA 
 
The researcher needed to integrate the data obtained for the various data-
generating approaches in a meaningful way. According to Bazeley (2009:204), 
integration happens when ‘qualitative and quantitative components can be 
considered integrated to the extent that these components are explicitly related 
to each other within a single study and in such a way as to be mutually 
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illuminating, thereby producing findings that are greater than the sum of the 
parts’.  
 
In this study both the data collection methods used could be regarded as 
related to each other as the second phase built on the information and insights 
of the initial phase. The researcher also adopted a similar approach during the 
analysis phase as the first phase was about describing the sample profile and 
the second phase focused on gaining meaning from the participants’ 
experiences but in their own words. The reporting of the data analysis and 
interpretation thereof will be done in an integrated manner for each identified 
theme in the next chapter.    
 
3.12 SUMMARY 
 
This chapter was dedicated to the review of the research methodology and 
design used in this research study. The study was both descriptive and 
exploratory in nature in that it was aimed at describing and exploring the social 
context of people living with HIV and AIDS and receiving ART. 
 
The measures taken to ensure reliability and validity in the quantitative 
research phase and trustworthiness in the qualitative research phase were 
also outlined. The ethical considerations taken during this research were also 
explained. 
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CHAPTER 4: PRESENTATION AND DISCUSSION OF FINDINGS 
 
4.1 INTRODUCTION  
 
This chapter focuses on the presentation of the findings from the research 
study. The demographic characteristics of the respondents are presented and 
their socio-economic circumstances as well as the patterns of adherence to 
their ART regimens are outlined.  
 
 
4.2 BACKGROUND CHARACTERISTICS OF THE RESPONDENTS 
The demographic data on the sample of patients receiving ART is presented in 
terms of age, gender, marital status, level of education, employment status 
and current place of residence. 
 
Table 4.1 shows the distribution of the respondents by age. From this 
information it is clear that the largest proportion of respondents falls within the 
age category of 30 to 39 years of age, that is, 39.3%.  Those 40 years and 
older account for 32.1% of the sample and those younger than 30 years 
comprise 28.6% of the sample. The mean age of the respondents for this 
study is 36.93 years. This was also similar in the qualitative data where at least 
44.4% of respondents fall within the 30 to 39-year-old categories. The majority 
of the respondents (71.4%) fall into the category of between 30 years and 
older. According to the developmental psychologist, Erik Erikson (Harder 
2002), these life stages are characterised by a need to form meaningful 
relationships, start families and develop careers as personal developmental 
milestones. It is, therefore, anticipated that most of the people in this category 
would be concerned about their health and well-being as it has a bearing on 
their ability to form meaningful relationships, start a family and be able to 
develop and keep a fulfilling career. 
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Table 4.1: Age group of respondents (N=28) 
 
 
 
Table 4.2 indicates an equal distribution between the sexes of the respondents 
which is at 50% (n=14) each (see Table 4.2). The researcher used the 
qualification criteria as outlined in section 3.5 of this dissertation to select the 
respondents and coincidentally it was a 50-50 gender distribution. This is not 
consistent with the normal trends in terms of gender distribution of people that 
are living with the virus and also the general population where there tend to be 
more females than males (Stats SA 2009). It is, however, important to take into 
cognisance that this study sample is very small and cannot be generalised to a 
wider population. In the qualitative phase though there were more females in 
the group than males at 66.7% compared to 33.3% of males. 
 
Table 4.2: Gender of respondents (N=28) 
 
 
 
Table 4.3 indicates that 50% of the respondents were single whilst only 7.1% 
were married, 17.9% cohabiting, 10.7% widowed and/or divorced and those 
married but having an extra-marital partner as well 7.1%. This was also 
evident in the qualitative phase of the study in which 77.8% of the respondents 
in the focus group were single and 22.2% were either married or cohabiting. 
AGE RANGES FREQUENCY % 
Younger than 30 years 8 28.6 
30-39 years 11 39.3 
40 years and older 9 32.1 
Total 28 100.0 
Mean age 36.93 years 
GENDER  FREQUENCY % 
Female 14 50.0 
Male 14 50.0 
Total 28 100.0 
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Table 4.3: Marital status of respondents (N=28) 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 depicts the level of education amongst the study respondents. It 
shows that 67.9% of the respondents had at least a secondary school level of 
education whilst 17.8% had primary school education and 14.3% no education 
at all. The fact that the majority of respondents had a secondary level of 
education might be indicative of the respondents’ ability to know their 
treatment well, understand and recognise its importance and the possible 
consequences of not adhering to treatment in the long run. There has, 
however, not been any correlation between illiteracy and non-adherence in 
terms of literature on adherence and in fact the contrary has been established 
(Heyer & Ogunbanjo 2006: 5-9). 
 
Table 4.4: Educational level of respondents (N=28) 
 
 
The respondents’ places of residence were evenly distributed throughout the 
11 villages which fall within the catchment area of the Shongwe hospital (see 
Table 4.5). Table 4.6, on the other hand, depicts that the majority of the 
MARITAL STATUS  FREQUENCY % 
Single 14 50.0 
Married 2 7.1 
Divorced 2 7.1 
Co-habiting 5 17.9 
Widowed 3 10.7 
Married plus a co-habiting girl/boyfriend 2 7.1 
Total 28 100.0 
EDUCATIONAL LEVEL FREQUENCY % 
None 4 14.3 
Primary 5 17.8 
Secondary 19 67.9 
Total 28 100.0 
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respondents (92.9%) resided in a predominantly rural area and only 7.1% in an 
urban area which is closer to the town of Malelane. The study area is 
predominantly rural and this profile is indicative of that fact.  
 
Table 4.5: Current place of residence (N=28) 
 
PLACE OF RESIDENCE FREQUENCY % 
Bosfontein 2 7.1 
Driekoppies 1 3.6 
Emangweni 1 3.6 
Jeppes Reef 3 10.7 
Kamhlushwa 4 14.3 
Langeloop 4 14.3 
Magogeni 3 10.7 
Magudu 2 7.1 
Mgobodzi 1 3.6 
Middelplaas 1 3.6 
Schoemansdal 6 21.4 
Total 28 100.0 
 
 
Table 4.6: Respondents’ residences in a rural or an urban area (N=28) 
 
 
 
 
 
 
 
 
 
PLACE OF RESIDENCE FREQUENCY % 
Urban 2 7.1 
Rural 26 92.9 
Total 28 100.0 
85 
 
4.3 SOCIAL AND ECONOMIC BACKGROUND VARIABLES  
 
Kagee (2006:415) suggests that social and economic factors may combine to 
yield poor adherence outcomes. This assertion is, however, disputed by Heyer 
and Ogunbanjo (2006:8) who state that socio-economic factors are not 
consistently predictive of adherence. They further assert that in studies carried 
out both in India and South Africa no association has been found between 
adherence and the patient’s economic status. This study aimed at establishing 
whether the socio-economic factors of these respondents had any bearing on 
their adherence to treatment. 
 
4.3.1 Employment status 
 
Table 4.7 shows that 53.6% of the respondents were employed whilst 46.4% 
were unemployed. Of the 53.6% of respondents who were  employed at the 
time, the data reveals that they held positions  across a wide spread of 
economic sectors such as security, construction, agriculture, general labour, 
assistants, the beauty industry, education and traditional healing (See Table 
4.8). The 46.4% who were unemployed included one person who was still at 
high school and another person who had been medically boarded and was no 
longer employed. Qualitative data on the other hand showed that 33.3% of the 
nine respondents in the focus group were unemployed whilst 66.7% were 
employed which is slightly higher than the percentages in the quantitative data. 
 
Table 4.7: Respondents’ current employment status (N=28) 
 
 
 
 
EMPLOYMENT STATUS FREQUENCY % 
Yes 15 53.6 
No 13 46.4 
Total 28 100.0 
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Table 4.8: Current employment positions (N=28) 
 
CURRENT EMPLOYMENT STATUS  FREQUENCY % 
Unemployed*  13 46.4 
Security guard 3 10.7 
Teacher 1 3.6 
Hairdresser 2 7.1 
Cleaner 1 3.6 
Secretary 1 3.6 
Miller 1 3.6 
General assistant 1 3.6 
Plumber 1 3.6 
Gardener 1 3.6 
Welder 1 3.6 
Traditional healer 1 3.6 
Irrigator 1 3.6 
Total 28 100.0 
*(including a scholar/student and a person medically boarded) 
 
4.3.2 Main source of income 
 
The findings of this section of the study showed that the main source of 
income for the respondents was a salary/wage in line with the number of 
people employed and this was estimated to be 53.5% as shown in Table 4.9. It 
also revealed an equal distribution between those who were dependent either 
on parents or grandparents’ pensions or on their own pensions at 3.6% each. 
About 7.1% were dependent on spouses’ incomes for survival. Those with 
absolutely no source of income were at 28.6% which is quite a substantial 
number of people with no income. In the qualitative data percentages, the 
number of people who were unemployed and dependent on a spouse or 
another person numbered three respondents out of nine. This is very likely to 
have an impact on adherence to their treatment in terms of regular attendance 
at the clinic, ensuring that they have adequate food to take with treatment and 
money to cover transport and other related costs.  
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Table 4.9: Main source of income of the respondents (N=28) 
 
MAIN SOURCE OF INCOME FREQUENCY % 
Salary/wage 15 53.5 
Solely dependent on parents 1 3.6 
Pension after having been medically boarded 1 3.6 
Dependent on grandmother's pension 1 3.6 
Spouse's income 2 7.1 
No income 8 28.6 
Total 28 100.0 
 
4.3.3 OTHER SOURCES OF INCOME 
 
Table 4.10 and 4.11 indicate that some of the respondents had other sources 
and means of income besides those indicated in Table 4.9. Table 4.10 
indicates that 35.7% of respondents had other sources of income besides 
those mentioned in Table 4.9. Table 4.11 shows these additional sources of 
income as 21.4% being dependent on the disability grant, 10.7% dependent on 
child maintenance which was sometimes not paid at all and 3.6% relying on 
their spouses for survival.  
 
Table 4.10: Households’ possible other sources of income besides the 
respondents’ salaries (N=28) 
 
OTHER SOURCES OF HOUSEHOLD 
INCOME 
FREQUENCY 
 
% 
 
Yes 10 35.7 
No 18 64.3 
Total 28 100.0 
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Table 4.11: Source of other income besides salary (N=10) 
 
SOURCES OF INCOME FREQUENCY % 
Disability grant 6 21.4 
Spouses’ incomes 1 3.6 
Fathers sometimes paid maintenance 3 10.7 
Total 10 35.7 
 
 
4.3.4 FINANCIAL LOSSES INCURRED DUE TO CLINIC ATTENDANCE 
 
 Table 4.12 indicates that about 92.8% of the respondents incurred transport 
expenses as they had to travel various distances to the clinic to obtain their 
medication. Of the respondents, 10.7% had to take sick leave from work which 
affected their wages; 7.1% either lost income through having to buy food when 
attending the clinic or lost income-earning opportunities as they could not 
actively look for a job whilst they were attending the clinic. Only one person 
(3.6%) in the group had to pay a child-minder when attending the clinic (see 
Table 4.12). The total number of responses exceeds the number of 
respondents as more than one response was applicable for some. Poverty and 
lack of financial resources can influence adherence as sometimes patients 
have to prioritise other family needs over treatment when faced with the many 
daily needs competing for limited resources (WHO 2003).  
 
Transportation costs have been identified as a factor that impacts on 
adherence in different studies conducted in the past (WHO 2003; Mukherjee et 
al 2006; Hardon et al 2006; Kagee 2006 & Simoni et al 2009). The findings of 
this study also show a similar trend as 92.8% of respondents indicated that the 
major costs incurred were those of transportation to the clinic. Lack of financial 
means to pay for transport to the clinic, paying a childminder or even to buy 
food whilst at the clinic may result in the patient not attending clinic 
appointments.  Long waiting times at the clinic may also be a possible barrier 
to attending a clinic appointment when a patient is faced with not receiving a 
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salary on the day and having to spend money on food whilst waiting. Some 
respondents (10.7%) reported having to take sick leave when attending clinic 
which they stated affected their wages. The likelihood of sometimes not 
honouring clinic appointments in order to receive full salaries is always there 
and may ultimately impact on adherence.  
 
Table 4.12: Type of financial losses incurred due to clinic attendance 
 
FINANCIAL LOSSES DUE TO CLINIC 
ATTENDANCE  
FREQUENCY % 
Taxi fare 26 92.8 
Had to take sick leave 3 10.7 
Lost income-earning opportunities 2 7.1 
Cost of food 2 7.1 
Had to pay child-minding fees 1 3.6 
Total 28 * 
 
* As respondents could give more than one answer here, the percentages 
summate to more than 100%. 
 
4.3.5 CONSTITUTION OF RESPONDENTS’ HOUSEHOLDS 
 
Just below a third of respondents, that is 32.1%, lived with their extended 
families whilst 28.6% lived with a spouse and children. Smaller proportions of 
respondents (7.1%) either lived with children under the age of 18 years or with 
their parents. Table 4.13 shows that 17.9% of the respondents lived with 
people who were not relatives whilst 3.6% lived with children older than 18 
years and a further 3.6% lived with a spouse. A recent study by Jury and 
Nattrass (2012) in Khayelitsha reveals that household compositions of people 
who are initiated on ART tend to include family members (especially parents) 
to a greater extent than people who are not HIV positive. Over time, as ART 
restores the health of the patient, the household compositions change so that 
the household compositions of people on ART and the general population 
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become indistinguishable. This suggests that family members act as 
caregivers in the early stages of ART. Whereas it is not possible to deduce this 
from Table 4.13, the researcher found it interesting that, although half of the 
respondents were single in terms of marital status, none of the 28 respondents 
were living completely on their own.  
 
Table 4.13: Constitution of respondents’ households (N=28) 
 
CONSTITUTION OF HOUSEHOLDS FREQUENCY % 
Extended family 9 32.1 
Spouse and children 8 28.6 
Other non-kin 5 17.9 
Children under 18 only 2 7.1 
Parents 2 7.1 
Spouse only 1 3.6 
Children older than 18 only 1 3.6 
Total 28 100.0 
 
 
4.3.6 SIZE OF RESPONDENTS’ HOUSEHOLDS  
 
The average size of the households of the 28 respondents was 4.89 people. A 
sizeable proportion (28.8%) of the respondents’ households consisted of five 
people whilst a quarter (25%) had households comprising four people. Another 
25% had 6 or more people living in the same household. The rest of the 
respondents (21.4%) had small households comprising 3 members.  
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Table 4.14: Size of respondents’ households 
 
SIZE OF HOUSEHOLDS FREQUENCY % 
3 people 6 21.4 
4 people 7 25.0 
5 people 8 28.6 
6 or more people 7 25.0 
Total 28 100.0 
Mean household size 4.89 people 
 
 
4.3.7 NUMBER OF LIVING CHILDREN  
 
Table 4.15 indicates that the average number of living children per respondent 
was 2.11. Half of the respondents had two children; 28.6% had three or more 
children and 7.1% had only one child. A small percentage (14.3%), however, 
had no children at all. This implies that 85.7% of the respondents had progeny 
that would be affected by the health status of their mothers or fathers.   
 
Table 4.15: Number of living children of respondents (N=28) 
 
NUMBER OF CHILDREN  FREQUENCY     % 
None 4 14.3 
1 child 2 7.1 
2 children 14 50.0 
3 or more children 8 28.6 
Total 28 100.0 
Mean number of children 2.11 
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4.3.8 AGES OF YOUNGEST CHILDREN LIVING WITH RESPONDENTS 
 
The mean age of the youngest child living with a respondent was 10.33 years 
as indicated in Table 4.16. Nearly half (45.8%) of the respondents had children 
younger than 6 years of age. Read in combination with Table 4.15, it can be 
deduced that a large proportion of the respondents had minors who might 
have been dependent on their care, making the issue of adherence for the 
survival of these parents a matter of crucial importance.  
 
Table 4.16: Ages of youngest living children of respondents (N=24) 
 
AGES OF CHILDREN FREQUENCY % 
Up to 1 year old 4 16.7 
2- 5 years old 7 29.1 
6-9 years old 3 12.5 
10-15 years old 4 16.7 
16-18 years old 3 12.5 
19 years and older 3 12.5 
Total 24 100.0 
Mean age of youngest child 10.33 years 
 
 
4.4 HIV DIAGNOSIS AND DISCLOSURE 
 
This section discusses the results of data-gathering concerning the 
experiences of each of the 28 respondents, their HIV-positive diagnosis and 
their disclosure behaviour. Some of the factors identified as having an impact 
on adherence to treatment include the diagnosis with HIV, reaction to that 
diagnosis and the decision whether to disclose or not. Denial of HIV diagnosis 
and a lack of disclosure to significant others have been identified as factors 
that determine the level of adherence to treatment (NDOH 2010:17). According 
to Mehta et al (1997:1669), patients’ knowledge of their status and acceptance 
thereof and the expected course of the illness and treatment have all been 
93 
 
associated with increased levels of adherence to treatment. The IMB model 
also proposes that having adequate health-related information and knowledge 
may motivate the person to make the necessary health behaviour changes 
(Martin et al 2009:19).  According to Van Dyk (2011) and Kagee (2006:419), 
lack of disclosure, fear of stigma and discrimination have also been associated 
with non-adherence to treatment.  People living with HIV are often subjected to 
a great deal of stigma and discrimination which may result in lack of disclosure 
of their HIV status for fear of being discriminated against. The Social Learning 
theory posits that personal expectancies and environmental factors determine 
behaviour (Martin et al 2009:16). This may negatively impact on their ability to 
adhere to their treatment regimens. 
  
4.4.1 Initial reaction to HIV diagnosis 
 
The respondents’ responses to how they reacted when they first tested HIV 
positive indicate that 39.3% claimed to have accepted their status immediately; 
32.1% did not feel afraid whilst 21.4% felt very upset upon receiving the news. 
Only one respondent (3.6%) indicated that he/she  did not think that he/she 
was at  risk of being infected and was shocked by the results and one more 
respondent indicated that he/she was not upset at all as he/she had  seen 
other people living with HIV (see Table 4.17) . On the whole, the quantitative 
data thus revealed an overall positive response to an HIV-positive result. The 
qualitative data revealed that of the nine respondents, three initially reacted 
with sadness, fear and anger but later accepted their HIV status whilst one 
respondent reported being shocked as he/she did not expect to test HIV 
positive at all. The rest of the group reported that they just accepted their 
status. These findings should be seen in the context of these respondents’ 
encapsulation in current ART care and cannot be generalised to all persons 
who have tested positive.   
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Table 4.17: Respondents’ initial reactions upon receiving an HIV positive 
diagnosis (N=28) 
 
INITIAL REACTION TO TESTING HIV POSITIVE FREQUENCY % 
Not afraid 9 32.1 
Accepted 11 39.3 
Very upset 6 21.4 
Did not think I was at risk 1 3.6 
I was not upset as I have seen other people living with HIV 1 3.6 
Total 28 100.0 
 
 
4.4.2 Disclosure 
 
The information received from the respondents indicated that all of them had 
disclosed their HIV status albeit to different people (see Table 4.18). A quarter 
of the respondents (25%) had disclosed to everyone whilst 17.9% had only 
disclosed to their mothers followed by those that had disclosed to their 
spouses (14.3%). The rest had disclosed to their children, parents, siblings, 
friends and colleagues respectively. From the qualitative data it is evident that 
of the nine respondents, eight had disclosed their status either to spouse, 
family and/or friends. It is, however, important to point out that only one 
respondent in the quantitative phase and none in the qualitative phase 
disclosed at their workplaces which affects adherence to some extent when at 
work. 
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Table 4.18: People to whom respondents disclosed (N=28) 
 
PERSONS RESPONDENTS DISCLOSED TO  FREQUENCY % 
To children and parents 2 7.1 
To eldest child 1 3.6 
To mother 5 17.9 
To everyone 7 25.0 
To sister and boyfriend 1 3.6 
To children 1 3.6 
To mother and boyfriend 1 3.6 
To sister 2 7.1 
To a friend 1 3.6 
To a spouse 4 14.3 
To father 1 3.6 
To a grandparent 1 3.6 
To a work colleague 1 3.6 
Total 28 100.0 
 
 
4.4.3 Reaction to respondents’ disclosure  
 
The data in table 4.19 shows that the majority of people that the respondents 
disclosed to were supportive (71.4%) compared with the 14.3% of those who 
found it hard to accept the status of the respondents. A small percentage 
(7.1%) reported, however, that they just accepted the fact that the person was 
HIV positive whilst 3.6% expressed fear that the respondent might die as a 
result of being HIV positive. Only one respondent (3.6%) reported being 
blamed for testing HIV positive. It has been reported in literature that a large 
number of people do not disclose their status for fear of being blamed and in 
some cases discriminated against. The AIDS Treatment for Life International 
Survey (ATLIS) conducted in 2010 found that 35% of people in a sample of 2 
035 did not disclose for fear of being stigmatised and discriminated against. 
(AVERT 2011). In the qualitative phase the researcher also found that two 
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thirds of the respondents reported positive responses upon disclosure, 
although some cases of emotional abuse and rejection by partners were 
reported.  
 
Table 4.19: People’s reaction/s when respondents disclosed to them 
(N=28) 
 
REACTION TO DISCLOSURE FREQUENCY % 
They were supportive 20 71.4 
They accepted the fact 2 7.1 
They were afraid that I would die 1 3.6 
They found it hard to accept 4 14.3 
I was blamed  1 3.6 
Total 28 100.0 
 
 
4.4.4 Respondents’ feelings about benefits of disclosure 
 
The information below indicates that all respondents found that disclosing their 
HIV status to significant others was beneficial for different reasons (see Table 
4.20).  A third (35.7%) of respondents felt that disclosing made it possible for 
them to receive the support they needed; 28.6% felt that their significant others 
gained a better understanding of what was happening in their lives; 17.9% 
gained a better perspective of their own illness and 14.3% felt that a burden 
had been lifted from their shoulders when they disclosed. One respondent 
stated that although he/she was blamed initially, this reaction to disclosure 
encouraged him/her to seek medical help in order to live a longer and 
meaningful life. 
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Table 4.20: Respondents’ feelings about benefits of disclosure (N=28) 
 
WHETHER DISCLOSURE WAS BENEFICIAL TO 
RESPONDENTS 
FREQUENCY 
 
% 
 
Yes, receive support now 10 35.7 
Yes, loved ones now understand what is happening 8 28.6 
Yes, I gained perspective 5 17.9 
Yes, a burden has been lifted 4 14,3 
Yes, encouraged to seek medical help 1 3.6 
Total 28 100.0 
 
 
4.5 TREATMENT AND ADHERENCE FACTORS 
 
The provision of ART to people living with HIV and AIDS has led to improved 
quality of life, reduced morbidity, reduced mortality rates and the number of 
deaths due to HIV- and AIDS-related illnesses and has generally prolonged 
the lives of many people living with the virus. To attain treatment success the 
patients have to adhere to their treatment at least 95% of the time in order to 
ensure complete suppression of the virus (NDOH 2004). A wide range of 
factors influence adherence to ART and this is the subject of the current study. 
The following sections focus on the findings relating to aspects of treatment 
and adherence. 
 
4.5.1 Year of commencement of ART 
 
The largest proportion of respondents in this study (46.4%) commenced 
treatment in 2010 whilst 21.4% began in 2008; 14.3% in 2009 and 10.7% in 
2011. The remainder of the respondents (3.6%) began ART in 2000 and 2006 
respectively (see Table 4.21). It is also noted from the findings that 92.8% of 
respondents had been on treatment for a period of fewer than five years whilst 
the rest (7.2 %) had been on treatment for over ten years. Being on treatment 
for a long time can also impact on adherence as patients may develop what is 
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referred to as ‘treatment or pill fatigue’ resulting in their being unable to adhere 
to the recommended treatment (AIDSinfonet 2012; Van Dyk 2011). Several 
research studies have reportedly shown adherence declining over time for 
people on long-term treatment and even with people who have been very 
successful in taking their medication (AIDSinfonet 2012). In this study the 
findings indicate that at least 7.2% of the respondents in the quantitative phase 
had been on treatment for over ten years and they might require more support 
to ensure that they remained adherent to their treatment regimens.  
 
In the qualitative phase of this study, findings show that eight of the nine focus 
group respondents had been on ART for fewer than five years as they were 
initiated between 2009 and 2011. One discussant had been on treatment for 
ten years after initiation in 2006.  
 
Table 4.21: Year in which respondents commenced ART (N=28) 
 
YEAR OF INITIATION ON TREATMENT FREQUENCY % 
2000 1 3.6 
2006 1 3.6 
2008 6 21.4 
2009 4 14.3 
2010 13 46.4 
2011 3 10.7 
Total 28 100.0 
 
4.5.2 Treatment regimen 
 
In terms of the South African Treatment Guidelines (NDOH 2010) only three 
categories of regimens are available to patients at this point, that is, the 1st 
line, 2nd line and the salvage line. Health care professionals aim to maintain 
their patients on the 1st line as long as possible so that they do not run out of 
treatment options.  Remaining on the first line regimen requires at least 95% of 
adherence to treatment and no adverse reactions on the part of the patient. 
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The data in Table 4.22 indicates that 75% of the respondents were on the first 
line regimen. This is a positive finding in terms of long-term adherence and the 
success of treatment. A small proportion (7.1%) of respondents were already 
on the second line regimen which left them with fewer options in the long run. 
The rest of the respondents (17.9%) did not know their treatment regimen and, 
therefore, could not provide information in this respect. The fact that 5 of the 
28 respondents did not know their regimen is disconcerting  as it is preferable 
that the patient be informed about and understand his/her treatment as this 
encourages  adherence. In the qualitative phase the researcher found that 5 of 
the 9 respondents were on the first line regimen, one was already on the 
second line regimen and 3 were on the salvage regimen.  
 
Table 4.22: Treatment regimen respondents were currently on (N=28) 
 
TREATMENT REGIMEN FREQUENCY        % 
1st line 21 75.0 
2nd line 2 7.1 
Don't know 5 17.9 
Total 28 100.0 
 
 
4.5.3 Meaning of adherence to respondents 
 
Adherence can be defined as ‘the extent to which a person’s behaviour – 
taking medication, following a diet, and/or executing lifestyle changes – 
corresponds to agreed recommendations from a health care provider’ (WHO 
2003:3). From table 4.23 it is evident that half of the respondents (50%) 
understood adherence to refer to taking their medication correctly. Whilst 7.1% 
understood it to refer to taking medicines correctly and practising safe sex, 
7.1% stated that it referred to self-care and 3.6% asserted that it meant eating 
regular meals. It is, however, of concern to note that 32.1% of the respondents 
did not know what adherence means. This may have a serious impact on 
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adherence as the person may not understand what is expected of them and as 
a result will not adhere very well to their treatment regimen. 
 
Table 4.23: The value of treatment adherence to respondents (N=28) 
 
THE VALUE OF TREATMENT ADHERENCE TO 
RESPONDENTS 
FREQUENCY 
 
% 
 
Taking medicines correctly (as prescribed) 14 50.0 
Do not know 9 32.1 
Taking medicines and using condoms 2 7.1 
Self-care 2 7.1 
Eating regular meals 1 3.6 
Total 28 100.0 
 
 
4.5.4 Perceived benefits of adherence counselling 
 
All 28 respondents confirmed that they attended adherence counselling 
sessions prior to commencing treatment. The respondents in the qualitative 
phase also reported that they all attended adherence counselling although one 
of them felt that the quality of counselling was not good. The findings of this 
study show a wide range of responses, some of which are positive and others 
negative (see Table 4.24). The largest proportion of respondents, (42.8%) 
reported that they found the adherence counselling sessions to be very good 
and informative whilst 28.6% reported that the sessions helped them to learn 
more about their medication, diet and living positively; how to deal with side 
effects, fear and stigma; helped with planning for the family; found it to be an 
enjoyable experience and it helped them make friends. A small percentage 
(3.6%) reported that attending the counselling sessions helped her see that 
she was not the only one who was living with HIV and that was very helpful. 
The rest of the respondents either reported that they were late for their 
sessions (3.6%); they found it confusing at first (10.7%); could not remember 
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what was discussed (3.6%) or could not even answer the researcher when 
interviewed (7.1%).   
 
Table 4.24: The perceived benefits of attending adherence counselling 
sessions (N=28) 
 
PERCEIVED BENEFITS OF ADHERENCE COUNSELLING FREQUENCY % 
It helped me with my fears about side effects 2 7.1 
I learnt about diet and how to live positively 1 3.6 
I found it informative 9 32.1 
It was very good 3 10.7 
I learnt how to take the medication 2 7.1 
It helped me to deal with my fear of stigma 1 3.6 
I was late for some of my counselling appointments 1 3.6 
I could see that I'm not the only one living with HIV 1 3.6 
It was a good experience and I made friends 1 3.6 
I found it confusing at first 3 10.7 
Cannot remember 1 3.6 
No answer 2 7.1 
Helped me with planning my family despite being HIV+ 1 3.6 
Total 28 100.0 
 
 
4.5.5 Treatment supporter 
 
This question relates to the person that was a treatment supporter for the 
respondents whilst attending adherence counselling sessions. The first SA 
National Treatment Guidelines (NDOH 2004:52-57) advocated ensuring that 
patients have adequate support systems including treatment supporters on 
initiation of treatment so as to improve adherence to their ART regimens. From 
a study conducted by Yoder, Mkhize and Nzimande (2009:70) in five different 
sites in KwaZulu-Natal on the experiences of patients on antiretroviral therapy, 
findings suggested that challenges such as the availability of a treatment 
supporter were determinants of patients’ adherence, non-adherence and/or 
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ultimate drop-out from their treatment. This can be a beneficial resource for 
patients especially those who may be extremely ill when initiating treatment 
and may have difficulty understanding and/or remembering all the information 
given. In this study, 71.4% of the respondents reported having no supporters 
during that stage whilst 17.9% were supported by their relatives and 10.7 % 
were supported by their spouses (see Table 4.25).  
 
Table 4.25: Respondents’ treatment supporters (N=28) 
 
RESPONDENTS’ TREATMENT SUPPORTERS FREQUENCY % 
Spouse 3 10.7 
Other relatives 5 17.9 
No one 20 71.4 
Total 28 100.0 
 
 
4.5.6 Travelling time between respondents’ homes and the ARV clinic 
 
The majority of the respondents (71.4%) spend between 30 minutes to an hour 
travelling to the clinic for their appointments. Only 17.9% of the respondents 
spend fewer than 30 minutes and these are the ones that live in close 
proximity to the clinic. A small number (10.7%) travels for more than an hour to 
get to the clinic for their appointments (see Table 4.26). It would thus seem 
that the clinic was accessible to all of the respondents albeit with varying 
degrees of travel involved.  
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Table 4.26: Travelling time between respondents’ homes and the ARV 
clinic (N=28) 
 
TRAVELLING TIME TO THE CLINIC FREQUENCY % 
Fewer than 20 minutes 2 7.2 
20-29 minutes 3 10.7 
30 minutes 10 35.7 
45 minutes to an hour 10 35.7 
More than an hour 3 10.7 
Total 28 100.0 
 
4.5.7 Mode of transport 
 
The majority of respondents (92.9%) relied on taxis for transport to the clinic 
for their ARV appointments. One respondent used company transport and 
another walked to the clinic (see Table 4.27).  
 
Table 4.27: Type of transport respondents relied on to visit the ARV clinic 
(N=28) 
 
TYPE OF TRANSPORT FREQUENCY % 
Taxi 26 92.9 
Company car 1 3.6 
Walk 1 3.6 
Total 28 100.0 
 
 
4.5.8 Respondents’ experience of first commencing treatment  
 
Table 4.28 indicates the different experiences of respondents when they were 
first initiated on ARVs. Respondents reported both negative and positive 
experiences in this regard with the majority (85.7%) reporting positive 
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experiences and 14.3% reporting negative ones. It is notable that some 
respondents reported experiencing both positive and negative reactions.  
 
4.5.8.1 Positive experiences 
 
The most common changes reported in this category were the improvement in 
health, sleeping better, being able to stop drinking, an increased appetite and 
feeling generally happy. A third (38.3%) of the respondents reported that there 
was notable improvement in their health and general well-being as a result of 
being put on ART.  It is also important to note that 14.3% of the respondents 
stated that even though they had no positive things to report they, however, 
did not experience any problems either. In the qualitative phase, the 
researcher found that all of the nine respondents reported a great 
improvement after treatment. 
 
4.5.8.2 Negative experiences 
 
The kinds of negative experiences reported pertained mostly to side effects 
such as diarrhoea, pins and needles and dandruff. Side effects are  common in  
patients in the first six weeks after  commencing ART and the data in this study 
is consistent with that information (Evian 2011:175). These side effects should, 
however, subside within the first six weeks of being on treatment. In the 
qualitative phase, the researcher found that of the nine respondents, only one 
reported having experienced some side effects which made him unable to 
cope with his schoolwork. These were his sentiments regarding side effects: 
 
 The treatment has affected my schooling … when I take the tablets I 
can’t concentrate and feel like sleeping all the time [Respondent 3]. 
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Table 4.28: Respondents’ experiences on commencement of ART (N=28)* 
 
EXPERIENCES ON INITIATION OF ART FREQUENCY % 
Positive experiences 24 85.7 
Improvement in health 11 38.3 
Felt happy/had hope for the future  3 10.7 
Slept better 1 3.6 
Good experience 3 10.7 
No problems 4 14.3 
Increased appetite 1 3.6 
Helped me to quit drinking 1 3.6 
Negative experiences 8 14.3 
Dandruff and sores on scalp 1 3.6 
Pins and needles in hands 1 3.6 
Powerlessness/decreased libido/sexual impotency 3 10.7 
Many side effects 1 3.6 
Diarrhoea 1 3.6 
Stopped menstruating 1 3.6 
* As respondents could give more than one answer here, the percentages 
summate to more than 100%. 
 
4.5.9 Changes respondents noticed after commencement of ART 
 
The changes noticed by respondents after commencement of ART were both 
positive and negative. As will become clear in the next section, most 
respondents became acutely aware of corporeal changes that were 
experienced as negative (side effects of medication) and positive (weight gain 
and feeling better).  Amongst the positive experiences cited was weight gain, 
starting to feel stronger and a general improvement in health. On the other 
hand, the negative changes noticed and reported were decrease in sexual 
interest and libido, body aches, skin problems, asthma and swollen feet. Three 
quarters (75%) of the respondents experienced positive changes with 50% of 
them reporting weight gain, 14.3% reporting feeling stronger after starting 
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treatment and 10.7% reporting a general improvement in health (see Table 
4.29). 
 
Being infected with HIV and being at stage four of the Aids disease is 
characterised by a loss of weight of more than 10% of body weight, wasting  
and a general deterioration in health and well-being (AVERT 2011). It is, 
therefore, encouraging that 75% of respondents reported weight gain, feeling 
stronger and a general improvement in health after starting treatment as it 
implies that treatment was working. A quarter (25%) of the respondents 
reported noticing negative changes after commencing treatment including one 
who reported a decreased libido; 10.7% reported skin problems and the rest of 
the respondents reported body aches, swollen feet and asthma. This is also 
consistent with findings from other studies in which  people report  
experiencing side effects as a result of commencing treatment (Evian 
2011:175; Van Dyk 2011). 
 
According to Van Dyk (2011), the most common treatment-related reason for 
non-adherence is the treatment side effects. This is evident in her study of 
patients on ART in which 60% of the patients studied experienced side effects 
at different points of their treatment span. Heyer and Ogunbanjo (2006:6) 
emphasise the importance of dealing with side effects effectively in order to 
prevent discontinuation of treatment and non-adherence.  According to Simoni 
et al (2009:194), the IMB model proposes that ARV adherence is a function of 
one’s fund of accurate regimen-specific information and understanding. It is 
important for patients to understand how their treatment works and the 
possible complications that may arise in order to take appropriate and timely 
action. Without this understanding, the side effects may be experienced as a 
threat or barrier to health as espoused in HBM and may result in premature 
termination of treatment.  
 
 
 
107 
 
Table 4.29: The changes respondents noticed when they commenced 
ART (N=28) 
 
CHANGES  SINCE COMMENCEMENT OF 
TREATMENT 
FREQUENCY 
 
% 
 
Positive changes 21 75.0 
Weight gain 14 50.0 
Starting to feel stronger 4 14.3 
General improvement in health 3 10.7 
Negative changes 7 25.0 
Sexual interest has decreased 1 3.6 
Whole body aching 1 3.6 
Skin problems 3 10.7 
Asthma 1 3.6 
Swollen feet  1 3.6 
 
 
4.5.10 respondents’ major challenges adhering to ART 
 
The major challenges as reported by respondents were mainly associated with 
medication side effects. It is important to mention at this point that respondents 
reported more than one challenge and as a result the percentages summate to 
more than 100%. In Table 4.30, 89.4% of respondents reported that the side 
effects had an impact on their adherence to treatment (this includes the 
responses to various side effects, diarrhoea, fever, hallucinations and 
nightmares). Only 10.7% attributed non-adherence to forgetfulness and/or 
mental disturbances, whilst 3.6% ‘felt sick’ which made it difficult to continue 
treatment and another 3.6% reported that she found it difficult to take her 
treatment on time. The latter respondent also included worries about 
medication, that men attending the clinic were disruptive, pressure at work 
made side effects worse and extreme poverty. 
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It is interesting to note that in the focus group interviews, barriers to adherence 
included matters of a more intimate nature between the patients and their 
spouses, partners or significant others. In the qualitative phase of data 
collection, the nine participants told the researcher that their major challenges 
regarding adherence included a lack of support from significant others; an 
inability to negotiate condom use with spouses and to practise safer sex; 
domestic violence; unemployment and lack of financial resources; 
homelessness and displacement; traditional and religious beliefs; 
forgetfulness; and irregular working hours. A third of the respondents told the 
researcher that they were forced to have unprotected sex despite both 
partners being HIV positive. Three participants also spoke of a lack of financial 
support as they were unemployed and had to depend on other people for daily 
upkeep. These issues are discussed in greater detail under sub-heading 4.8 in 
this chapter.  
 
The findings between the qualitative and quantitative phases of this study 
differed in terms of the factors that lead to the difficulty in adhering to ART 
regimens. In the quantitative phase the major reason cited for non-adherence 
was side effects – 89.4% of respondents reported this. This is consistent with 
the findings of another study conducted in which 60% of respondents reported 
experiencing side effects at some point of their treatment span (Van Dyk 2011) 
In terms of HBM, the side-effects can be perceived as a barrier as their 
severity discourages patients from continuing taking treatment (Hayden 
2009:33).  
 
In the qualitative research though the findings showed that lack of cooperation 
and support from significant others; an inability to negotiate condom use with 
spouses and practise safer sex; and an inability to take treatment owing to 
irregular working hours were major factors impacting on adherence. In terms of 
the social learning theory, individual actions are largely determined by both 
personal and environmental factors which is consistent with the emerging 
picture from these findings (Martin et al (2009:16; Rosenstock et al 1988:177).  
The social circumstances and experiences of these patients determined their 
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actions as far as adherence to treatment was concerned. Four of the nine 
respondents reported difficulty in negotiating for safer sex and three of the nine 
reported irregular working hours and fear of being seen taking treatment by 
colleagues as impacting on their adherence to their treatment. The difference 
in these findings could be owing to the fact that the focus group participants 
were different from those in the face-to-face interview. In the focus group, 
prolonged engagement with participants resulted in the establishment of a 
good rapport and a safe environment in which to be open. This resulted in their 
being able to discuss more intimate reasons affecting their adherence. The 
common reasons cited in the two phases were the following: working irregular 
hours including night shift, forgetting to take treatment until much later than 
prescribed and having to hide their medication. 
 
Table 4.30: Major challenges experienced by respondents when trying to 
adhere to ART (N=28)* 
 
RESPONDENTS’ MAJOR CHALLENGES WHEN 
TRYING TO ADHERE TO ART 
FREQUENCY % 
Diarrhoea 1 3.6 
Forgetfulness or mental disturbances 3 10.7 
Feeling feverish 1 3.6 
Finds it difficult to take the medicine on time 1 3.6 
Pressure at work makes side effects worse 1 3.6 
Hallucinations and nightmares 5 17.9 
Extreme poverty 1 3.6 
Worries about medication 1 3.6 
Various side effects 18 64.3 
The men at the clinic are noisy and disruptive 1 3.6 
Sleeps too much 1 3.6 
Total 28 * 
* As respondents could give more than one answer here, the percentages 
summate to more than 100%. 
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4.5.11 Specific side effects experienced by respondents on ART 
 
Table 4.31 shows what the specific side effects were as experienced and 
reported by respondents whilst on ART. It indicates that 39.3% of respondents 
reported rashes, swollen feet and feeling cold, followed closely by those who 
experienced drowsiness (32.1%) and those who suffered from hallucinations 
(7.1%). Other side effects reported were a distended stomach, swollen breasts 
and weight gain. One respondent (3.6%) reported experiencing all the side 
effects mentioned here and another 3.6% also had side effects but sought help 
at the clinic and these then subsided.  
 
It is very common for patients to experience side effects within the first two 
weeks of starting treatment but these should subside within the first six weeks. 
The majority of these side-effects are short-lived and self-limiting (Evian 
2011:175) and some may need to be reported to the health care professional 
so that they can be attended to in good time. One respondent (3.6%) reported 
experiencing none of the side effects. This is supported by literature as not 
every person experiences side effects on treatment (Evian 2011:175).  In the 
qualitative phase of the study only one respondent cited experiencing some 
side effects which made it hard to cope at school. This is what he had to say: 
 
The treatment has affected my schooling … when I take the tablets I 
can’t concentrate and feel like sleeping all the time’. 
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Table 4.31: Specific side effects experienced by respondents on ART 
(N=28) 
 
SPECIFIC SIDE EFFECTS EXPERIENCED ON ART FREQUENCY % 
Rash, swollen feet, feels cold 11 39.3 
Distended stomach 1 3.6 
None 1 3.6 
Had side effects, but was treated at clinic 1 3.6 
Drowsiness 9 32.1 
Swollen breasts 1 3.6 
Everything (all possible side effects) 1 3.6 
Weight gain 1 3.6 
Hallucinations 2 7.1 
Total 28 100.0 
 
4.5.12 Specific problems related to taking medication on time 
 
Patients may experience a wide range of problems relating to the taking of 
medication which may impact on adherence. According to Kagee (2006) and 
Mehta et al (1997), these may include factors such as the complexity of the 
treatment regimen, dosages, schedules, food requirements, toxicity and side-
effects. Table 4.32 shows that 82.1% of respondents reported having no 
problems relating to taking their medication whilst 17.9% cited various reasons 
that made it difficult for them to adhere to their treatment. These findings 
should, however, also be seen against the reported rates of missed dosages 
commented on later in this chapter. 
 
Two respondents (7.1%) reported having difficulty taking their medication 
whilst at work as no one knew about their HIV status; one (3.6%) reported 
having no money to buy the kind of food needed when taking his/her 
medication. Of the remaining two respondents, each (3.6%) reported having 
difficulty taking medication when fasting and when having her menstrual period 
respectively. This was attributed to religious and traditional beliefs respectively 
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by the respondents. In terms of the reports in this aspect it seems that most 
respondents were able to take their medication as prescribed at least most of 
the time. But when this finding is compared with the results on missed dosages 
in the previous section, the findings show that most patients have difficulty 
adhering to their regimens as 64.3% reported missing a dose some time 
during their treatment span. 
 
It is, however, important also to view the treatment specific problems in 
conjunction with other factors that may interact with these and amplify the 
impact on adherence. These may include issues such as disclosure and fear 
of discrimination as evidenced by the two respondents who reported being 
unable to take their medication whilst at work. This was as a result of both lack 
of disclosure and the treatment schedules and times. According to the NSP 
(NDOH 2010:9), in SA poverty is one of the major contributors to poor health 
and treatment outcomes through food insecurity in as far as HIV and TB 
acquisition and treatment adherence are concerned. In this study, however, 
only one respondent reported food as a factor which contributed to non-
adherence and the others ensured adherence in one way or another. The SA 
government,  in order to reduce the impact of poverty, introduced a chronic 
disease grant assistance for those living with HIV who could not support 
themselves and their families so as to encourage adherence (NDOH 
2007:114; ETU 2012). The qualification criterion for the grant is that the PLHIV 
must be too sick to work and when their health improves the grant is 
terminated (SASSA 2012).  
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Table 4.32: Specific problems related to taking medication on time (N=28) 
 
SPECIFIC PROBLEMS RELATED TO TAKING 
MEDICATION ON TIME 
FREQUENCY 
 
% 
 
No problems 23 82.1 
Cannot take medication while menstruating 1 3.6 
No money for food one has to eat whilst taking medication 1 3.6 
Cannot take medication while fasting 1 3.6 
Finds it difficult to take it when at work 2 7.1 
Total 28 100.0 
 
4.5.13 Specific problems related to following a prescribed diet 
 
It is necessary for every human being to follow a healthy balanced diet but 
even more important for an HIV positive person because of their compromised 
immune system. A balanced diet is integral to the success of ART and patients 
are encouraged to follow a diet consisting of all the five basic food groupings: 
namely, carbohydrates; proteins; fruits and vegetables; milk and dairy; fats and 
oils (Evian 2011:137). This prescribed diet is in no way different from the diet 
required by every other human being. A healthy diet helps delay the 
progression from HIV infection to Aids, helps improve the performance of the 
immune system, protects the body against opportunistic infections and 
illnesses and helps develop and repair cells and tissues. Good nutrition also 
helps the body tolerate medical treatments more easily and improves one’s 
sense of well-being (Health24:2009). The specific problems relating to diet 
reported by respondents were mainly poverty and an inability to buy the 
necessary food (See Table 4.33). Of the total number of respondents, 46.4% 
reported that they simply could not afford to buy all the necessary food whilst 
another 46.4% stated that it was rather difficult but somehow they coped. The 
rest of the respondents (7.1%) reported having initiated food gardens and 
these had provided much needed relief as they also could not afford to buy 
basics such as vegetables and fruit. With unemployment and poverty levels 
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being high these food gardens can only be a worthwhile supplementation 
alternative.  
 
Investigating the local shops, the researcher found that one needs at least 
R250 per week to buy basics such as vegetables, fruit and bread in order to 
meet the daily dietary requirements. This amount increases significantly when 
other basic necessities like proteins are included. This can be a challenge for 
people with no reliable source of income or with no income at all. In SA, 
poverty is one of the major contributors to poor health and treatment outcomes 
through food insecurity in as far as HIV and TB acquisition and treatment 
adherence are concerned  (NDOH 2010:9). The unavailability of these basic 
foods can be regarded as a barrier to good adherence as some patients may 
not take their treatment when they have no food at home. Literature also 
shows that there is a strong association between poverty and lack of food and 
poor adherence to ART (WHO 2003:28; Kagee 2006:415; Hardon et al 
2006:10; Mukherjee et al (2006:124). The SA government has put resources in 
place such as the chronic disease grant, social relief and food parcels but all 
these are temporary and sometimes may promote non-adherence when these 
measures are terminated as mentioned in chapter 2 of this dissertation.    
   
Table 4.33: Specific problems related to following a prescribed diet whilst 
taking medication (N=28) 
 
SPECIFIC PROBLEMS RELATED TO FOLLOWING A 
PRESCRIBED DIET 
FREQUENCY 
 
% 
 
Cannot afford food 13 46.4 
Poverty is a problem, but we cope 13 46.4 
Have enough food, because we have a food garden at 
home 
2 7.1 
Total 28 100.0 
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4.5.14 Specific problems related to receiving support whilst taking 
medication 
 
The study shows that all respondents disclosed their status to someone and as 
a result almost all had someone to support them through this process. Table 
4.34 shows that 96.4% of respondents reported having someone who was a 
source of support; someone they confided in and someone who helped them 
adhere to their treatment. It is, however, important to note that one respondent 
reported having no one to discuss the HIV with. Despite having disclosed and 
received support from significant others, the findings here show that the 
majority of respondents were still having difficulty achieving optimal adherence 
to their regimens. 
 
The SA National Treatment Guidelines (NDOH 2004) stipulate that whilst 
disclosure is not a requirement for a person initiating ART, it is highly 
recommended that they disclose to at least one family member or a trusted 
friend and join a support group. Disclosure is important for those diagnosed 
with HIV in order for them to obtain support and help them reduce the stress of 
coping on their own; it can also help them to protect themselves and their 
sexual partners (NDOH 2010:17; Evian 2011:467).  It, however, needs to 
happen when the patient is ready and counsellors can assist with preparation 
for disclosure (Norval 2012). When people disclose their status they become 
vulnerable to negative responses such as discrimination, rejection, 
abandonment and even antagonism which may result in isolation for those 
disclosing (Norval 2012). According to Van Dyk (2011), stigma, discrimination 
and lack of social support are often the main reasons for people on ART hiding 
their HIV status and treatment-taking from colleagues, friends and family. 
Adherence counselling can, therefore, play a significant role in assisting with 
disclosure as much as possible.  
 
Literature also shows that clients who have not disclosed their status and are 
required to take their treatment in secret have a poorer chance of adhering to 
their regimens (Evian 2011:467; NDOH 2010:17; Van Dyk 2011; Kagee 
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2006:419). It has, however, been shown from practical experience that not all 
patients disclose their HIV status for fear of being discriminated against as HIV 
as a disease carries a great deal of stigma. This is not the case with this 
current study as the majority have disclosed. In the qualitative phase it was 
discovered that eight of the nine participants had disclosed to their significant 
others and seven of them were being supported by their loved ones. However, 
one of them disclosed to her partner and he was not supportive towards her, 
and instead allegedly acted in an abusive way towards her.  
  
Table 4.34: Specific problems related to receiving support whilst taking 
medication (N=28) 
 
SPECIFIC PROBLEMS RELATED TO RECEIVING 
SUPPORT WHILST ON MEDICATION 
FREQUENCY 
 
% 
 
Has no one to discuss HIV with 1 3.6 
Mother is very supportive 3 10.7 
Confides in sister 2 7.1 
Spouse/girlfriend/boyfriend helps me adhere 20 71.4 
Family member helps me adhere 1 3.6 
I have sufficient support 1 3.6 
Total 28 100.0 
 
 
4.5.15 Specific problems related to adherence 
 
Table 4.35 shows that more than three quarters of all the respondents (78.5%) 
have no problems adhering to their ART. The specific problems relating to 
adherence to medication cited by the remaining 21.5% of respondents, that is, 
six respondents, included the inability to purchase all necessary food like fruit 
and vegetables; being unable to take medication when at work; forgetting; and 
feeling depressed. Half of those with a challenge, that is three of the six 
respondents who reportedly had difficulty adhering to their treatment, cited 
being unable to be adherent whilst at work. Factors identified as playing a role 
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in adherence include ‘internalized stigma and external discrimination, lack of 
disclosure, shift work, time off work to attend clinic appointments’ (NDOH 
2010:17-18). This is consistent with the findings of this study in which patients 
cited inability to take their treatment when at work and that working irregular 
hours impacted on their treatment adherence in both qualitative and 
quantitative phases. The common specific problems mentioned during the 
qualitative phase of the study were unemployment, lack of food, working night 
shift and forgetting to take treatment at times.  
 
Table 4.35: Specific problems related to adherence (N=28) 
 
SPECIFIC PROBLEMS RELATED TO 
ADHERENCE 
FREQUENCY 
 
% 
 
No problems 22 78.5 
Unable to buy fruit and vegetables 1 3.6 
Very depressed 1 3.6 
Finds it difficult to adhere when at work 3 10.7 
Forgets when favourite TV programme starts 1 3.6 
Total 28 100.0 
 
 
4.5.16 Respondents who missed a single dosage 
 
Table 4.36 indicates that just under two thirds (64.3%) of the respondents 
reported that they had missed a dose of treatment. Only 35.7% reported not 
missing a single dose of their treatment. Ideal adherence means that  patients 
must take more than 95% of their prescribed doses, which is equivalent to 
missing not more than three doses per month (NDOH 2004: 53). Non-
adherence, on the other hand, means ‘not taking medication at all, self-
adjusting doses so as to modulate side-effects, prematurely terminating 
treatment, not honouring clinic appointments and not filling prescriptions’ 
(Kagee 2008:414). It also extends to not making the recommended 
behavioural changes and lifestyle adjustments such as practising safer sex 
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and stopping alcohol usage. Being adherent with taking  medication but still 
engaging in unprotected sexual intercourse with an HIV positive person may 
expose the patient to possible re-infection with the virus and, therefore, 
insufficient suppression of the HI virus.  
 
According to Jean-Baptiste (2008:5), poor adherence implies ‘missing doses 
and taking medication inappropriately’. The findings clearly indicate that almost 
three quarters of the respondents were adhering poorly to their treatment as 
suggested in the above definition of what poor adherence is. This is a cause 
for concern for long-term treatment outcomes as with missed dosages viral 
suppression is limited owing to insufficient medication taken (Van Dyk 2011). 
These gaps in treatment provide the virus with a chance to replicate which 
may result in the immune system becoming weak again and unable to fight 
any opportunistic infections.  Literature has, however, shown that subjective 
reporting of adherence can sometimes be under- or over-estimated as patients 
may tend to over-exaggerate their self-reported levels of adherence (WHO 
2003:96). The probability of a higher percentage of non-adherence amongst 
the respondents in this study exists.   
 
Table 4.36: Respondents who missed a single dosage (N=28) 
 
WHETHER RESPONDENTS HAVE EVER 
MISSED A DOSAGE 
FREQUENCY 
 
% 
 
Yes 18 64.3 
No 10 35.7 
Total 28 100.0 
 
 
4.5.17 Number of times a dosage has been missed 
 
Table 4.37 shows a mixed picture of instances when a dosage was missed. 
From the 28 respondents interviewed, 10 reported never missing a single dose 
and 18 reported having missed a dose during their treatment span as shown in 
table 4.37. About a third (33.3%) of the 18 who had missed a dosage did so 
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rarely, followed by 22.2% who missed a dosage once a week; 22.2% who 
missed a dosage once a month; 16.7% who missed a dosage once in three 
months and one respondent who had completely stopped taking ARVs for the 
two months prior to the interview.  
 
If one takes into account the definitions of adherence, non-adherence and poor 
adherence as cited in paragraph 4.5.16 above, the findings clearly depict a 
mixed picture of both non-adherence and poor adherence. Fewer than a 
quarter (22.2%) of the respondents reported missing a dose at least once a 
week, which is equivalent to four times a month and that clearly shows poor 
adherence as ideal adherence is equivalent to missing no more than three 
doses per month. At least one person also reported stopping treatment 
completely two months prior to these interviews which is in essence non-
adherence to treatment as it was prematurely stopped. The rest of the 
respondents had either missed a dose once a month, once in three months or 
very rarely and this can be considered being adherent as 95% of the treatment 
was reportedly taken but nevertheless it was poor adherence. This is, 
however, a subjective report of adherence and according to WHO (2003:96) 
patients may tend to over-exaggerate their self-reported level of adherence. 
This could be owing to a recall bias, a desire to please the health care provider 
or to avoid criticism from HCP. A third (33.3%) of those who missed a dose 
reported rarely missing one and the researcher is of the view that the 
probability of under- or over-reporting of adherence in this instance exists. The 
findings in this study nevertheless give a clear indication of poor adherence 
levels albeit at different levels. 
 
In the qualitative data one respondent reported completely stopping treatment 
owing to religious beliefs as he/she believed God would heal him/her. This is 
what he/she had to say:  
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I do not see the need to be on treatment as I believe God has the power 
to heal. I know my health improved when I was started on treatment but 
God was still responsible for my health improvement even then. 
[Respondent 3] 
 
 
Table 4.37: Number of times a dosage was missed (N=28) 
 
HOW OFTEN A DOSAGE HAS BEEN MISSED FREQUENCY 
 
% OF 
TOTAL 
 
% of those 
who have 
missed 
Once a week 4 14.3 22.2 
Once a month 4 14.3 22.2 
Once in three months 3 10.7 16.7 
Rarely 6 21.4 33.3 
Never 10 35.7 - 
Stopped for 2 months 1 3.6 5.6 
Total 28 100.0 100.0 
N=18 
 
 
4.5.18 Circumstances that lead to respondents missing a dosage 
 
Patients normally cite various reasons for missing a dosage of their treatment. 
As shown in Table 4.38, the major reasons cited by the 18 respondents who 
missed a dosage, are the respondent attending a funeral (22.1%) or being 
away from home (27.8%). Other reasons cited were respondents forgetting to 
take their treatment (5.6%); no food at home (11.1%); attending a soccer 
match (11.1%); having severe financial problems at home which impacted on 
travelling cost and availability of food (5.6%); and respondents having difficulty 
taking medication at work when there was no privacy (11.1%) The findings in 
this study indicated that the majority of respondents (61%) found it difficult to 
adhere when they were not at home attending some kind of social function. 
One respondent also reported forgetting to take his/her medication. This is 
consistent with the literature as forgetfulness and lack of planning are patient-
related factors associated with non-adherence (NDOH 2010:18; Van Dyk 
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2011). These manifest when patients attend social functions on weekends or 
when they are away from home and when no provision has been made to 
have adequate treatment in their possession. This is an important issue to be 
addressed during adherence counselling sessions to ensure that patients are 
empowered and skilled to plan accordingly. On the other hand, lack of 
adequate financial resources and availability of food were also reported to 
have an impact on the ability to adhere (NDOH 2010) which is consistent with 
the findings of this study. This is evident as 5.6% and 11.1% of respondents 
reported experiencing severe financial problems at home and having nothing 
to eat respectively. 
 
Table 4.38: Circumstances that lead to respondents missing a dosage 
(N=18) 
CIRCUMSTANCES THAT LEAD TO RESPONDENTS 
MISSING A DOSAGE 
FREQUENCY 
 
% 
 
When attending a funeral 4 22.1 
When I forget 1 5.6 
When I had nothing to eat 2 11.1 
When away from home 5 27.8 
When playing soccer/attending/watching a soccer 
match 
2 11.1 
When having severe financial problems at home 1 5.6 
When working/earning an income 2 11.1 
When I have no privacy to take my medication 1 5.6 
Total 18 100.0 
 
4.5.19 Factors that encourage adherence 
 
Respondents cited various reasons that encourage and promote adherence to 
their treatment regimens. Almost a third (32.1%) reported that being aware of 
the benefits of ART encouraged them to adhere, whilst 18% noticed 
improvement in their well-being and 7.1% were grateful to be alive as a result 
of being on ART. Another category of respondents (32.1%) reported that 
having support from loved ones played a very significant role in their 
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adherence and 10.7% felt that having accepted their HIV status also 
encouraged them to adhere to their treatment (see Table 4.39).   
 
According to Heyer & Ogunbanjo (2006:6), understanding the treatment 
regimen plays a very significant role in encouraging adherence. They state that 
patients on ART who do not have a good understanding of the relationship 
between adherence, viral load and disease progression adhere significantly 
more poorly than those who understand.  In terms of HBM, the perceived 
benefits of a recommended health action can serve as an incentive for patients 
to follow positive health regimens so as to achieve positive treatment 
outcomes (Masokoane 2009:21) The premise here is that people on ART who 
have a good understanding of what positive changes the treatment will bring 
about physically and otherwise are more likely to adhere to their regimens. 
This implies that for the behaviour to be undertaken the patient must evaluate 
the benefits of the recommended change as more valuable than the action 
required. This seems to be consistent with the findings here as 32.1% of 
respondents felt that awareness helped them with adherence. 
 
 Denial of HIV diagnosis and a lack of disclosure to significant others have also 
been identified as factors that determine levels of adherence to treatment 
(NDOH 2010:17). According to Mehta et al (1997:1669), patients’ knowledge 
of their status and acceptance thereof, the expected course of illness and the 
treatment have all been associated with increased levels of adherence to 
treatment. 
 
Lack of effective social support networks has also been reported to have a 
significant impact on adherence (WHO 2003:28). Findings from studies carried 
out in Sub-Saharan Africa indicate that although patients may be motivated to 
adhere to their regimens, lack of support undermines their good intentions 
(Hardon et al 2006). In this study the findings are consistent with this 
information as respondents reported social support as playing a very 
significant role in their adherence. 
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Table 4.39: Factors that encourage adherence (N=28) 
 
FACTORS THAT ENCOURAGE ADHERENCE FREQUENCY % 
Because I’m aware of the benefits 9 32.1 
Support from spouse/loved ones 9 32.1 
It improves my well-being 5 18.0 
To have accepted my status 3 10.7 
I am grateful to be alive 2 7.1 
Total 28 100.0 
 
 
4.5.20 Perceptions of the service received at the clinic 
The majority of respondents (67.9%) felt that the service offered at the 
wellness clinic was generally good. They, however, cited varying feelings 
regarding the service which ranged from some feeling free when they were at 
the clinic and feeling that they were treated equally with no discrimination 
whilst others felt that the health care professionals were sometimes strict with 
them. Further to this, 3.6% of the respondents felt that the waiting times were 
too long at the clinic and others (3.6%) felt that some nurses were rude to 
them. It is important to point out that at least 14.3% of the respondents had no 
answer to this question and did not want to commit themselves (see table 
4.40). Negative staff attitudes and a perceived lack of caring by health facility 
staff (NDOH 2012:17) impact on how the service is viewed and received by 
patients. Long waiting times at the clinic (Roura et al 2009:48; Hardon et al 
2006:9) have also been associated with poor adherence and in this study it 
emerged that some respondents felt that this affected the service offered at the 
clinic. The possibility is great that this was a perceived reality but it was how 
the respondents experienced the interaction with staff and the service offered. 
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Table 4.40: Perceptions of the service received at the clinic (N=28) 
 
PERCEPTIONS OF THE SERVICE FREQUENCY % 
Generally a good service 19 67.9 
Good, but strict 1 3.6 
Felt free 1 3.6 
Treated the same 1 3.6 
Long waiting times 1 3.6 
No answer 4 14.3 
Some of the nurses are rude to patients 1 3.6 
Total 28 100.0 
 
 
4.5.21 Perceptions of the attitudes of the health care professionals at the 
clinic 
Table 4.41 indicates that 85.7% of respondents did not want to respond to this 
question whilst 10.7% stated that it did not matter what they thought about the 
health care professionals’ attitudes. Only 3.6% (n=1) felt that the HCP were 
supportive towards their adherence. Negative staff attitudes; a perceived lack 
of caring by health facility and staff (NDOH 2012:17); poor communication; and 
provider-patient relationship (Oldridge 2001:337) were all identified  as factors 
that impact on the provider-patient interaction and ultimately adherence to 
treatment. The majority of the respondents (85.7%) were not willing to express 
their opinions on this and the researcher is of the opinion that they feared 
possible victimisation from staff if they expressed negative sentiments. It is 
also possible that the researcher was associated with the clinic staff as she 
had worked in that clinic before and they did not feel at ease discussing the 
issue with her. It is also interesting to note that 67.9% of the respondents (see 
Table 4.40) felt that the service was generally good but at the same time the 
majority at 85.7% seemed afraid to talk about the attitude of the staff towards 
them. 
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Table 4.41: Perceptions of the attitudes of the health care professionals 
at the clinic (N=28) 
 
PERCEPTIONS ABOUT ATTITUDES OF HCP FREQUENCY % 
It doesn't matter 3 10.7 
They are supportive of my adherence 1 3.6 
No answer 24 85.7 
Total 28 100.0 
 
4.5.22 Respondents’ rating of the service received at the clinic 
 
The respondents rated the service at Shongwe hospital wellness clinic as 
either good or very good with more than half of the respondents (57.1%) rating 
the service positively (see Table 4.42). 
 
Table 4.42: Respondents’ rating of the service received at the clinic 
(N=28) 
RATING OF SERVICE AT THE CLINIC FREQUENCY % 
Good 16 57.1 
Very good 12 42.9 
Total 28 100.0 
 
 
4.6 A SYNTHESIS OF THE QUANTITATIVE PHASE 
 
The quantitative phase of the study provided an overview of the respondents 
as being of potential wage-earning ages; however 46.4% of the respondents 
were unemployed at the time of the interview despite the fact that 67.9% of 
them have at least a secondary school level of education. Many had young 
children that could potentially lose a parent if the patient did not adhere to the 
treatment.   
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Although only 21.5% of the respondents reported that they have had difficulty 
adhering to their treatment regimens, a staggering 64.3% of them admitted to 
having missed a dosage. Those who cited specific difficulties in adherence 
named finding it difficult to take their treatment whilst at work; being forgetful; a 
shortage of food; and depression as reasons for failing to adhere to their 
treatment.  
 
Nearly two thirds (64.3%) of respondents also reported having missed a dose 
of their treatment with 14.3% of them missing at least a dose per week. In 
terms of adherence, a patient should be adherent at least 95% of the time 
which is equivalent to missing three doses per month. It is an issue of concern 
when such a large percentage of respondents miss at least four doses per 
month as this may result in treatment failure in the long run. 
 
The major reason cited for missing a dose is being away from home for 
reasons including attending a funeral. Half (50%) of the respondents reported 
that the reason for missing their dosages was being away from home, either 
attending a funeral or visiting family. This was in most cases because they did 
not bring enough tablets for fear of being seen by others taking treatment. 
 
The majority of respondents reported having no problems adhering to their 
treatment. At least 78.5% reported that they did not experience any problems 
relating to treatment adherence. In terms of the Health Belief Model and the 
Information Motivation Behaviour Model, it is possible for patients to attain 
adherence to their treatment if they have the relevant knowledge; motivation to 
see positive changes in their health status; skill to bring about the change; and 
the belief in their ability to bring about this change. Social support of the 
spouses and loved ones and a supportive network in the community can serve 
as motivating factors for people living with HIV and receiving treatment. 
 
The two major reasons cited for encouraging adherence among the 
respondents was being aware of the benefits of being on treatment and 
receiving the support of family and friends. Nearly a third of the respondents 
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(64.2%) cited these two reasons as encouraging them to adhere, followed by 
the improvement brought about by ART in their health and having accepted 
their status. The majority of respondents received enough support from their 
significant others with 80% reporting positive and consistent support. In terms 
of HBM, the support of the family can serve as a cue to action for a patient 
who can be influenced by the support from family to take the recommended 
health action in order to bring about positive health outcomes. 
 
The three health-seeking behaviour models emphasise that for patients to 
adhere to their ART regimens there must be perceived benefits to taking the 
recommended treatment as proposed by HBM; positive expectancies about 
consequences of their actions in terms of the Social Cognitive Theory; and 
having the knowledge, motivation and skill to bring about change as espoused 
by the IMB model.  
 
4.7 RESULTS OF THE FOCUS GROUP DISCUSSIONS 
 
The researcher adopted a thematic analysis method to analyse data from 
focus group interviews. From the transcripts it was possible to identify main 
themes and these became the basis for the analysis of the data obtained. 
These identified themes were categorised under the following themes that 
affect adherence, that is, patient-related, socio-economic, therapy-related 
factors and health care provider-related factors. This section reports on the 
findings of the data analysis in terms of the themes identified.  Each of the 
themes will be introduced briefly and described and then followed up with a 
direct quotation from the respondents’ utterances to support the identified 
theme. It should be noted that some of the salient findings from the focus 
group discussions that either corroborated or contradicted the findings from the 
quantitative survey were mentioned under sub-headings 4.2 to 4.6. 
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4.7.1 Theme 1: Patient-related factors  
 
4.7.1.1 Feelings regarding receiving an HIV-positive diagnosis 
 
It is normal for people to experience strong feelings and emotions on receiving 
an HIV positive diagnosis. In this study, the respondents also expressed varied 
feelings after testing HIV positive. Feelings such as shock, guilt, fear, denial 
and/or acceptance of an HIV diagnosis have been reported to affect 
adherence (NDOH 2010:17). These determine responses and attitudes to the 
disease and the available treatment and readiness to engage in the long-term 
commitment of ART. 
 
Fear, sadness, shock and upset 
Three of the nine respondents reported that they initially felt very afraid, sad 
and upset but had since accepted their statuses. 
 
‘When I was told I am HIV positive I felt very sad and afraid as I thought 
I will die.’ [Respondent 1] 
 
 ‘I felt sad and upset when I tested positive but I have accepted.’ 
[Respondent 2] 
  
‘I discovered that I am HIV positive when I was tested during my second 
pregnancy. I was shocked as I was not expecting it. To make matters 
worse the quality of counselling I received was not good but I have 
been exposed to good counselling in recent years.’ [Respondent 9] 
 
Acceptance 
 Acceptance of an HIV-positive status is an important factor in the person’s 
readiness for treatment adherence. Enriquez (2002:12) defines readiness as ‘a 
conscious awareness, on the part of an individual, based on free will, that 
he/she has considered and determined that a particular behaviour change (i.e., 
taking his/her anti-HIV medication as prescribed) will be beneficial’. It implies 
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that a person realises that the status quo is not likely to change and therefore 
he or she needs to accept and learn ways of living with it meaningfully. It is 
also evident in the statements of these three respondents who initially felt 
angry, afraid and upset but had to accept and move on with their lives.  
 
Stress 
Two participants reported experiencing a great deal of stress after losing their 
jobs owing to absenteeism when attending the clinic, losing their homes and 
as a result being displaced. 
 
Respondent 4 reported losing his job because of taking time off work to attend 
the clinic. He used to work as a petrol attendant and the employer did not 
understand that he had to attend clinic at least once a month. This was also 
compounded by the fact that he had not disclosed his status. He was then fired 
and as a direct result of this lost his rented home and became displaced. He 
stated: 
‘I was fired from my job as I used to take time off for clinic visits. Being 
unemployed and having no food and depending on other people who 
do not even know my status put pressure on me and as a result I feel 
really stressed.’ 
 
Respondent 9 reported being separated from her partner and the father of her 
children as a result of being diagnosed with HIV. The respondent said that she 
was financially dependent on her partner for survival and that they had shared 
a home. When the relationship ended, she and her children became homeless 
and displaced as a result. 
 
‘When my relationship broke down I lost someone who was taking care 
of me and my children. I lost my home and now have no source of 
income but have to depend on other people for everything.’ 
 
 
 
130 
 
4.7.1.2 Irregular working hours and forgetfulness 
 
Two of the nine focus group discussants reported working irregular hours that 
included night shift or late shifts. These irregular working hours made it difficult 
for the discussants to take their treatment properly as this coincided with either 
the time when still busy at work or when travelling back home. Practical and 
environmental factors like working odd hours have been associated with an 
inability to take treatment properly (Van Dyk 2011). This is consistent with the 
report by discussants that sometimes it is practically not possible to take 
treatment when working such hours. In terms of the social learning theory it is 
also postulated that environmental factors play a significant role in determining 
action. The fact that a person is busy at work may result in his/her being 
unable to take time off in order to take treatment as required or even forgetting 
to take the treatment. This was reported by two participants in the focus group 
but was not established in the quantitative phase of the study and cannot 
therefore be generalised to the wider population.  This is what they said in this 
regard:  
 
 ‘My work schedule …working night shift make it difficult to take my 
treatment. I even forget to take my treatment when I am working at 
night.’ [Respondent 2] 
 
 ‘I work very irregular hours … sometimes I work an early morning 
shift and sometimes it’s a late afternoon shift. This affects my daily 
routine and I have not been able to find a suitable time to take my 
treatment properly.’ [Respondent 6] 
 
4.7.2 Theme 2: Socio-economic factors: social support factors 
 
This section is aimed at discussing themes categorised under socio-economic 
factors that influence adherence. These include factors such as attitude of 
family and significant others towards HIV; religious and traditional beliefs; 
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transport costs; long waiting times; lack of food; stigma; discrimination; and 
lack of social support. 
 
4.7.2.1 Denial of HIV by a sexual partner and condom use 
 
Four of the nine respondents reported having sexual partners who were in 
denial regarding the respondents’ status and their own had a bearing on their 
adherence. All four of these respondents were female and they reported that 
their spouses were also HIV positive but they were not practising safe sex. 
This is what they had to say:  
 
‘We are both HIV positive, but my partner refuses to use a condom. 
This has affected our sexual relations. I just feel like he doesn’t care 
about me at all and I do not have much say in this.’ [Respondent 1] 
 
 ‘My partner is not co-operative and he refuses to use a condom when 
we have sexual intercourse.  He also does not want me to take my ARV 
medication and I have to hide it from him … it is so difficult because we 
are staying together.’ [Respondent 5] 
 
 ‘I currently live with my boyfriend and he is supporting me as I am 
unemployed. Sometimes we use the condoms and sometimes we don’t. 
It is just difficult.’ [Respondent 7] 
 
‘My partner is also HIV positive but he refuses to use a condom. He 
uses traditional medicines and do not want to take ARVs.’ [Respondent 
8] 
 
4.7.2.2 Support system and disclosure 
 
People affected by and infected with HIV and Aids are often subjected to 
discrimination and rejection by their friends, family, sexual partners and work 
colleagues (Evian 2011:464). Even though they may be motivated to adhere to 
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their ART for personal reasons, lack of or poor support from their loved ones, 
or feelings of being discriminated against or stigmatised as a result of being 
HIV positive may negatively impact on adherence. Of the nine respondents 
only one respondent reported that he had not disclosed to anyone his HIV 
status. His reasons for not disclosing his status were that he did not see any 
benefit and was also afraid of disclosing to the wrong person. This is what he 
had to say: 
 
 ‘I have not disclosed to anyone as I see no need for that … I also fear 
that I might tell a wrong person. I always have a problem though since I 
now have a new partner to whom I have not disclosed. When she is 
around I have to hide my tablets and take them in secret and 
sometimes it is not easy.’ [Respondent 2] 
 
The rest of the respondents reported having disclosed their status to different 
people. Some disclosed only to their partners, others to family and friends and 
yet others to their parents. The reasons for disclosing to particular people and 
not to others also varied within this group of respondents. Here are some of 
the examples of reasons cited by respondents: 
 
 ‘I disclosed to my sister because she is also HIV positive and I 
thought we can be in a position to support each other.’ 
[Respondent 1] 
 
 ‘I have only disclosed to my partner and not the whole family as I 
am not sure how they will respond.’ [Respondent 4] 
 
‘I have disclosed to my partner but it has not helped me in any 
way. He is not supportive of me taking my treatment and is very 
abusive towards me. Sometimes I wish I had just kept it from him 
because maybe things could have been better now.’ [Respondent 
5] 
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 ‘I have told everyone … my partner, family and friends. I have not 
told anyone at work and it is difficult for me to take my medication 
when I am at work as no one knows about my illness.’ 
[Respondent 6] 
 
 ‘I have told everyone and they are all very supportive.’ 
[Respondent 7] 
 
 ‘I decided to tell everyone so that everyone knows what I am 
going through. Everyone has been very supportive except for 
partner who decided to leave me to suffer with my kids.’ 
[Respondent 8] 
 
 ‘My partner knows my status since we tested together and he is also 
HIV positive. I haven’t told anyone at work though as I am scared I 
might be discriminated or victimised.’ [Respondent 9] 
 
The last respondent had a different story to tell as he was born HIV positive 
and therefore did not have to disclose. He was only tested in 2009 when he 
became very sick having herpes zoster which is one of the common 
opportunistic infections for people at a stage four of the disease (Evian 
2011:39). This information was also corroborated by the patient’s father and 
the health care professionals at the clinic. This is what he had to say: 
 
 ‘I was told by my dad that I got the virus from my mother who passed 
away when I was very young. I have accepted the fact that I am HIV 
positive though I do not want any HIV medication.’ [Respondent 3] 
 
4.7.2.3 Belief system 
 
An individual’s belief system plays a major role in determining how he/she 
perceives situations and it largely determines attitudes, behaviour and actions 
(Kagee 2006:423). This is also true for people living with HIV who may have 
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their own beliefs regarding the HIV disease which may have an impact on 
whether they believe ARVs will help them or not. 
 
In this section the researcher considered traditional beliefs that participants 
might use to understand their illness and traditional ways of coping with the 
illness. It emerged from the discussion that these traditional beliefs sometimes 
may lead to non-adherence. Of the nine respondents, only one respondent 
reported that her partner believed in traditional medicine and as a result he did 
not want her to take ARVs. Although she did not stop taking medication, it 
affected her adherence levels as she had to take it in secret. The researcher 
found it interesting that no other person reported belief in or use of traditional 
medicines amongst the respondents who reside in a rural area where 
traditional and cultural beliefs still significantly influence health seeking 
behaviour. Literature suggests that traditional healers are the primary health 
care providers in rural areas for at least 80 to 85% of rural people both in 
Tanzania and South Africa (Mustapher 2012; AIDS Foundation 2010).  This is 
what one participant had to say: 
 
 ‘He does not want me to take my ARV medication and I have to hide it 
from him … it is so difficult because we are staying together. He is 
taking his traditional medicine which he believes will cure him.’ 
[Respondent 5] 
 
The researcher explored how religious beliefs might affect adherence with the 
focus group participants. One participant claimed to being a born again 
Christian who started treatment in 2009 when he was very sick. He has, 
however, stopped taking his ART as he strongly believes there is no need for 
treatment as God will heal him of the disease. These are his sentiments:  
 
 ‘I do not see the need to be on treatment as I believe God has the 
power to heal. I know my health improved when I was started on 
treatment but God was still responsible for my health improvement even 
then.’ [Respondent 3] 
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4.7.2.4 Unemployment and financial dependence 
 
Unemployment plays an important role in whether patients are able to adhere 
to their treatment regimens or not. It relates to factors such as costs that 
patients incur when they attend clinic like transport costs and ensuring they 
have sufficient food in order to take their medication well (NDOH 2010; WHO 
2003). Of the nine respondents, three reported being unemployed and having 
to depend on other people like spouses and relatives.  
 
 ‘Unemployment, having no food, being stressed can have an effect on 
one’s ability to adhere; being homeless and living with people who are 
not even aware of your  HIV status ... It’s really tough!’ [Respondent 4]. 
 
 ‘Dependence on your spouse for everything you need can be very 
difficult especially if that person is not very supportive towards you and 
your taking of ART. You find yourself agreeing to everything that they 
tell you just to keep the peace.’ [Respondent 5] 
 
 ‘Being unemployed and having no source of income makes it really 
hard to cope. I am under so much stress but despite all that, I make 
sure that I take all my treatment regularly.’ [Respondent 9] 
 
4.7.3 Theme 3: Therapy-related factors: side effects 
 
The majority of people when initiated on ART tolerate some discomfort 
resulting from side effects  as these usually present as  mild and self-limiting 
symptoms such as headaches, nausea and abdominal discomfort (Evian: 
2011:175). In instances of more serious side-effects such as diarrhoea and 
lukopenia, some patients might then stop taking their medication or adjust their 
dosages so as to decrease the severity of the side effects. This has also been 
found to be true in a study of mentally ill patients who discontinued treatment 
owing to the fear of side effects (Mehta et al 1997:1668-1669). Of the nine 
respondents, one reported having experienced some side effects which made 
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him unable to cope with his schoolwork. These are his sentiments regarding 
side effects: 
 
 ‘The treatment has affected my schooling ... when I take the tablets I 
can’t concentrate and feel like sleeping all the time.’ [Respondent 3] 
 
4.7.4 Theme 4: Health care provider-related factors 
 
This refers to those factors related to the health care providers, the services 
provided and the relationship they have with patients which may impact on 
adherence. These include factors such as poor communication between 
provider and patient (Oldridge 2001:337) and the relationship between the 
HCP and patient (Frank & Duncan 2009:23). 
 
4.7.4.1 Adherence counselling 
 
One of the most important components of patients’ commencement of ART is 
adherence counselling as it prepares the patient for the long-term commitment 
required. It is essential that patients be provided with a comprehensive 
treatment plan to support adherence and this is negotiated during adherence 
counselling sessions with all the relevant players involved (NDOH 2004). NSP 
2012-2016 further advocates that adherence counselling be offered at each 
clinic visit to increase patients’ understanding and ensure that they are 
retained in care (NDOH 2011:49). The emphasis is on the fact that adherence 
counselling is not a once-off event but it should be an on-going process aimed 
at ensuring that patients do not fall out of the programme unnecessarily (Van 
Dyk 2011) 
 
Some patients attend adherence counselling sessions when they are already 
very sick and have difficulty understanding what is happening. This is likely to 
have an impact on whether the patients understand the treatment and what is 
expected of them in terms of diet and behaviour change. The introduction of 
treatment advocates or supporters nominated by patients is advocated when 
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initiating treatment as it helps provide support to the patient (NDOH 2004). All 
of the nine respondents in this focus group discussion stated that they 
attended adherence counselling and eight respondents found it to be of good 
quality. These are examples of their responses: 
 
 ‘The quality of counselling I received when I first discovered I was HIV 
positive in 1999 was not good but I have since been exposed to good 
counselling in recent years.’ [Respondent 9] 
 
 ‘I received good counselling from the counsellors. It really helped me 
understand my medication and side effects.’ [Respondent 2] 
 
In the quantitative phase it was noted that all of the 28 respondents reported 
attending adherence counselling but that 32.1% of them stated that they did 
not know what adherence was all about and could not remember what had 
been discussed. This is an issue of concern as adherence counselling is the 
basis of an effective ART programme.  
 
4.8 RESULTS OF THE FACE-TO-FACE INTERVIEWS WITH KEY 
INFORMANTS 
 
Interviews were held with the social worker, lay counsellors and the pharmacist 
assistant.  The main findings are reported below.  
 
4.8.1 Lay counsellors 
 
The lay counsellors stated that the main reasons cited by patients as barriers 
to treatment adherence were side effects, belief in traditional medicine as an 
alternative to ART and alcohol abuse which resulted in their forgetting to take 
their treatment. In the literature it has been established that side effects are the 
most commonly cited factors impacting on adherence (Van Dyk 2011; Evian 
2011:175). Active substance and alcohol abuse or addiction has also been 
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associated with poor adherence to treatment (Chesney 2000:172) although 
this was not evident in this study. This is what the lay counsellors had to say: 
 
‘Most patients, when we ask them, they tell us that side effects make 
them to stop taking their treatment. They say that sometimes it feels like 
these tablets are going to kill them. So, what do they do ... they stop 
taking them!’ 
 
‘During counselling we tell the patients that they cannot take their ARV’s 
with traditional medicines. But then you see them not getting any better 
and the viral load going up.  When you are doing re-adherence with 
them, they will admit to consulting and taking traditional medicines. 
Most people around here believe in those things and it is not easy to 
change them. That’s how they live.’  
 
‘I just think that some patients drink too much and when they are drunk, 
they forget about their treatment, especially on weekends and during 
holidays.’ 
 
There are some similarities between what the lay counsellors reported and the 
findings in the quantitative phase in which 89.4% of the respondents reported 
experiencing side-effects which influenced their adherence. In the focus group 
discussion only one participant reported belief in traditional medicine by a 
partner which indirectly impacted on her adherence. No evidence of the effect 
of alcohol abuse could be established in all the phases of this study and this 
could have been anticipated as it is not easy to admit abusing alcohol or any 
other substances readily. 
 
4.8.2 Pharmacist assistant 
 
The two biggest factors identified by the pharmacist assistant as the reason for 
less-than-perfect adherence were lack of disclosure and side effects. 
Disclosure is seen as a major challenge in that patients are afraid to disclose 
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their status for fear of being stigmatised and discriminated against. This, 
therefore, makes it difficult for them to take their medication in front of other 
people. This is in sharp contrast to the findings of this study which showed that 
all respondents during the quantitative phase had disclosed to different 
persons in their lives and in the qualitative phase only one participant had not 
disclosed. It is, however, important to point out that the findings of this survey 
cannot be generalised because of the small sample size.   
 
The second most significant factor mentioned by the pharmacist assistant 
impacting on adherence was side effects which sometimes caused patients to 
stop or adjust their treatment in order to minimise the side-effects.  The 
findings of the current study were consistent with this as 89.4% of respondents 
reported experiencing some side effects at one point of their treatment life 
span. One had this to say: 
 
‘The biggest challenge here is that patients don’t disclose their status 
and as a result, they refuse to be down-referred to their local clinics as 
they fear being known in their local communities. When you talk with 
them you discover that some even have difficulty taking their medication 
in front of people who are not aware of their status.’  
 
‘Side effects also pose a serious problem and you will find them 
complaining that the tablets make them sleepy and they can’t function 
properly. Some even decide to stop the treatment or take it at night only 
even though we advise them to come back if the side effects are 
severe!!’  
 
4.8.3 Social worker 
 
The social worker identified two major barriers to adherence, with lack of food 
being the highest, followed closely by lack of transport money to attend the 
clinic. She reported that since many patients were unemployed, some ran out 
of money for transport to the clinic. This has not been established as a major 
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problem in the study even though 92.8% of respondents incurred transport- 
related costs when attending the clinic.  In addition, the social worker said that 
many patients dropped out of the programme during the initiation phase. 
These included patients who started with adherence counselling in preparation 
for ART but then dropped out fearing an inability to commit to lifelong therapy. 
In terms of HBM, this can be regarded as lack of self-efficacy which may 
impact on the ability to adhere if the patient does not believe he/she can do it. 
This aspect is not relevant to this study as all respondents had already 
commenced ART. 
 
Patients, who remained on the programme after initiation, reportedly stated 
that it was difficult to take tablets without any food as taking the abrasive 
medication on an empty stomach caused nausea. Lack of adequate financial 
resources and food insecurity have been identified as major factors associated 
with poor adherence to treatment (NDOH 2010). In this study, 92.8% of 
respondents reported experiencing financial difficulties but only half of them 
(46.4%) admitted being unable to afford food owing to lack of financial 
resources. The other half reported coping somehow despite the difficulties. 
 
At the service level, the social worker identified ‘down-referral’ of patients as a 
challenge as most of the patients refused to be referred back to their local 
clinics. This was not established during this survey so no comparisons can be 
made. This is what she had to say: 
 
‘Most patients complained of having no food and feel they cannot take 
tablets on an empty stomach as the tablets are harsh and abrasive in 
the stomach.’ 
 
‘Patients always complain of having no money for transport to come to 
the clinic when referred for re-adherence after defaulting. They however 
refuse to be down-referred to their local clinics as they will be known to 
be taking ARV’s. Some even tell me that they want a disability grant!!’ 
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‘Some patients drop out of adherence counselling as they are scared to 
start ARV because they cannot stop any more. I guess they are just 
afraid of this long term commitment.’ 
 
4.9 A SYNTHESIS OF THE QUALITATIVE PHASE 
 
The objective of the qualitative phase of the study was to gain an 
understanding of the respondents’ experiences in their own words. This 
information was obtained through the use of a focus group interview held with 
nine participants. 
  
Factors cited as affecting adherence were the stress and fear associated with 
the HIV diagnosis; the uncooperativeness of sexual partners in terms of 
condom use and the taking of antiretroviral medication; unemployment and 
financial dependence on partners; homelessness and displacement; traditional 
and religious beliefs; irregular working hours; and forgetfulness. 
 
Factors that were cited as promoting adherence were having accepted one’s 
HIV status; receiving support from loved ones; a desire to see children grow up 
and be there for them; and living a good quality of life. 
 
The Health Belief Model emphasises that for adherence to happen there must 
be a perceived benefit of the recommended health action and a perceived 
susceptibility to the consequences of not adhering to the recommended health 
action. The Social Cognitive Theory, on the other hand, espouses that behaviour 
is largely determined by incentives and expectancies. There must be a 
perceivable incentive for changing one’s behaviour and expectancies about 
consequences of one’s actions.  
 
From the qualitative phase the belief that following a recommended health 
action would be beneficial in reducing the perceived threat was very evident. 
The respondents reported that they believed that taking their treatment would 
enable them to continue having a good quality of life; give them an opportunity 
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to see their children grow up and be an example to their families and friends 
for them to see that one can live positively with the virus for many years. 
 
4.10 CONCLUSION 
 
In this chapter the findings of the research study were presented and 
discussed and integrated with the theoretical models of health behaviour. This 
study used a mixed research design and as a result both qualitative and 
quantitative data were presented in this chapter. Conclusions and 
recommendations arising from the findings will be the focus of the next 
chapter. 
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CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 INTRODUCTION 
 
The previous chapter presented all the data and findings of both the 
quantitative and qualitative phases of the study.  In this chapter the researcher 
discusses a summary of the findings, conclusions and recommendations for 
both health authorities and for further research opportunities. These are 
discussed in relation to the objectives of the study as set out at the beginning. 
The researcher also outlines the identified strengths and weaknesses of the 
study. 
 
5.2 SUMMARY OF FINDINGS ACCORDING TO THE OBJECTVES 
 
The main aims of the study were to investigate the social context of patients on 
ART living in rural Mpumalanga so as to identify the major factors that affect 
adherence to ART, identify factors that support adherence as well as those 
factors that drive non-adherence amongst rural people living with HIV and 
Aids. 
 
5.2.1 Objective 1: social context of patients on ART  
 
The first objective of the study was to investigate the social context of patients 
on ART so as to identify the main contributing factors to adherence, non-
adherence and fall out (that is, patients’ loss to follow-up, LTFU) from the 
treatment programme. From the study it emerged that a great many factors 
within the person’s social context play a role in determining whether they 
adhere to their regimens or not. This is supported by the social learning theory 
which suggests that personal, behavioural and environmental factors largely 
determine one’s actions (Martin et al 2009:16). On the other hand, HBM 
suggests that one’s actions and behaviours are influenced by perceptions and 
beliefs which are regarded as primary motivators of health behaviours (Martin 
et al 2009; Masokoane 2009:21). The patients’ view of their circumstances, the 
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support they receive both from significant others and the health care providers 
may influence their behaviour and the decisions they make. It is not only 
individual factors that are important but also the interaction between those 
individual factors and the social factors such as the belief systems; support 
systems that exist; attitudes and reactions of significant others towards PLHIV; 
attitudes of health care professionals and the available resources such as 
transport infrastructure and accessibility of the clinics. 
 
The belief system entails the values, cultural and religious beliefs that dictate 
people’s perceptions of situations and their behaviour. Belief systems can 
impact on issues such as disclosure; the nature of the relationship with 
partners which may affect issues of safer sex practices; roles and expectations 
of women specifically; and even the taking of ART instead of traditional 
medicines. In this study, only one respondent cited the issue of traditional 
beliefs as having an influence on their treatment adherence. It is very 
interesting to note that in a rural area where traditional and cultural beliefs still 
significantly influence health-seeking behaviour, only one participant admitted 
to this belief affecting their adherence to some extent. Literature suggests that 
traditional healers are the primary health care providers in rural areas for at 
least between 80 and 85% of rural people in Tanzania and South Africa 
(Mustapher 2012; AIDS Foundation 2010).  It would seem that almost all the 
respondents had internalised the importance of not mixing ART medication 
with traditional medicine as suggested in the South African ART guidelines 
(NDOH 2010:18) which is a great achievement for the ART programme. This 
might not be an indicator for general trends in this community since this is a 
small sample size but the progress made in raising awareness on the use of 
traditional medicine for PLHIV is worth acknowledging. Support systems 
include the availability of support from family members and friends and support 
groups where available. All of these factors within the patients’ social 
environments interact in a way that will either promote or inhibit proper 
adherence to treatment. 
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The prominent factors identified in this study were that all the respondents 
except for one disclosed their status with positive outcomes as 78.5% of them 
were being supported by family and friends. This is a positive success 
indicator for the ART programme in terms of HIV status disclosure as only one 
person was not able to disclose to anyone. This high rate of disclosure has 
reportedly impacted positively on their adherence as a result as they are 
supported by significant others. The rest of these respondents did not obtain 
the support they expected after disclosure and they consisted of those who 
were either blamed (3.6%), their family were afraid the respondent might die 
(3.6%) or families finding it difficult to accept the HIV diagnosis and the 
respondents’ status (14.3%). This percentage of non-disclosure is negligible 
when one compares it with the information on the study conducted by ATLIS in 
2010 which found that 35% of people in a sample of 2 035 did not disclose for 
fear of being stigmatised and discriminated against. This is a very positive 
finding as a large number of people do not disclose their status for fear of 
being blamed and in some cases being discriminated against (AVERT 2011).  
It was, however, also noted that of all those respondents who were employed, 
three had not disclosed at work and all of them reported difficulty in taking their 
treatment whilst at work.  
 
In the qualitative phase, the following factors were reported as having a 
negative bearing on adherence: being unemployed; homeless and displaced; 
dependency on spouses and the inability to negotiate for safer sex practices; 
and difficulty of taking medication at work. In the quantitative phase 46.4% of 
respondents reported having no income and poverty as having an impact on 
their ability to adhere properly as sometimes there was no food and no money 
for transport to honour clinic appointments. In the qualitative phase three of the 
nine respondents were unemployed and had to depend on someone else for 
survival but had managed to be adherent with medication despite the 
unfavourable financial circumstances.  
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5.2.2 Objective 2: Factors supporting adherence 
 
The second objective was to identify those socio-economic factors that support 
adherence amongst rural people living with HIV (PLHIV) accessing ART. The 
following factors were cited as encouraging for respondents to take their 
treatment. 
 
5.2.2.1 Social support 
 
Having solid support systems is very important for people living with HIV and 
Aids as it plays a significant role in ensuring adherence to their treatment 
regimens (WHO 2003:28; AIDSmap 2012). Social support from family, friends 
and the community at large has been associated with increased and better 
adherence to treatment in many instances in which patients are on long term 
treatment (Heyer & Ogunbanjo 2006:6-7). This support system is there to buoy 
up the patients emotionally and to motivate them to take the recommended 
health actions. Social support of significant others can also serve as ‘cues to 
action’ as espoused in the Health Belief Model where patients can be 
influenced by external factors such as family to take action (Hayden 2009:33). 
Support does not only refer to social and emotional support but in many cases 
it includes financial support from significant others.  
 
In this study, the two main reasons cited as encouraging adherence among the 
respondents were being aware of the benefits of being on ART and receiving 
the support of family and friends. Nearly two thirds (64.2%) of the respondents 
cited these two reasons as encouraging them to adhere, followed by the 
improvement brought about by ART in their health. Having accepted their HIV 
status also helped as it meant the status quo had been accepted and the 
patient was dealing with the situation positively.  
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5.2.2.2 Knowing and understanding the benefits of ART 
 
Having a good understanding of how ART works and the benefits the patients 
can derive from being on treatment may encourage patients to take their 
treatment as recommended. From a review of many studies on adherence, 
Heyer and Ogunbanjo (2006:6) have established that patients who receive 
inadequate information about ART or have difficulty understanding medication 
schedules adhere less than those who have a good understanding of the 
purpose of ART. This understanding is crucial for patients to appreciate the 
importance of the treatment and the required adherence for it to work optimally 
and produce positive outcomes. Two of the reasons cited by respondents for 
encouraging adherence were appreciating how it works and understanding the 
benefits obtained from taking treatment as recommended. Some of the 
benefits cited by respondents were being able to live a better life; live long 
enough to see their children grow up; have an opportunity to plan for their 
family’s future; be an example to other people and show that it is possible to 
live a good life even with HIV.  
 
5.2.3 Objective 3: Factors driving non-adherence and loss to follow up  
 
The objective here was to identify those socio-economic factors that drive non-
adherence and ultimately fall out amongst rural PLHIV accessing ART. Hardon 
et al (2006:7) in their studies conducted in three African countries, that is, 
Tanzania, Uganda and Botswana, review constraints such as transport costs, 
user fees, long waiting times, hunger, stigma and discrimination, lack of social 
support, side effects and lack of appropriate counselling. All undermine 
adherence to therapy. It is important to indicate at this point that the majority of 
respondents (78.5%) reported having no problems adhering to their ART whilst 
64.3% of the respondents agreed but admitted to having missed some doses 
of treatment at some point at varying degrees. The findings clearly indicate 
that almost three quarters of the respondents were not adhering to their 
treatment as recommended. This is a cause for concern for long-term 
treatment outcomes.  
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Taking into account the definitions of adherence, non-adherence and poor 
adherence as cited in paragraph 4.5.16, the findings clearly depict a mixed 
picture of both non-adherence and poor adherence. Nearly a quarter (22.2%) 
reported missing a dose at least once a week, which is equivalent to four times 
a month and that clearly shows poor adherence. The patient can still be 
considered adherent if no more than three doses per month have been missed 
as the treatment will still suppress the virus sufficiently (NDOH 2004:53). At 
least one person also reported stopping treatment completely two months prior 
to these interviews which is in essence non-adherence to treatment as it was 
prematurely stopped. The rest of the respondents had either missed a dose 
once a month, once in three months or very rarely and this can be considered 
as being adherent as 95% of the treatment was reportedly taken. The findings 
nevertheless show that there is generally poor adherence to treatment 
regimens in this study. This is, however, a subjective report of adherence by 
respondents and generally patients have been found to have a tendency to 
over-exaggerate their self-reported levels of adherence for various reasons 
(WHO 2003:96).  
 
The following factors were identified as having an impact on adherence in this 
study. 
 
5.2.3.1 Lack of social support 
 
The presence of social support for people living with HIV and Aids has been 
associated with good adherence to treatment. Conversely the lack of this 
support can have a negative impact on patients’ ability to adhere to their 
treatment regimens. This was also confirmed in a review of many studies done 
by Heyer and Ogunbanjo (2006:8) in which they discovered that lack of 
support, specifically social and familial support, and fear of stigmatisation are 
generally associated with non-adherence to treatment.  
 
One respondent in this study reported having no one to discuss and share 
their feelings about HIV status and treatment.  In the qualitative phase of the 
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study three respondents reported not getting any cooperation and the 
necessary support from their spouses despite both partners being reportedly 
HIV positive which made adherence difficult to achieve as they were unable to 
negotiate the practice of safer sex.  
 
5.2.3.2 Unemployment and lack of financial resources 
 
Mukherjee et al (2006:124) state that studies undertaken in several different 
settings show that costs such as payment for transportation to and from clinics 
serve as a deterrent to ART adherence. They further affirm that the lack of 
adequate food has also been associated with poor adherence to ART. In this 
study, 46.4% of respondents in the quantitative phase and three of the nine 
respondents in the qualitative phase were unemployed and had to depend on 
significant others for financial support. In instances in which this financial 
support was discontinued, patients’ lives were destabilised. This may result in 
displacement and homelessness but in this study only two focus group 
participants reported being homeless. This was not reported as a factor 
affecting adherence for them. From a review of many studies, Heyer and 
Ogunbanjo (2006:8) have established that a lack of support from significant 
others, homelessness and displacement are all generally associated with 
poorer adherence.  
 
The majority of respondents (92.8%) reported incurring transport expenses as 
they had to travel various distances to the clinic to obtain their medication but 
this was not regarded as a problem as they were nevertheless able to attend 
clinic regularly. Poverty and a lack of financial resources to provide themselves 
with food was reported by at least 46.4% of respondents who could not afford 
to buy food and another 46.4% who reported financial difficulties but they 
somehow found ways to cope. Some respondents reported missing a dose as 
a result of having no food at home. This was also one of the reasons cited by 
key informants as contributing to patients missing their appointments but this 
was not correlated by the findings.  
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5.2.3.3 Traditional and religious beliefs 
 
Traditional beliefs and religion shape and determine our actions and it can 
impact on the acceptance of one’s HIV status; the willingness to disclose; fears 
about stigma and discrimination and ultimately willingness and preparedness 
to enrol on the ART programme (Kagee 2006:422; Hardon et al 2006:68). Our 
responses and actions with respect to these beliefs are more than likely to 
impact on adherence to treatment. In a study conducted in Tanzania by Zou, 
Yamanaka, John, Watt, Ostermann and Thielman (2009:79) it was discovered 
that 80.8% of respondents believed that prayer could cure HIV and a 
correlation between refusal to take treatment and lack of knowledge about 
ART was established amongst this group. In this study there was evidence of 
this belief when one respondent stopped treatment as he believed that God 
would cure him of HIV even though he had been on treatment for two years 
and was doing well. In this instance religious beliefs had a negative impact on 
treatment adherence. No respondent reported believing in traditional or 
alternative medicine per se but some reported that the spouse did not believe 
in ART and as a result did not want them to take the treatment.  
 
5.2.3.4 Irregular working hours and lack of disclosure 
 
People infected with and affected by HIV and AIDS are often subjected to 
discrimination and rejection by their friends, family and partners and even work 
colleagues (Evian 2011:464). Many people who have disclosed their HIV 
status to someone are often met with mixed responses and reactions. Whilst 
most literature advocates disclosure of one’s status, it is important to point out 
that disclosure may not be good for everyone. Hence many people decide not 
to disclose especially at the workplace where there are no guarantees of 
unconditional acceptance and support. The disadvantage with disclosure is 
that the reaction to it cannot be predicted. Once a patient has disclosed to 
someone and the reaction is negative, it cannot be taken back or withdrawn. 
Even though disclosure may sound like a good thing to do and patients may be 
motivated to adhere to their ART, if there is a slight sense of discrimination and 
151 
 
stigmatisation as a result of having disclosed this may negatively impact on 
their adherence. Three of the nine discussants in the focus group reported 
having difficulty taking their treatment when they were at work and when they 
were working irregular shifts. The main reason cited was being unable to take 
treatment when working late or on night shift as it sometimes clashed with 
work routines or coincided with travelling times. One respondent also 
mentioned fear of discrimination and victimisation. 
 
5.2.3.5 Adherence counselling 
 
The role of health care professionals, particularly lay counsellors is to help 
prepare patients for initiation on ART. This is done through adherence 
counselling mainly and if this process is not handled efficiently it can impact on 
adherence in the long run. Adherence counsellors should consider whether 
patients are in a position to fully comprehend the discussions and can apply 
this knowledge in their day-to-day situations. 
 
In this study it emerged that although all respondents reported attending 
adherence counselling sessions before starting treatment, some of them 
reported that they were confused, did not understand what adherence was all 
about and some even cited poor quality of counselling offered. According to 
Heyer and Ogunbanjo (2006:6), patients who have difficulty concentrating, 
have received inadequate information about ART or are struggling to 
understand how treatment works will adhere poorly to their treatment. The 
importance of adequate counselling when preparing patients for initiation and 
ensuring that the patients gain adequate insight is of great importance and it 
cannot be over emphasised. From the findings, 50% of the respondents 
reported having difficulty with adherence when they were away from home 
either attending a funeral or some other social function. The researcher is of 
the opinion that there could be a link between this and with the nature of 
counselling received. The aim of adherence counselling is to help prepare 
patients for initiation on treatment and assist them with developing strategies 
to overcome such challenges. In this instance, it seems that the respondents 
152 
 
were not adequately coping with the challenges and hence the inability to 
devise strategies to ensure adherence even when they were not in their 
natural environment. From the interview with the social worker it emerged that 
she does not play any role with regard to adherence counselling; only the lay 
counsellors render this service. The researcher is of the opinion that the social 
worker can and should play a significant role in rendering of adherence 
counselling. It is also very important to emphasise that adherence counselling 
is not a once-off event but should be on-going to ensure that patients do not 
fall out of the programme unnecessarily (Van Dyk 2011). NSP 2012-2016 
(NDOH 2011:49) advocates that adherence counselling be offered at each 
clinic visit to increase patients’ understanding and ensure that they are 
retained in care.  
 
5.2.3.6 Side effects 
 
It is very common for patients to experience side effects within the first two 
weeks of starting treatment but these normally subside within the first six 
weeks. Some can be short term and self-limiting and others need the attention 
of health care providers like fat redistribution form one body part to another. 
Patients are always encouraged to seek help as soon as possible if this 
happens (Evian 2011:166). A high percentage (89.4%) of respondents in the 
quantitative phase of this study reported experiencing different side effects and 
that these had a direct impact on their adherence to treatment. In the 
qualitative phase of the study only one respondent cited experiencing some 
side effects which made it hard to cope at school. This is also consistent with 
the information obtained from the key informants who reported side effects as 
one of the major problems identified as leading to non-adherence. 
 
5.2.3.7 Treatment regimens 
 
In the quantitative phase of the study 75% of the respondents were on the first 
line regimen which is a good thing in terms of long-term adherence and the 
success of treatment whilst 7.1% of the respondents were already on the 
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second line regimen which leaves them with fewer options in the long run. The 
rest of the respondents (17.9%) did not know their treatment regimen and 
could not provide information in this respect. This is a worrying factor as it is 
ideal for the patients to know and understand their treatment as this 
encourages good treatment adherence. Qualitative data showed that five of 
the nine focus group participants were on the first line regimen, one was on the 
second line regimen and three were on the salvage regimen. This is a concern 
as these three individuals may run out of treatment options soon if adherence 
levels do not improve. These are indicative of serious challenges in terms of 
treatment adherence which may be as a result of lack of adequate knowledge 
of treatment, side effects or circumstances which are not conducive to 
adherence.  
 
5.3 STRENGTHS AND WEAKNESSES OF THE STUDY 
 
5.3.1 Strengths of the study 
(i) The study was able to meet the objectives as set out in the beginning 
of the study which was to describe the social context of people living 
with HIV and Aids in rural Mpumalanga and explore factors that support 
adherence and those that encourage non-adherence to treatment. 
 
(ii) The study contributes to the existing body of knowledge in relation to 
understanding of adherence and non-adherence of people living with 
HIV and receiving ART. Previous studies focused more on the 
psychosocial factors leading to non-adherence but this study focused 
more on the socio-economic factors. It has emphasised the role played 
by side-effects in adherence; the importance of adherence counselling 
with respect to long-term treatment adherence; and the impact of 
disclosure and social support on the patient’s adherence. 
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5.3.2 Weaknesses of the study 
 
(i) The researcher had a very limited budget when undertaking this 
study and as a result could not choose a very large sample. A relatively 
small sample was chosen owing to budgetary constraints and this small 
sample size means that the findings of the study cannot be generalised 
to a larger population. 
 
(ii) Non-probability sampling was used in the selection of respondents 
which implies that the probability of being chosen to participate was 
unknown. The findings of the study, therefore, are not representative. 
 
(iii) Another shortcoming in this study was the language barrier as the 
respondents predominantly spoke SiSwati and the researcher is an 
IsiZulu speaker. Although both these languages are Nguni languages 
and there are similarities in some instances it still posed a challenge in 
communication which may have impacted on the responses. Where a 
difficulty was identified the researcher explained further in English when 
the respondent was able to understand and also explained and clarified 
it further in SiSwati.  
 
(iv) The interviews were conducted at the CCMT site for the 
convenience of both the interviewer and some respondents and as a 
result the researcher was viewed as part of the staff and this could lead 
to over-reporting of adherence to appease the researcher. 
 
(v) The researcher also had challenges regarding gaining permission to 
access the health facility to conduct research owing to the delays in the 
granting of this consent. This impacted negatively on the progress of the 
study itself and it resulted in delays in starting and completing the study. 
 
(vi) Further delays were also experienced when the researcher had no 
personal laptop to do her work and this had a major impact on the 
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progress of the study. This was overcome with the assistance of the 
Postgraduate Financial Assistance Programme from UNISA. 
 
5.4 RECOMMENDATIONS STEMMING FROM THE FINDINGS 
 
(i) The importance of adherence counselling when preparing patients for 
initiation on ART and its association with non-adherence if not done 
properly has been positively established. The findings of the study 
showed that there may be gaps in terms of adherence counselling and 
this needs to be addressed to ensure better counselling quality. 
Adequate training of the relevant personnel may assist in ensuring that 
counselling is done efficiently. It is also recommended that the social 
worker be actively involved in ensuring that adherence counselling is 
consistently of a higher quality and that social worker renders in-service 
training where necessary. 
 
(ii) The findings also depicted that 92.8% of respondents incur transport 
costs in order to attend clinic which is far from their residential localities. 
It is recommended that the down-referral to local primary health care 
clinics of those patients who are stable on treatment be explored further 
and strengthened for easy accessibility of services for patients at no 
extra cost.  
 
(iii) At least four of the nine participants in the focus group discussion 
indicated that their partners were not cooperative with respect to issues 
such as condom use, taking ART and traditional practices. This cannot 
be generalised as a big problem since the sample size was small but 
the issue is significant enough to be explored. It is recommended that 
the involvement of partners in the development of a treatment plan for 
the patient, especially if both partners are HIV positive, be ensured as 
far as possible. 
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5.5 RECOMMENDATIONS FOR FURTHER RESEARCH 
(i) The researcher was not able to do an extensive research on the 
socio-economic factors owing to budgetary limitations and there might 
be a need to explore this aspect further. It is recommended that further 
studies be carried out on these factors in order to gain a better 
understanding of the impact they can have on adherence.  
 
(ii) It seems as if down referral of patients from hospitals to local clinics 
might go a long way in alleviating problems of non-adherence as a 
result of lack of money to attend clinic appointments. This aspect needs 
to be explored and strategies relevant to localities developed for proper 
implementation. 
 
(iii) Adherence counselling in order to prepare patients for ART is very 
important and if it is not done effectively it can have an impact on the 
adherence to treatment and outcomes thereof. It is recommended that 
the role of adherence counselling in ART initiation be explored with the 
objective of developing improved implementation strategies. 
 
5.6 CONCLUSION 
 
The aim of this study was to describe and explore factors that influence 
adherence amongst people living with HIV and Aids in the rural Mpumalanga 
province. It is envisaged that the findings will assist health care professionals 
to develop intervention programmes that will assist in identifying those patients 
most at risk of and vulnerable to being non-adherent to their regimens. The 
factors affecting adherence can be divided into five categories, that is, 
treatment-related, condition-related, patient-related, health care team-related 
and socio-economic factors.  
 
The most commonly cited reasons affecting adherence in this study were 
being away from home for social events like funerals; inability to take treatment 
whilst at work owing to irregular working hours; fear of stigmatisation and/or 
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victimisation; treatment side effects; and forgetting their treatment. A very clear 
picture that emerged from the study was the inability of women respondents to 
negotiate safer sex practices like condom use which made them non-adherent 
with their treatment regimens. 
 
The study revealed how the individual factors interacted with other factors in 
the respondents’ social environment to impact and influence treatment 
adherence. It indicated that the majority of women experience difficulty in 
gaining the cooperation of their spouses in terms of condom use and taking of 
treatment in case of concurrent HIV positive diagnosis of both partners. 
Another issue that was evident is the financial dependence of female partners 
on their spouses which in most cases makes it difficult to negotiate safer sex 
practices. In this study, three respondents from the focus group reported being 
financially dependent on partners and felt a sense of obligation which made it 
difficult to negotiate condom use. The issue of adherence counselling and the 
quality thereof was another factor identified as possibly having an impact on 
the ability to adhere to treatment regimens. The significant role that adherence 
counselling can play in promoting adherence by all cannot be over 
emphasised.  
 
 
 
‘Access- to-all’ campaigns are no longer acceptable without adding the 
important ‘adherence-by-all’ message – Van Dyk 2011 
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ANNEXURE 1 
                                                                                                                       7 Eagle Creek 
                                                                                                 Rugby Road 
                                                                                                 Weltevreden Park 
                                                                                                 1709 
                                                                                                 11 April 2011 
 
The Hospital Chief Executive Officer 
Shongwe Hospital 
Private Bag. X301 
Shongwe Mission 
1331 
 
For Attention:  Mrs. M.T. Themba 
 
Dear Madam, 
 
RE: REQUEST FOR ACCESS TO CONDUCT RESEARCH AT SHONGWE 
HOSPITAL 
I am a student registered for Master’s Degree (Social Behaviour Studies in HIV/Aids) 
with the University of South Africa. I intend doing research in your area and would like 
to request permission to access information on your patients’ files for the purposes of 
conducting this research and interviewing individual patients for more detailed 
information. The title for my dissertation is:  
 “Factors that influence treatment adherence for people living with HIV and 
accessing antiretroviral therapy in rural communities in Mpumalanga”. 
 
The objectives of this study are to: 
 Investigate the social context of patients on antiretroviral therapy (ART) so as 
to identify the main contributing factors to adherence and fall out (that is, 
patients lost to follow-up, LTFU)  
 Identify the socio-economic factors that support adherence amongst rural 
PLWH and accessing ART 
 Identify the socio-economic factors that drive fall out (LTFU) amongst rural 
PLWH and accessing ART 
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The proposed research design is a mixed-method research design. As patients lost to 
treatment may be particularly hard to trace and interview, the researcher intends to 
use a mixed design in which the background information on patients as noted in their 
case files are used in addition to in-depth, face-to-face interviews with adherent and 
non-adherent patients. The goal is to compare and describe the socio-economic 
contexts of these two groups so that the socio-economic factors that either support or 
hinder adherence can be discovered.  
The proposed data sources are thus patient records and interviews conducted 
according to an interview schedule. Given the nature of confidentiality, the researcher 
will rely on non-random sampling and ask for volunteer research participants from the 
case files. Although this limits generalizability, the nature of the topic means that 
voluntary participation in the study is essential. 
 
I will ensure that: 
 The patients’ consent is obtained prior to commencement of research 
interview 
 The patients’ well-being and dignity is not harmed or compromised in any way  
 The participation of patients is completely voluntary and that they can withdraw 
from participation at any point should they wish to without any penalty 
 The anonymity of the respondent, privacy and confidentiality of the session is 
maintained at all times  
 The information obtained from this study will be analysed using relevant data 
analysis tools and be reported as part of the research report of this study and 
submitted as part fulfilment of the academic requirements at Unisa 
 
Attached please find the ethical clearance letter from the Mpumalanga Provincial 
Department of Health for your information. Should you wish to contact me urgently my 
contact details are as follows: 
Email: mildred.sithole@righttocare.org  
Cell: 084 588 6322  Tel: 011- 7107143 
Thanking you in anticipation of a positive response. 
 
Yours faithfully 
 
Mrs. B. M. Sithole 
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ANNEXURE 2 
“FACTORS THAT INFLUENCE TREATMENT ADHERENCE FOR PEOPLE 
LIVING WITH HIV AND ACCESSING ANTIRETROVIRAL THERAPY IN 
RURAL COMMUNITIES IN MPUMALANGA” 
 
CONSENT FORM 
 
Dear research participant,  
My name is Bongani Mildred Sithole and I am currently completing a Master’s degree 
in Social Behaviour Studies in HIV/AIDS at the University of South Africa (UNISA). As 
a requirement for the degree, I have to conduct a research study about the response 
to HIV and AIDS in Africa. 
 
The purpose of the study is to investigate the social and economic  context of patients 
on antiretroviral therapy (ART) so as to identify the main contributing factors to 
adherence and fall out (that is, patients loss to follow-up, LTFU).  For this reason, I will 
interview both adherent and non-adherent patients so as to compare and describe the 
socio-economic contexts of these two groups so that the socio-economic factors that 
either support or hinder adherence can be discovered.  
 
This is therefore an invitation to participate in this study. If you agree to do so, it is 
important to take note of the following: 
 
 You will be asked to respond to questions about you and your experiences 
in an interview that will take approximately two hours.  
 Your participation is voluntary and you will not be penalised in any way 
should you decide not to participate.  However, without your kind co-
operation, we cannot gather scientific data that will help us understand the 
problems experienced and improve service delivery. This is therefore an 
urgent appeal to you to please participate.  
 No personal particulars or identifying details such as names will be 
documented on the research guide. This is because nobody outside the 
research team has to know who answered what.  
 Everything we discuss during the interview will be kept confidential i.e. 
between you and the person asking the questions. So you can feel free to 
answer the questions as honestly as possible without fear that someone will 
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know what you said. 
 You will be asked to sign the consent form and the signed forms will be 
kept separate from the questionnaires in a locked safe and destroyed 3 
years after the study has been completed. 
 You have the right to withdraw from participating in the study at any time 
should you feel you do not want to be part of the study anymore. If, 
however, you want to be part of the study, the interviewer will discuss a 
possible date and time for the interview and ask you to sign this document 
in two copies: one will remain with you and the other one will be kept by the 
interviewer. 
 Other participants in the community will also be asked to participate in this 
study.  
 
 Should you need to contact the researcher for support she can be 
contacted on 0845886322. 
 
I have read and understood this consent form, and I agree to participate 
in this study. 
 
Participant’s signature:  Interviewer’s name: 
   
Signature  Signature 
   
Date  Date 
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ANNEXURE 3 
INTERVIEW SCHEDULE 
 
SECTION A: DEMOGRAPHIC INFORMATION 
 
1.  Age         :………………. 
 
2. Gender    : 
   
F  M  
 
3. Marital Status        
           
Single   
Married  
Divorced  
Cohabiting  
Widowed  
Separated  
 
4. Educational Level 
 
No schooling  
Primary School  
Secondary School  
Tertiary Institution  
 
 
5. What is your place of residence?  
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
 
6. Is this an urban or rural area? 
____________________________________________________________________
____________________________________________________________________ 
 
7. Are you currently employed?  
 
Yes  No  
 
8. If yes, what type of job do you do? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
9. If not, what is the major source of income for your family? 
 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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SECTION B: SOCIAL AND ECONOMIC FACTORS 
 
 
10. Do you have any other source of income besides a salary?  
 
Yes  No  
 
 
11. If yes please specify, nature of income. 
____________________________________________________________________
___________________________________________________________________ 
___________________________________________________________________ 
 
12. Do you incur any losses in terms of income as a result of attending the clinic? 
 
Probe: Transport cost to attend clinic 
___________________________________________________________________ 
___________________________________________________________________ 
Probe: Time lost to search for job, if unemployed 
___________________________________________________________________ 
___________________________________________________________________ 
Probe: Do you have to take leave 
___________________________________________________________________ 
___________________________________________________________________ 
Probe: Do you have to pay a child minder 
___________________________________________________________________ 
___________________________________________________________________ 
 
13. Who do you stay with at home? (Answer all options)  
 
       Yes        No 
Spouse   
Children under 18 years   
Children 18 years and older   
Parents   
Extended family   
Any other (Please specify)   
 
 
14. How many people stay in your house? 
 
____________________________________________________________________
____________________________________________________________________ 
 
15. Do you have any children? What are their ages? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
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16. How did you feel when you were told that you were infected with the HIV? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
 
17. Did you disclose your HIV status to anyone? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
 
18. If yes, how did they respond towards you after the disclosure? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
 
19. If not, what were your reasons for not disclosing? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
20. Looking back do you think disclosing was of any benefit to you? 
Probe: How have you benefitted? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
 
 
SECTION C. TREATMENT AND ADHERENCE FACTORS 
 
21. Can you remember when exactly did you start taking your antiretroviral treatment?  
Date:________________________ 
 
22. Which regimen of treatment are you currently on? 
 
TREATMENT REGIMEN 
 
TICK 
1st line  
2nd line  
Salvage  
  
 
23. What does treatment adherence mean to you? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
24. Did you attend any adherence counselling sessions before starting treatment?  
 
Yes  No  
183 
 
25. How was that experience for you? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
26. Who was your treatment supporter during adherence counselling sessions? 
 
 
TREATMMENT SUPPORTER 
 
TICK 
Spouse   
Children   
Relative/Family  
Friend  
Any other  
 
27. How often do you normally attend clinic to get your treatment? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
28. When was the last time you attended the clinic to get your ARV treatment? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
29. How long does it take you to come to the clinic? Here I refer to the travelling time  
      between your departure point (home or work) and the clinic. 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
30. How do you get to the clinic and what transport do you use per trip? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
 
31. Tell me about your experiences of being on ARV’s? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
32. Can you share with me the changes you have noticed after being initiated on 
treatment, if any? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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33. What are the major challenges or difficulties you face as a result of being on ARV 
treatment? 
____________________________________________________________________
Probe: Side effects – have you experienced any; what did you do when you 
experienced those. 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
Probe: Taking medicines on time – are you able to take your medicines on time. If not, 
what are the major barriers to taking your medicines timeously? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
Probe: Diet – do you normally have sufficient food to take with your medications and 
how does this impact on adherence. 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
Probe: Support – do you have anyone to discuss your challenges with regarding 
treatment?  
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
Probe: Adherence – would you be able to share your experiences as far as adherence 
is concerned? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
 
34. Have you ever missed a dosage of your treatment?  
 
Yes  No  
 
35. How often does this happen 
 
MSISSED DOSAGE  
 
Once a week/often  
Once a month  
Once in three months   
Rarely  
Never  
 
 
36. Under what circumstances do this normally happen? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
 
37.  What are the things or circumstances that make it difficult for you to take your 
treatment as prescribed by the health care worker?  
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Probe: Personal (time, memory, adherent, intrinsically) 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
Probe: Interpersonal (stigma, hide, pressure, non-support) 
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
38. What are the things or circumstances that encourage or make it easier for you to 
take your treatment as prescribed by the health care worker? 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
Probe: Personal versus interpersonal issue 
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
 
39. How do you feel about the service that you receive at the clinic?  
 
Probe whether experience of service enables or hinders adherence. How do you think 
the attitude of health care professionals impacted or contributed to your treatment 
adherence? 
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
40. If you were to rate the service, on a scale of 1 to 5 with 1 being very poor and 5 
being very good what score would you give them in terms of service ? 
 
1 Very Poor  
2 Poor  
3 Average  
4 Good   
5 Very good  
 
 
THANK YOU FOR YOR PATICIPATION. 
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ANNEXURE 4 
 
FOCUS GROUP QUESTIONS 
 
1. LEARNING ABOUT HIV STATUS 
 
Can you tell me about the circumstances that led you to getting an HIV test for the first 
time: where and when, and how it happened? 
 
PROBES 
 What were the circumstances that made you decide or 
motivated you to take the test 
 Where and when were you tested 
 How do you feel about the counselling  received when you 
were given your results 
 Who did you share your results with or disclosed your status 
to. 
 What were your reasons for disclosing to that particular 
individual(s) 
 Looking back do you think disclosing was of any benefit to 
you? 
 If so how have you benefitted? 
 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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2. TREATMENT AND ADHERENCE FACTORS 
 
2.1 ARV Regimen 
 
Could you please tell me about the ARVs that you take: which ones, how often, where 
you get them, etc? 
 
PROBES  
 
 Specifics of taking the medications 
 Who knows about their taking ARVs 
 How they learned, why they were told 
 How and how often they collect the drugs 
 Meeting with counsellors or health care providers at clinic 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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2.2   Effects on them of taking the drugs 
 
Once you started taking the drugs regularly, how did the ARVs affect you and your 
life? 
 
Probes 
 Health 
 Daily routine/schedule 
 Interpersonal and/or social relations 
 Sexual relations 
 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
 
2.3. Who can tell us what they think they have benefitted from being on ARV 
therapy. 
 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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2.4. Circumstances or things that has encouraged or enabled you to take your 
treatment well?  
 
I am interested in hearing about how people find ways to keep taking their drugs or 
don’t take them anymore. How has this been for you? 
 
PROBES 
 
 What are the ways that you have found helpful in taking your drugs? 
 
 Other people who assist them 
 Getting the food necessary 
 Hiding from others that they take ARVs 
 Things they have tried to help themselves that have failed 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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2.5. Circumstances that make it difficult to take your treatment as 
prescribed. 
 
What kinds of things make it difficult for you to take the treatment regularly? 
 
PROBES  
 
 Having others know they take drugs 
 Remembering the right time 
 Finding the right food to eat 
 
 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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ANNEXURE 5 
 
INTERVIEW QUESTIONS FOR HEALTH CARE PROFESSIONALS 
 
HCP: ________________________________________ 
 
Knowledge of how patients manage to take their medication or not 
 
I would like to hear about experiences of patients who have done well with 
taking their treatment and those who have done poorly. 
 
PROBES: 
 
 Examples of patients who have done well 
 Examples of patients who have struggled 
 Strategies you think work well for patients 
 Circumstances that make it difficult for patients to take their medication 
 Experiences with patients who miss treatment 
 Contacts with patients who have missed taking their drugs 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
____________________________________________________________________ 
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ANNEXURE 6: UNISA ETHICAL CLEARANCE LETTER 
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ANNEXURE 7:  
PERMISSION TO ACCESS RESEARCH SITE FROM DEPARTMENT OF HEALTH. 
